<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":4.604186,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpFDgMTC1IAC1xcX0tKVBQWCAVfBhcfGRdUFV0HEE9UA1FUHgYNBlEHVE0HE18P","queueTime":0,"ttGuid":"f5bf9b30dd4c72ac"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full">
<meta property="description" name="description" content="Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patien...">
<meta property="og:title" name="title" content="Frontiers | Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1">
<meta property="og:description" name="description" content="Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patien...">
<meta name="keywords" content="short QT syndrome,arryhthmias,antiarryhthmic drugs,Disopyramide,Human-induced pluripotent stem cell-derived cardiomyocytes">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="11">
<meta name="citation_journal_title" content="Frontiers in Pharmacology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Pharmacol.">
<meta name="citation_issn" content="1663-9812">
<meta name="citation_doi" content="10.3389/fphar.2020.554422">
<meta name="citation_firstpage" content="554422">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1">
<meta name="citation_keywords" content="short QT syndrome; arryhthmias; antiarryhthmic drugs; Disopyramide; Human-induced pluripotent stem cell-derived cardiomyocytes">
<meta name="citation_abstract" content="Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patients with SQTS type 1(SQTS1). The aim of this study was to investigate the mechanisms of disopyramide underlying its antiarrhythmic effects in SQTS1 with the N588K mutation in HERG channel. Human-induced pluripotent stem cellderived cardiomyocytes (hiPSC-CMs) from a patient with SQTS1 and a healthy donor, patch clamp and calcium imaging measurements were employed to assess the drug effects. Disopyramide prolonged the action potential duration (APD) in hiPSC-CMs from a SQTS1-patient (SQTS1-hiPSC-CMs).  In spontaneously beating SQTS1-hiPSC-CMs challenged by carbachol plus epinephrine, disopyramide reduced the arrhythmic events. Disopyramide enhanced the inward L-type calcium channel current (ICa-L), the late sodium channel current (late INa) and the Na/Ca exchanger current (INCX), but it reduced the outward small-conductance calcium-activated potassium channel current (ISK), leading to APD-prolongation. Disopyramide displayed no effects on the rapidly and slowly activating delayed rectifier and ATP-sensitive potassium channel currents. In hiPSC-CMs from the healthy donor, disopyramide reduced peak INa, ICa-L, IKr and ISK but enhanced late INa and INCX.The results demonstrated that disopyramide may be effective for preventing tachyarrhythmias in SQTS1-patients carrying the N588K mutation in HERG channel by APD-prolongation via enhancing ICa-L, late INa, INCX and reducing ISK.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2020/09/16">
<meta name="citation_publication_date" content="2020/10/12">
<meta name="citation_author" content="Lan, Huan ">
<meta name="citation_author_institution" content="Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, China">
<meta name="citation_author" content="Xu, Qiang ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="El-Battrawy, Ibrahim ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Zhong, Rujia ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Li, Xin ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Lang, Siegfried ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Cyganek, Lukas ">
<meta name="citation_author_institution" content="DZHK (German Center for Cardiovascular Research), Partner Site Gttingen, Germany">
<meta name="citation_author" content="Borggrefe, Martin ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Zhou, Xiaobo ">
<meta name="citation_author_institution" content="Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, China">
<meta name="citation_author" content="Akin, Ibrahim ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="dc.identifier" content="doi:10.3389/fphar.2020.554422">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1","author":[{"@type":"Person","name":"Huan Lan","affiliation":["Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, China"]},{"@type":"Person","name":"Qiang Xu","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","Department of Histology and Embryology, Southwest Medical University, China"]},{"@type":"Person","name":"Ibrahim El-Battrawy","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Germany"]},{"@type":"Person","name":"Rujia Zhong","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany"]},{"@type":"Person","name":"Xin Li","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany"]},{"@type":"Person","name":"Siegfried Lang","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Germany"]},{"@type":"Person","name":"Lukas Cyganek","affiliation":["DZHK (German Center for Cardiovascular Research), Partner Site Gttingen, Germany","Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center Gttingen, Germany"]},{"@type":"Person","name":"Martin Borggrefe","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Germany"]},{"@type":"Person","name":"Xiaobo Zhou","affiliation":["Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, China","First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Germany"]},{"@type":"Person","name":"Ibrahim Akin","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Germany"]}],"datePublished":"2020-10-12","dateModified":"2025-11-26","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2020","isPartOf":{"@type":"PublicationVolume","volumeNumber":"11","isPartOf":{"@type":"Periodical","name":"Frontiers in Pharmacology"}}},"citation":["https://doi.org/10.3389/fphar.2020.554422"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/pharmacology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Pharmacology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=62&amp;specialtyid=0&amp;entitytype=2&amp;entityid=176" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/pharmacology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Pharmacology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/cardiovascular-and-smooth-muscle-pharmacology" data-event="iBarJournal-sections-a_id_182">Cardiovascular and Smooth Muscle Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drug-metabolism-and-transport" data-event="iBarJournal-sections-a_id_199">Drug Metabolism and Transport</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drugs-outcomes-research-and-policies" data-event="iBarJournal-sections-a_id_202">Drugs Outcomes Research and Policies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/ethnopharmacology" data-event="iBarJournal-sections-a_id_184">Ethnopharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/experimental-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_183">Experimental Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/gastrointestinal-and-hepatic-pharmacology" data-event="iBarJournal-sections-a_id_186">Gastrointestinal and Hepatic Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/inflammation-pharmacology" data-event="iBarJournal-sections-a_id_188">Inflammation Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/integrative-and-regenerative-pharmacology" data-event="iBarJournal-sections-a_id_178">Integrative and Regenerative Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/neuropharmacology" data-event="iBarJournal-sections-a_id_26">Neuropharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/obstetric-and-pediatric-pharmacology" data-event="iBarJournal-sections-a_id_196">Obstetric and Pediatric Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacoepidemiology" data-event="iBarJournal-sections-a_id_2186">Pharmacoepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-infectious-diseases" data-event="iBarJournal-sections-a_id_2216">Pharmacology of Infectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-ion-channels-and-channelopathies" data-event="iBarJournal-sections-a_id_179">Pharmacology of Ion Channels and Channelopathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/predictive-toxicology" data-event="iBarJournal-sections-a_id_195">Predictive Toxicology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/renal-pharmacology" data-event="iBarJournal-sections-a_id_1357">Renal Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/respiratory-pharmacology" data-event="iBarJournal-sections-a_id_190">Respiratory Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/translational-pharmacology" data-event="iBarJournal-sections-a_id_1251">Translational Pharmacology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=62&amp;specialtyid=0&amp;entitytype=2&amp;entityid=176" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/pharmacology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Pharmacology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/cardiovascular-and-smooth-muscle-pharmacology" data-event="iBarJournal-sections-a_id_182">Cardiovascular and Smooth Muscle Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drug-metabolism-and-transport" data-event="iBarJournal-sections-a_id_199">Drug Metabolism and Transport</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drugs-outcomes-research-and-policies" data-event="iBarJournal-sections-a_id_202">Drugs Outcomes Research and Policies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/ethnopharmacology" data-event="iBarJournal-sections-a_id_184">Ethnopharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/experimental-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_183">Experimental Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/gastrointestinal-and-hepatic-pharmacology" data-event="iBarJournal-sections-a_id_186">Gastrointestinal and Hepatic Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/inflammation-pharmacology" data-event="iBarJournal-sections-a_id_188">Inflammation Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/integrative-and-regenerative-pharmacology" data-event="iBarJournal-sections-a_id_178">Integrative and Regenerative Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/neuropharmacology" data-event="iBarJournal-sections-a_id_26">Neuropharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/obstetric-and-pediatric-pharmacology" data-event="iBarJournal-sections-a_id_196">Obstetric and Pediatric Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacoepidemiology" data-event="iBarJournal-sections-a_id_2186">Pharmacoepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-infectious-diseases" data-event="iBarJournal-sections-a_id_2216">Pharmacology of Infectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-ion-channels-and-channelopathies" data-event="iBarJournal-sections-a_id_179">Pharmacology of Ion Channels and Channelopathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/predictive-toxicology" data-event="iBarJournal-sections-a_id_195">Predictive Toxicology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/renal-pharmacology" data-event="iBarJournal-sections-a_id_1357">Renal Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/respiratory-pharmacology" data-event="iBarJournal-sections-a_id_190">Respiratory Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/translational-pharmacology" data-event="iBarJournal-sections-a_id_1251">Translational Pharmacology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/pharmacology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Pharmacology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/cardiovascular-and-smooth-muscle-pharmacology" data-event="iBarJournal-sections-a_id_182">Cardiovascular and Smooth Muscle Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drug-metabolism-and-transport" data-event="iBarJournal-sections-a_id_199">Drug Metabolism and Transport</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drugs-outcomes-research-and-policies" data-event="iBarJournal-sections-a_id_202">Drugs Outcomes Research and Policies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/ethnopharmacology" data-event="iBarJournal-sections-a_id_184">Ethnopharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/experimental-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_183">Experimental Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/gastrointestinal-and-hepatic-pharmacology" data-event="iBarJournal-sections-a_id_186">Gastrointestinal and Hepatic Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/inflammation-pharmacology" data-event="iBarJournal-sections-a_id_188">Inflammation Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/integrative-and-regenerative-pharmacology" data-event="iBarJournal-sections-a_id_178">Integrative and Regenerative Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/neuropharmacology" data-event="iBarJournal-sections-a_id_26">Neuropharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/obstetric-and-pediatric-pharmacology" data-event="iBarJournal-sections-a_id_196">Obstetric and Pediatric Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacoepidemiology" data-event="iBarJournal-sections-a_id_2186">Pharmacoepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-infectious-diseases" data-event="iBarJournal-sections-a_id_2216">Pharmacology of Infectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-ion-channels-and-channelopathies" data-event="iBarJournal-sections-a_id_179">Pharmacology of Ion Channels and Channelopathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/predictive-toxicology" data-event="iBarJournal-sections-a_id_195">Predictive Toxicology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/renal-pharmacology" data-event="iBarJournal-sections-a_id_1357">Renal Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/respiratory-pharmacology" data-event="iBarJournal-sections-a_id_190">Respiratory Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/translational-pharmacology" data-event="iBarJournal-sections-a_id_1251">Translational Pharmacology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=62&amp;specialtyid=0&amp;entitytype=2&amp;entityid=176" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Pharmacol.</span><span>, 12 October 2020</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Cardiovascular and Smooth Muscle Pharmacology</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 11 - 2020 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fphar.2020.554422">https://doi.org/10.3389/fphar.2020.554422</a></p><!----></div><!----><!----></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract"><a id="h1" name="h1"></a><div class="authors"><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/957655" class="user-id-957655"><img class="pr5" src="https://loop.frontiersin.org/images/profile/957655/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Huan Lan&#x;">Huan Lan</a><sup>1&#x2020;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Qiang Xu,&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Qiang Xu<sup>2,3&#x2020;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/368363" class="user-id-368363"><img class="pr5" src="https://loop.frontiersin.org/images/profile/368363/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Ibrahim El-Battrawy,">Ibrahim El-Battrawy</a><sup>2,4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Rujia Zhong" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Rujia Zhong<sup>2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Xin Li" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Xin Li<sup>2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Siegfried Lang," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Siegfried Lang<sup>2,4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/822000" class="user-id-822000"><img class="pr5" src="https://loop.frontiersin.org/images/profile/822000/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Lukas Cyganek,">Lukas Cyganek</a><sup>5,6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Martin Borggrefe," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Martin Borggrefe<sup>2,4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/815918" class="user-id-815918"><img class="pr5" src="https://loop.frontiersin.org/images/profile/815918/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Xiaobo Zhou,,*">Xiaobo Zhou</a><sup>1,2,4*</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Ibrahim Akin," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Ibrahim Akin<sup>2,4</sup></span></div><ul class="notes"><li><span><sup>1</sup></span>Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China</li><li><span><sup>2</sup></span>First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany</li><li><span><sup>3</sup></span>Department of Histology and Embryology, Southwest Medical University, Luzhou, China</li><li><span><sup>4</sup></span>DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Mannheim, Germany</li><li><span><sup>5</sup></span>DZHK (German Center for Cardiovascular Research), Partner Site G&#xf6;ttingen, G&#xf6;ttingen, Germany</li><li><span><sup>6</sup></span>Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany</li></ul><p>Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patients with SQTS type 1(SQTS1). The aim of this study was to investigate the mechanisms of disopyramide underlying its antiarrhythmic effects in SQTS1 with the N588K mutation in HERG channel. Human-induced pluripotent stem cell&#x2013;derived cardiomyocytes (hiPSC-CMs) from a patient with SQTS1 and a healthy donor, patch clamp, and calcium imaging measurements were employed to assess the drug effects. Disopyramide prolonged the action potential duration (APD) in hiPSC-CMs from a SQTS1-patient (SQTS1-hiPSC-CMs). In spontaneously beating SQTS1-hiPSC-CMs challenged by carbachol plus epinephrine, disopyramide reduced the arrhythmic events. Disopyramide enhanced the inward L-type calcium channel current (I<sub>Ca-L</sub>), the late sodium channel current (late I<sub>Na</sub>) and the Na/Ca exchanger current (I<sub>NCX</sub>), but it reduced the outward small-conductance calcium-activated potassium channel current (I<sub>SK</sub>), leading to APD-prolongation. Disopyramide displayed no effects on the rapidly and slowly activating delayed rectifier and ATP-sensitive potassium channel currents. In hiPSC-CMs from the healthy donor, disopyramide reduced peak I<sub>Na</sub>, I<sub>Ca-L</sub>, I<sub>Kr</sub>, and I<sub>SK</sub> but enhanced late I<sub>Na</sub> and I<sub>NCX</sub>. The results demonstrated that disopyramide may be effective for preventing tachyarrhythmias in SQTS1-patients carrying the N588K mutation in HERG channel by APD-prolongation <i>via</i> enhancing I<sub>Ca-L</sub>, late I<sub>Na</sub>, I<sub>NCX</sub>, and reducing I<sub>SK</sub>.</p><div class="clear"></div></div><div class="JournalFullText"><a id="h2" name="h2"></a><h2>Introduction</h2><p class="mb15">Short QT syndrome (SQTS) is a rare, inheritable cardiac channelopathy associated with abbreviated corrected QT interval (QTc), tachyarrhythmias and sudden cardiac death (SCD) (<a href="#B17">Gussak et al., 2000</a>; <a href="#B6">Brugada et al., 2004</a>). So far, worldwide more than 200 SQTS-patients with different gene mutations have been reported and different types of SQTS have been described (<a href="#B3">Bjerregaard, 2018</a>; <a href="#B7">Campuzano et al., 2018</a>). SQTS types 1&#x2013;3 are linked to a gain of function of potassium channels led by mutations in the KCNH2 (SQTS1), KCNQ1 (SQTS2), and KCNJ2 (SQTS3) gene. SQTS types 4-6 are linked to a loss of function of calcium channels resulting from mutations in CACNA1C (SQTS4), CACNB2 (SQTS5), and CACNA2D1 (SQTS6) gene. Recently, a mutation in the cardiac Cl/HCO3 exchanger AE3 was detected in two SQTS-families (<a href="#B35">Thorsen et al., 2017</a>; <a href="#B7">Campuzano et al., 2018</a>).</p><p class="mb15">The diagnostic and treatment approaches are still challenging because the prevalence of the disease is very low. Although implantable cardioverter defibrillator (ICD) can be useful for terminating arrhythmias in SQTS-patients, ICD cannot be used for every patient (<a href="#B15">Giustetto et al., 2006</a>; <a href="#B23">Mazzanti et al., 2014</a>). Therefore, pharmacotherapy is required at least for some SQTS-patients.</p><p class="mb15">To date, only a limited number of drugs have been examined in a small number of patients with SQTS1 (<a href="#B1">Abriel and Rougier, 2013</a>), among which only one drug quinidine has been shown to be effective in the treatment (<a href="#B27">Mizobuchi et al., 2008</a>; <a href="#B16">Giustetto et al., 2011</a>). Quinidine cannot be used in some patients due to its severe side effects. Hence, searching for further drugs is urgently required. SQTS1 is caused by a gain-of-function of the KCNH2 channel. KCNH2 channel blockers should prolong QT interval and hence suppress arrhythmias in SQTS1patients. Surprisingly, clinical data demonstrated that some KCNH2 channel blockers including sotalol and ibutilide failed to prolong QT-interval in SQTS1-patients with KCNH2 mutations (<a href="#B14">Gaita et al., 2004</a>). The reason for ineffectiveness of drugs is that the mutation (N588K) in the KCNH2 channel impairs inactivation of the channel and renders the channel resistant to blockers, which have the highest affinity to the inactivated state of KCNH2 channels. Quinidine has high affinity to both the open and inactivated states of KCNH2 channels. Therefore, its affinity is only partially reduced and it is effective in treating SQTS1. Given that a mutation in KCNH2 (or other channels) may change the sensitivity of channels to drugs (<a href="#B24">McPate et al., 2008</a>), other factors like epigenetic and environmental factors may also influence drug effects. In different types of cells or in the same type of cells under different states, a drug may show different effects. It will be important to test drug effects in &#x201c;diseased&#x201d; cells if we want to know the efficacy of a drug for treating the disease.</p><p class="mb15">Disopyramide is a multiple channel blocker, mainly a sodium channel blocker (<a href="#B28">Morady et al., 1982</a>; <a href="#B33">Sunami et al., 1991</a>; <a href="#B21">Koumi et al., 1992</a>). It has been used for atrial and ventricular arrhythmias (<a href="#B28">Morady et al., 1982</a>; <a href="#B37">Verlinden and Coons, 2015</a>). It was also tested in a SQTS-patient with unknown genotype (<a href="#B27">Mizobuchi et al., 2008</a>). Although it normalized QT interval in that patient, its efficacy for treating SQTS is unclear because only one patient was recruited for the study. Disopyramide effects on HERG (also called I<sub>Kr</sub> or KCNH2) channels, either the wild type or mutated, were investigated in different types of cells (<a href="#B38">Virag et al., 1998</a>; <a href="#B25">McPate et al., 2006</a>; <a href="#B11">El Harchi et al., 2012a</a>; <a href="#B12">El Harchi et al., 2012b</a>), but not in SQTS-cardiomyocytes. Recently, disopyramide was tested in hiPSC-CMs from a patient with SQTS1 and beneficial effects (APD-prolonging and antiarrhythmic effects) were detected (<a href="#B31">Shinnawi et al., 2019</a>). However, in that study, the mechanisms of disopyramide underlying the APD-prolonging and antiarrhythmic effects were not investigated.</p><p class="mb0">This study was designed to investigate the ionic mechanisms for the APD-prolonging and antiarrhythmic effects of disopyramide using the cellular model of SQTS1-hiPSC-CMs established recently by our group.</p><a id="h3" name="h3"></a><h2>Methods</h2><h3>Ethics Statement</h3><p class="mb0">A skin biopsy from a SQTS1 patient was obtained with written informed consent. The study was approved by the Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg (approval numbers: 2018-565N-MA), the Ethics Committee of University Medical Center G&#xf6;ttingen (approval number: 10/9/15), and the Ethics Committee of Southwest Medical University (approval number:KY2013019). The study was carried out in accordance with the approved guidelines and conducted in accordance with the Helsinki Declaration of 1975 (<a href="https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/">https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/</a>), revised in 2013.</p><h3>Clinical Data</h3><p class="mb0">The fibroblasts for iPS cell generation were from a 29-year-old male patient with familial SQTS1 carrying a missense mutation (C to G substitution at nucleotide 1764). This mutation results in substitution of an amino acid at the position of 588 from asparagine to lysine (N588K) in the KCNH2 (also called HERG or <i>I<sub>Kr</sub></i>) channel. The clinical data of the patient has been provided in our recent publication (<a href="#B13">El-Battrawy et al., 2018</a>).</p><h3>Generation of Human iPS Cells</h3><p class="mb0">The methods for the generation of iPS cells from the patient and a healthy donor have been described in our previous study (<a href="#B13">El-Battrawy et al., 2018</a>). Briefly, human iPS cells (hiPSCs) were generated from primary human fibroblasts derived from a skin biopsy. The hiPSC line was generated under feeder free culture conditions using the integration-free CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, #A16517). The Kit contains the reprogramming factors OCT4, KLF4, SOX2, c-MYC and was used according to manufacturer&#x2019;s instructions with modifications. The generated hiPSCs were characterized for their pluripotency and their <i>in vitro</i> differentiation potential (<a href="#B13">El-Battrawy et al., 2018</a>).</p><h3>Generation of hiPSC-CMs</h3><p class="mb0">The hiPSCs were cultured without feeder cells and differentiated into hiPSC-CMs as described with some modifications (<a href="#B36">Tiburcy et al., 2017</a>). In our lab the differentiation of hiPS cells into cardiomyocytes (hiPSC-CMs) is regularly performed every 2 to 3 weeks. The hiPSC-CMs from different differentiations were used for studies and the data were combined. Three clones of the hiPSCs were alternately used for the differentiation. At 40 to 60 days of culture with basic culture medium, cardiomyocytes were dissociated from 24 well plates and plated on Matrigel-coated 3.5&#xa0;cm petri dishes for patch-clamp and calcium transient measurements.</p><h3>Patch-Clamp</h3><p class="mb15">Standard patch-clamp recording techniques were used to measure the action potential (AP) and channel currents in the whole-cell configuration at room temperature. Patch electrodes were pulled from borosilicate glass capillaries (MTW 150F; world Precision Instruments, Inc., Sarasota, FL) using a DMZ-Universal Puller (Zeitz-Instrumente Vertriebs GmbH, Martinsried, Germany) and filled with pre-filtered pipette solution (see below). Pipette resistance ranged from 1&#x2013;2 M&#x3a9; and 4&#x2013;5 M&#x3a9; for current and AP measurements, respectively. Electrode offset potentials were zero-adjusted before a Giga-seal was formed. After a Giga-seal was obtained, fast capacitance was first compensated and then the membrane under the pipette tip was disrupted by negative pressure to establish the whole-cell configuration. Signals were acquired at 10 kHz and filtered at 2 kHz with the Axon 200B amplifier and Digidata 1440A digitizer hardware as well as pClamp10.2 software (Molecular Devices, Sunnyvale, CA). APs were recorded in current clamp mode. For recording APs, brief current pulses (2 ms, 1 nA) were applied with different frequencies to trigger APs.</p><p class="mb15">The bath solution (PSS) for AP measurements contained (mmol/l): 130 NaCl, 5.9 KCl, 2.4 CaCl<sub>2</sub>, 1.2 MgCl<sub>2</sub>, 11 glucose, 10 HEPES, pH 7.4 (NaOH). The pipette solution contained (mmol/l): 10 HEPES, 126 KCl, 6 NaCl, 1.2 MgCl<sub>2</sub>, 5 EGTA, 11 glucose and 1 MgATP, pH 7.2 (KOH).</p><p class="mb15">The bath solution for L-type (I<sub>Ca-L</sub>) calcium channel current recordings contained (mmol/l): 140 TEA-Cl, 5 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 0.01 E-4031, 10 HEPES, 0.02 TTX, 3 4-AP, pH 7.4 (CsOH). Microelectrodes were filled with (mmol/l): 6 NaCl, 135 CsCl, 2 CaCl<sub>2</sub>, 3 MgATP, 2 TEA-Cl, 5 EGTA, 10 HEPES, pH7.2 (CsOH).</p><p class="mb15">The bath solution for Na<sup>+</sup>-Ca<sup>2+</sup> exchanger current (I<sub>NCX</sub>) measurements contained (mmol/l): 135 NaCl, 10 CsCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 Hepes, 10 glucose, 0.01 nifedipine, 0.1 niflumic acid, 0.05 lidocaine, 0.02 dihydroouabain, pH 7.4 (CsOH). Microelectrodes were filled with (mmol/l): 10 NaOH, 150 CsOH, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 75 aspartic acid, 5 EGTA, pH7.2 (CsOH). NiCl<sub>2</sub> (5mM) was used to separate I<sub>NCX</sub> from other currents. I<sub>NCX</sub> was defined as NiCl<sub>2</sub>-sensitive current.</p><p class="mb15">The bath solution for Na+ current measurements contained (mmol/l): 135 NaCl, 20 CsCl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 Hepes, 10 glucose, 0.001 nifedipine, pH 7.4 (CsOH). Microelectrodes were filled with (mmol/l): 10 NaCl, 135 CsCl, 2 CaCl<sub>2</sub>, 3 MgATP, 2 TEA-Cl, 5 EGTA, and 10 HEPES (pH7.2 CsOH).</p><p class="mb15">The bath solution for K<sup>+</sup> channel current measurements contained (mmol/l): 130 NaCl, 5.9 KCl, 2.4 CaCl<sub>2</sub>, 1.2 MgCl<sub>2</sub>, 11 glucose, 10 HEPES, pH 7.4 (NaOH). For slowly delayed rectifier (I<sub>Ks</sub>) measurements, 10 &#xb5;M nifedipine, 3 mM 4-AP and 10 &#xb5;M TTX were added. The pipette solution contains 10 mM HEPES, 126 mM KCl, 6 mM NaCl, 1.2 mM MgCl<sub>2</sub>, 5 mM EGTA, 11 mM glucose, and 1 mM MgATP, pH 7.4 (KOH). For measuring small conductance calcium-activated potassium channel currents (I<sub>SK</sub>), appropriate CaCl<sub>2</sub> was added to get the free-Ca<sup>2+</sup> concentration of 0.5 &#xb5;M according to the calculation by the software MAXCHELATOR (<a href="http://web.stanford.edu/~cpatton/downloads.htm">http://web.stanford.edu/~cpatton/downloads.htm</a>). For measuring ATP-sensitive K<sup>+</sup> channel currents (I<sub>KATP</sub>), the ATP-free pipette solution was used. I<sub>Ks</sub> was defined as 3R4S-chromanol 293B-sensitive, I<sub>KATP</sub> as nicorandil-sensitive and I<sub>SK</sub> as apamin-sensitive currents.</p><p class="mb0">To separate I<sub>Kr</sub> from other K<sup>+</sup> channel currents, the Cs<sup>+</sup> currents conducted by KCNH2 (<i>I<sub>Kr</sub></i>) channels were measured. External solution for Cs<sup>+</sup> currents (mmol/L): 140 CsCl, 2 MgCl<sub>2</sub>, 10 HEPES, 10 Glucose, pH=7.4 (CsOH). Pipette solution: 140 CsCl, 2 MgCl<sub>2</sub>, 10 HEPES, 10 EGTA, pH=7.2 (CsOH).</p><h3>Measurement of Intracellular Calcium Transients</h3><p class="mb0">To measure the intracellular Ca<sup>2+</sup> transients, cells were loaded with the fluorescent Ca<sup>2+</sup>-indicator Fluo-3 AM. First, 1.5&#xa0;ml PSS (see above) was added into a petri dish with hiPSC-CMs cultured for 2 to 4 days. Then, 50 &#xb5;g of the membrane permeable acetoxymethyl ester derivative of Fluo-3 was dissolved in 44&#xa0;&#xb5;l of the Pluronic F-127 stock solution (20% w/v in DMSO) to get a 1 mM Fluo-3 AM stock solution, which can be stored at -20&#xb0;C for a maximum of 1 week. Next, 15 &#xb5;l of the Fluo-3 AM stock solution were added into 1.5&#xa0;ml PSS resulting in a final concentration of 10 &#xb5;M Fluo-3 and the dish was agitated carefully. The cells were incubated at room temperature for 10&#xa0;min in an optically opaque box to protect from light. Thereafter, the PSS was carefully sucked out and discarded. The cells were washed with PSS for 4&#x2013;5 times. Finally, the cells in PSS were kept at room temperature for about 30&#xa0;min for de-esterification before measurements. After de-esterification, the fluorescence of the cells was measured by using Cairn Optoscan calcium imaging system (Cairn Research, UK). Fluorescence is excited by 488&#xa0;nm and emitted at 520&#xa0;nm. The calcium transients were recorded at room temperature.</p><h3>Drugs</h3><p class="mb0">Disopyramide is from SigmaAldrich. The drug was applied to a cell sequentially from low to high concentrations by a perfusion pipette. The tested concentrations were selected according to previous or our preliminary studies in hiPSC-CMs. E-4031, chromanol 293B, nifedipine, NiCl<sub>2</sub>, niflunic acid, lidocaine, and dihydroouabain are from Sigma Aldrich, 4-AP from RBI, apamin from Alomone Labs, TTX from Carl Roth. E-4031, NiCl<sub>2</sub>, TTX, 4-AP, apamin, niflumic acid, and dihydrooubain were dissolved in H<sub>2</sub>O. Nifedipine, and chromanol 293B were dissolved in DMSO, lidocaine in ethanol. Stock solutions were kept at -20 &#xb0;C.</p><h3>Statistical Analysis</h3><p class="mb0">Data are shown as mean &#xb1; SEM and were analyzed using InStat<sup>&#xa9;</sup> (GraphPad, San Diego, USA) and SigmaPlot 11.0 (Systat GmbH, Germany). By analyzing the data with the Kolmogorov Smirnov test, it was decided whether parametric or non-parametric tests were used for analysis. For parametric data of more than two groups, multiple comparisons with one-way ANOVA and Holm-Sidak post-test were performed. For repeated measurements, the method of one-way repeated measures ANOVA with Holm-Sidak post-test was applied. The I-V curve data were analyzed with mixed model analysis using repeated values for the same cells measured as control and treatment at different voltages. Paired t-test was used for comparisons of data before and after application of a drug. p&lt;0.05 (two-tailed) was considered significant.</p><a id="h4" name="h4"></a><h2>Results</h2><h3>Disopyramide Prolonged the Action Potential Duration in SQTS1-hiPSC-CMs</h3><p class="mb0">Although disopyramide has been shown to prolong action potential duration and suppress arrhythmias in SQTS cells, we checked both effects in our SQTS1-hiPSC-CMs before investigating its ionic mechanisms. The AP parameters including action potential amplitude (APA), the maximal upstroke velocity (Vmax) and action potential durations at 50% and 90% repolarization (APD50 and APD90) were analyzed in the presence of disopyramide. Indeed, disopyramide at the concentration of 10 and 30 &#xb5;M prolonged APD90, while at 10 &#xb5;M significantly prolonged APD50 (<a href="#f1">Figures 1A&#x2013;C</a>). At all the tested concentrations, disopyramide did not significantly affect RP, APA (<a href="#f1">Figures 1D, E</a>), but reduced Vmax in a concentration-dependent manner (<a href="#f1">Figure 1F</a>), consistent with its Na channel-blocking effect. In hiPSC-CMs from the healthy donor, disopyramide showed similar effects on AP parameters (<a href="#h12">Figure S1</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg" alt="www.frontiersin.org" id="f1" loading="lazy">
  </picture>
</a><p><strong>Figure 1</strong> Effects of disopyramide on action potentials in SQTS1-hiPSC-CMs. Action potentials were recorded at 1&#xa0;Hz. Disopyramide was applied to cells sequentially from low to high concentration (3 &#xb5;M, 10 &#xb5;M and 30 &#xb5;M). <strong>(A)</strong> Representative action potential traces in absence (Ctr) and presence of 3 &#xb5;M, 10 &#xb5;M, and 30 &#xb5;M disopyramide. <strong>(B)</strong> Averaged values of action potential duration at 50% repolarization (APD50). <strong>(C)</strong> Averaged values of action potential duration at 90% repolarization (APD90). <strong>(D)</strong> Averaged values of resting potential (RP). <strong>(E)</strong> Averaged values of action potential amplitude (APA). <strong>(F)</strong> Averaged values of maximal depolarization velocity (Vmax). Shown are mean &#xb1; SEM, n represents number of cells. The statistical significance was examined by One Way Repeated Measures ANOVA followed by Holm-Sidak method. ns, not significant.</p></div><div class="DottedLine"></div><p class="mb0">To check the effects of disopyramide at different beating frequencies, the same measurements were repeated in cells paced by stimulations at 0.5&#xa0;Hz, 1&#xa0;Hz, and 3&#xa0;Hz. As expected, disopyramide prolonged APDs at all the three frequencies without clear frequency-dependence (<a href="#f2">Figure 2</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg" alt="www.frontiersin.org" id="f2" loading="lazy">
  </picture>
</a><p><strong>Figure 2</strong> Effects of disopyramide on action potential duration (APD) at different frequencies in SQTS1-hiPSC-CMs. <strong>(A, B)</strong> Averaged values of APD50 and APD90 at 0.5&#xa0;Hz, 1&#xa0;Hz, and 3&#xa0;Hz in absence (Ctr) and presence of 3 &#xb5;M, 10 &#xb5;M and 30 &#xb5;M disopyramide. <strong>(C, D)</strong> Percent prolongation of APD50 and APD90 by disopyramide at 0.5&#xa0;Hz, 1&#xa0;Hz, and 3&#xa0;Hz. The values were calculated from the data in <strong>(A, B)</strong>. Shown are mean &#xb1; SEM. The statistical significance was examined by One Way Repeated Measures ANOVA followed by Holm-Sidak method. *p&lt;0.05, **p&lt;0.01.</p></div><div class="DottedLine"></div><h3>Disopyramide Reduced Arrhythmic Events in SQTS1-hiPSC-CMs</h3><p class="mb0">Due to the APD-prolonging effect of disopyramide, its antiarrhythmic effects were further examined in SQTS1-hiPSC-CMs. In spontaneously beating cells challenged by carbachol (CCh, 10 &#xb5;M) plus epinephrine (Epi, 10 &#xb5;M), spontaneous calcium transients were measured to monitor arrhythmic events. CCh+Epi reduced the beating frequency but increased the episodes of arrhythmic events such as &#x201c;immature&#x201d; or irregularly triggered beats. Disopyramide reduced arrhythmic events induced by CCh+Epi (<a href="#f3">Figures 3A&#x2013;D</a>). Of note, the duration of calcium transients was prolonged but the amplitude and basal line of calcium transients were not changed (<a href="#f3">Figures 3E&#x2013;G</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg" alt="www.frontiersin.org" id="f3" loading="lazy">
  </picture>
</a><p><strong>Figure 3</strong> Disopyramide reduced arrhythmic events in SQTS1-hiPSC-CMs. Calcium transients were measured in spontaneously beating cells. Then carbachol (10 &#xb5;M) plus epinephrine (10 &#xb5;M) was applied to cells to trigger arrhythmic events. In cells showing arrhythmias, disopyramide (10 &#xb5;M) was applied to the cell in presence of carbachol and epinephrine. <strong>(A)</strong> Representative traces of calcium transients in a cell before challenging (Ctr). <strong>(B)</strong> Representative traces of calcium transients in the cell challenged by carbachol plus epinephrine (CCh+Epi). <strong>(C)</strong> Representative traces of calcium transients in the cell in the presence of carbachol plus epinephrine and disopyramide (CCh+Epi+Dis). <strong>(D)</strong> Averaged values of arrhythmic events per minute. CCh+Epi slowed the beating but led to small and irregularly triggered beating. The arrhythmic events were defined as transients that are larger than 10% but smaller than 80% of the normal regular transients. The arrows indicate arrhythmic events. <strong>(E)</strong> Mean values of the amplitude of calcium transients in absence (Ctr) and presence of disopyramide (10 &#xb5;M). <strong>(F)</strong> Mean values of the duration of calcium transients. <strong>(G)</strong> Mean values of the diastolic baseline of calcium transient. Shown are mean &#xb1; SEM, n represents number of cells. p values were determined by One Way ANOVA followed by Holm-Sidak method <strong>(D)</strong> or paired t-test <strong>(E&#x2013;G)</strong>. ns, not significant.</p></div><div class="DottedLine"></div><h3>Disopyramide Failed to Suppress the HERG Channel Current in SQTS1-hiPSC-CMs</h3><p class="mb0">The prolongation of action potential duration (APD) in SQTS1-hiPSC-CMs observed in this and previous study (<a href="#B31">Shinnawi et al., 2019</a>) and the weak influence of the pathogenic mutation N588K in HERG channels on the channel-blocking by disopyramide (<a href="#B25">McPate et al., 2006</a>)&#xa0;suggest that disopyramide should inhibit the HERG channel currents (I<sub>Kr</sub>). Surprisingly, disopyramide up to 30 &#xb5;M failed to suppress I<sub>Kr</sub> in SQT1-hiPSC-CMs under our conditions (<a href="#f4">Figures 4A, B</a>). Likewise, disopyramide displayed no effects on the slowly activating delayed rectifier potassium channel current (<i>I<sub>Ks</sub></i>) (<a href="#f4">Figures 4C, D</a>). In hiPSC-CMs from the healthy donor, disopyramide inhibited significantly I<sub>Kr</sub> (<a href="#h12">Figure S2</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 4</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg" alt="www.frontiersin.org" id="f4" loading="lazy">
  </picture>
</a><p><strong>Figure 4</strong> Effects of disopyramide on I<sub>Kr</sub> and I<sub>Ks</sub> in SQTS1-hiPSC-CMs. The currents (I<sub>Kr</sub> and I<sub>Ks</sub>) were evoked by the protocol indicated in <strong>(A, C)</strong>. I<sub>Kr</sub> was measured as Cs<sup>+</sup> currents. I<sub>Ks</sub> was analyzed as Chromalol-293B (10 &#xb5;M) sensitive currents. <strong>(A)</strong> Representative traces of I<sub>Kr</sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). <strong>(B)</strong> I-V curves of I<sub>Kr</sub> in absence (Ctr) and presence of disopyramide. <strong>(C)</strong> Representative traces of I<sub>Ks</sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). <strong>(D)</strong> I-V curves of I<sub>Ks</sub> in absence (Ctr) and presence of disopyramide. n, number of cells.</p></div><div class="DottedLine"></div><h3>Disopyramide Reduced Small Ca<sup>2+</sup>-Activated K<sup>+</sup> Currents in SQTS1-hiPSC-CMs</h3><p class="mb0">Then, we assessed other outward currents including the ATP-sensitive K channel current (I<sub>KATP</sub>) and the small conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channel current (I<sub>SK</sub>). Disopyramide at the highest concentration (30 &#xb5;M) used in this study showed no significant effects on I<sub>KATP</sub> but it reduced I<sub>SK</sub> already at 10 &#xb5;M (<a href="#f5">Figure 5</a>). In hiPSC-CMs from the healthy donor, disopyramide inhibited also I<sub>SK</sub> (<a href="#h12">Figure S3</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 5</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg" alt="www.frontiersin.org" id="f5" loading="lazy">
  </picture>
</a><p><strong>Figure 5</strong> Effects of disopyramide on I<sub>KATP</sub> and I<sub>SK</sub> in SQTS1-hiPSC-CMs. The currents (I<sub>KATP</sub> and I<sub>SK</sub>) were evoked by the protocol indicated in <strong>(A, D)</strong>. I<sub>KATP</sub> was measured as nicorandil (10 &#xb5;M) sensitive currents. I<sub>SK</sub> was analyzed as apamin (100 nM) sensitive currents. <strong>(A)</strong> Representative traces of I<sub>KATP</sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M) at -120 mV. <strong>(B)</strong> I-V curves of I<sub>KATP</sub> in absence (Ctr) and presence of disopyramide. <strong>(C)</strong> Mean values of I<sub>KATP</sub> at -120 mV in absence (Ctr) and presence of disopyramide (10 &#xb5;M). <strong>(D)</strong> Representative traces of I<sub>SK</sub> at +40 mV in absence (Ctr) and presence of disopyramide (10 &#xb5;M). <strong>(E)</strong> I-V curves of I<sub>SK</sub> in absence (Ctr) and presence of disopyramide. <strong>(F)</strong> Mean values of I<sub>SK</sub> at +40 mV in absence (Ctr) and presence of disopyramide (10 &#xb5;M). n, number of cells. *p&lt;0.05.</p></div><div class="DottedLine"></div><h3>Disopyramide Enhanced L-Type Calcium Channel Currents in SQTS1-hiPSC-CMs</h3><p class="mb0">Disopyramide (10 &#xb5;M) was applied to SQTS1-hiPSC-CMs through an extracellular perfusion-system to check the drug effects on L-type calcium channel currents (I<sub>Ca-L</sub>) evoked by stimulations at a fixed frequency (1&#xa0;Hz). The I<sub>Ca-L</sub> was significantly enhanced by 10 &#xb5;M disopyramide (<a href="#f6">Figures 6A, B</a>). The activation curve of I<sub>Ca-L</sub> was largely shifted to more negative potentials and the inactivation curve was only slightly shifted to more positive potentials, whereas the recovery from inactivation was decelerated (<a href="#f6">Figures 6C&#x2013;H</a>). In hiPSC-CMs from the healthy donor, disopyramide inhibited significantly I<sub>Ca-L</sub> (<a href="#h12">Figure S4</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 6</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg" alt="www.frontiersin.org" id="f6" loading="lazy">
  </picture>
</a><p><strong>Figure 6</strong> Effects of disopyramide on L-type calcium channel currents in SQTS1-hiPSC-CMs. The L-type Ca channel currents (I<sub>Ca-L</sub>) were evoked by the protocol indicated in <strong>(A)</strong>. <strong>(A)</strong> Current-voltage relationship (I-V) curves of I<sub>Ca-L</sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). <strong>(B)</strong> The representative traces of I<sub>Ca-L</sub> (upper panel) and current density (bottom panel) at 0 mV in absence (Ctr) and presence of disopyramide. <strong>(C)</strong> The activation curves of I<sub>Ca-L</sub>. <strong>(D)</strong> Mean values of the potential at 50% activation (V0.5). <strong>(E)</strong> The inactivation curves of I<sub>Ca-L</sub>. <strong>(F)</strong> Mean values of the potential at 50% inactivation (V0.5). <strong>(G)</strong> The curves of recovery of I<sub>Ca-L</sub> from inactivation. <strong>(H)</strong> Mean values of the time constants (tau) of the recovery curves. Shown are mean &#xb1; SEM, n represents number of cells. <sup>#</sup>p&lt;0.05.</p></div><div class="DottedLine"></div><h3>Disopyramide Enhanced the Na/Ca Exchanger Currents in SQTS1-hiPSC-CMs</h3><p class="mb0">To separate the Na/Ca exchanger current (I<sub>NCX</sub>) from other currents, NiCl<sub>2</sub> (5mM) was applied to cells and the NiCl<sub>2</sub>-sensitive currents were defined as I<sub>NCX</sub>. Disopyramide (10 &#xb5;M) increased I<sub>NCX</sub>, especially the inward current at negative potentials (<a href="#f7">Figures 7A&#x2013;C</a>). In hiPSC-CMs from the healthy donor, disopyramide enhanced also I<sub>NCX</sub> (<a href="#h12">Figure S5</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 7</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg" alt="www.frontiersin.org" id="f7" loading="lazy">
  </picture>
</a><p><strong>Figure 7</strong> Effects disopyramide on late Na channel and Na/Ca exchanger currents in SQTS1-hiPSC-CMs. Late Na channel currents (late I<sub>Na</sub>) were evoked by the protocol indicated in <strong>(D)</strong> and measured at 300 ms after initiation of the depolarization pulse. TTX (30&#xb5;M) sensitive currents were analyzed as late I<sub>Na</sub>. The Na/Ca exchanger currents (I<sub>NCX</sub>) were evoked by the protocol indicated in <strong>(A)</strong>. I<sub>NCX</sub> was analyzed as NiCL2 (5mM) sensitive currents. <strong>(A)</strong> Representative traces of I<sub>NCX</sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). <strong>(B)</strong> Mean values of I<sub>NXC</sub> at +60 mV in absence (Ctr) and presence of disopyramide. <strong>(C)</strong> Mean values of I<sub>NXC</sub> at -100 mV in absence (Ctr) and presence of disopyramide. <strong>(D)</strong> Representative traces of peak and late I<sub>Na</sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). <strong>(E)</strong> Mean values of late I<sub>Na</sub> at -40 mV in absence (Ctr) and presence of disopyramide. n, number of cells.</p></div><div class="DottedLine"></div><h3>Disopyramide Enhanced the Late Na Channel Currents in SQTS1-hiPSC-CMs</h3><p class="mb0">Measuring late Na channel current is challenging due to its small amplitude. To improve the measurements and reduced the influence of other currents, high concentration of extracellular Na concentration (140 mM) was used to increase the driving force and TTX (30&#xb5;M)-sensitive currents (late I<sub>Na</sub>) were analyzed at 300 ms after initiation of depolarizing pulse. Under this condition 10 &#xb5;M disopyramide enhanced significantly the late I<sub>Na</sub>, although it suppressed the peak I<sub>Na</sub> (<a href="#f7">Figures 7D, E</a>). In hiPSC-CMs from the healthy donor, disopyramide exerted similar effects (<a href="#h12">Figure S6</a>).</p><a id="h5" name="h5"></a><h2>Discussion</h2><p class="mb15">In the current study, for the first time, we investigated the ionic mechanism underlying the APD-prolonging and antiarrhythmic effects of disopyramide in hiPSC-CMs from a patient with SQTS type 1. The new findings in this study are: (1) Disopyramide enhanced I<sub>Ca-L</sub>, I<sub>NCX</sub> and late I<sub>Na</sub> in SQTS1-hiPSC-CMs; (2) Disopyramide reduced I<sub>SK</sub> in SQTS1-hiPSC-CMs. These effects may underlie the APD-prolonging and antiarrhythmic effect of disopyramide.</p><p class="mb15">Disopyramide is a class Ia antiarrhythmic drug used in the therapy of atrial and ventricular arrhythmias. A major feature of class Ia antiarrhythmic drugs is a use-dependent block of the cardiac fast sodium current, which underlies the suppression of excitability and conduction speed (<a href="#B33">Sunami et al., 1991</a>; <a href="#B41">Zunkler et al., 2000</a>). The sodium channel blocking is an important effect of class I antiarrhythmic drugs including disopyramide for terminating tachyarrhythmias.</p><p class="mb15">Disopyramide has been reported to prolong the QTc interval and is considered to be a promising agent for normalizing the QTc by blocking potassium channels (<a href="#B10">Dritsas et al., 1992</a>; <a href="#B30">Sherrid et al., 2005</a>; <a href="#B29">Schimpf et al., 2007</a>; <a href="#B19">Johnson et al., 2011</a>).</p><p class="mb15">Disopyramide has also anticholinergic effect that may contribute to QT prolongation (<a href="#B26">Mirro et al., 1980</a>; <a href="#B34">Teichman, 1985</a>). At cellular level, disopyramide has been shown to prolong APD (<a href="#B31">Shinnawi et al., 2019</a>), consistent with the QT-prolongation at organ level (<a href="#B27">Mizobuchi et al., 2008</a>). The APD-and QT-prolongation could be another reason for disopyramide effect terminating arrhythmias.</p><p class="mb15">In the current study, we used hiPSC-CMs from a patient with SQTS1 to examine the APD-prolonging and antiarrhythmic effects of disopyramide, mainly the ionic mechanisms of the effects. In the SQTS1-hiPSC-CMs, disopyramide changed significantly APs, mainly the Vmax, APD50, and APD90 and reduced arrhythmic events induced by CCh+Epi. The reduction of Vmax is consistent with its Na channel blocking effect (suppressing peak I<sub>Na</sub>). Both the reduction of Vmax and the APD-prolongation may contribute to the antiarrhythmic effect of disopyramide in SQTS1-hiPSC-CMs. However, how the APD was prolonged by disopyramide in SQTS1-hiPSC-CMs needs to be clarified.</p><p class="mb15">I<sub>Kr</sub> is an important repolarizing current for determining APD and is the target of many drugs that influence APD. Although the effect of disopyramide on I<sub>Kr</sub> has already been examined in different types of cells (<a href="#B38">Virag et al., 1998</a>; <a href="#B12">El Harchi et al., 2012b</a>), whether the APD-prolongation in SQTS1-hiPSC-CMs resulted from the suppression of I<sub>Kr</sub> by disopyramide is still unknown. The effect of disopyramide on I<sub>Kr</sub> has not been tested in SQTS1-hiPSC-CMs. In the current study, we examined the effects on I<sub>Kr</sub> in our SQTS1-hiPSC-CMs carrying the HERG channel mutation N588K, which has been well investigated and confirmed as a pathogenic mutation for SQTS1 (<a href="#B13">El-Battrawy et al., 2018</a>; <a href="#B31">Shinnawi et al., 2019</a>). The result is surprising, showing that disopyramide did not significantly reduce I<sub>Kr</sub> in our SQTS1-hiPSC-CMs, although it suppressed I<sub>Kr</sub> in donor-hiPSC-CMs. The HERG channel mutation (N588K) in our cells could be a reason for the ineffectiveness of disopyramide because the mutation has been shown to render I<sub>Kr</sub> resistant to other drugs (<a href="#B24">McPate et al., 2008</a>; <a href="#B31">Shinnawi et al., 2019</a>). Of note, in CHO cells expressing I<sub>Kr</sub> channels carrying N588K, disopyramide inhibited I<sub>Kr</sub> with an efficacy similar to that in cells expressing wild type I<sub>Kr</sub> channels (<a href="#B25">McPate et al., 2006</a>), indicating the mutation did not change the efficacy of disopyramide in CHO cells. Considering the difference between CHO cells and cardiomyocytes, we expect that some unknown factors in addition to the gene mutations can influence the drug effects. Why disopyramide did not inhibit I<sub>Kr</sub> in SQTS1-hiPSC-CMs remains to be clarified.</p><p class="mb15">The failure of I<sub>Kr</sub>-blocking suggests extra ionic mechanisms for the APD-prolongation by disopyramide in SQTS1-hiPSC-CMs. Therefore, other ion channel currents that may influence APD were investigated.</p><p class="mb15">Disopyramide was shown to block I<sub>Kur</sub> (<a href="#B2">Arechiga et al., 2008</a>), I<sub>KAch</sub>, and I<sub>to</sub> (<a href="#B38">Virag et al., 1998</a>), but those currents were found specifically or predominantly in atrial myocytes. It is unlikely that those three currents contribute to the APD-prolongation by disopyramide in ventricular-like hiPSC-CMs measured in this study. I<sub>Ks</sub> and I<sub>KATP</sub> can also influence APD in cardiomyocytes. Disopyramide did not change both currents in our study, indicating that both currents are not involved in the APD-prolongation by disopyramide. The I<sub>KATP</sub>, which is activated in ischemic/hypoxic conditions and leads to arrhythmogenic shortening of the APD, was reported to be suppressed by disopyramide (<a href="#B18">Horie et al., 1992</a>; <a href="#B9">de Lorenzi et al., 1995</a>). The disparity may result from differences of species or gene mutation related changes.</p><p class="mb15">I<sub>SK</sub>, another outward K channel current, can also influence APD (<a href="#B32">Skibsbye et al., 2014</a>; <a href="#B40">Zhang et al., 2014</a>). We observed that disopyramide, indeed, reduced I<sub>SK</sub> in our SQTS1- and donor-hiPSC-CMs, indicative of contribution of I<sub>SK</sub> to the APD-prolongation in the presence of disopyramide.</p><p class="mb15">Disopyramide was shown to inhibit I<sub>Ca-L</sub> in rabbit sinus node cells and sheep Purkinje fibers (<a href="#B8">Coraboeuf et al., 1988</a>; <a href="#B20">Kotake et al., 1988</a>). The second surprising finding in this study is the enhancement of I<sub>Ca-L</sub> by disopyramide in SQTS1-hiPSC-CMs. Since disopyramide inhibited I<sub>Ca-L</sub> in donor-hiPSC-CMs, the reason for the disparity is probably the mutation or disease related alteration. To date, the effect of disopyramide on I<sub>Ca-L</sub> has been not tested in cardiomyocytes from SQTS-patients. The enhancement of I<sub>Ca-L</sub> in SQTS1-hiPSC-CMs by disopyramide, which may contribute to APD-prolongation, suggests that the mutation in KCNH2 may cause changes in channels in addition to the HERG channel.</p><p class="mb15">The inward currents I<sub>NCX</sub> and late I<sub>Na</sub> may also influence APD. To our knowledge, disopyramide effect on I<sub>NCX</sub> has not been reported. Inhibitory effect of disopyramide on late I<sub>Na</sub> has been reported. A study showed that disopyramide inhibited persistent late human cardiac Na<sup>+</sup> currents conducted by inactivation-deficient mutant Na<sup>+</sup> channels (hNav1.5-CW mutant) expressed in HEK293 (<a href="#B39">Wang et al., 2013</a>). Another study demonstrated that when the fast component of I<sub>Na</sub> inactivation was removed by chloramine-T, I<sub>Na</sub> amplitude was reduced by disopyramide (20 &#xb5;M) (<a href="#B21">Koumi et al., 1992</a>). Those data indicate that disopyramide can reduced late I<sub>Na</sub>. In current study, we observed that disopyramide enhanced I<sub>NCX</sub> and late I<sub>Na</sub> in both donor and SQTS1 hiPSC-CMs. How disopyramide enhanced both currents is not clear. Given that other types of sodium channels including SCN10A and SCN1B are also expressed in cardiomyocytes, it could be possible that disopyramide can activate SCN10A or other ion channels or proteins that can enhance late I<sub>Na</sub>. Although exact mechanisms for the surprising findings in this study need to be clarified in future studies, these effects may help explain the APD-prolongation by disopyramide.</p><p class="mb15">Recently, a study (<a href="#B22">Blinova et al., 2019</a>) examined effects of two drugs (dofetilide and moxifloxacin) on QT-intervals in subjects and action potential durations in hiPSC-CMs from the same subjects. The study showed no significant correlation between the subject-specific APD response slopes and clinical QT response slopes to either moxifloxacin (P = 0.75) or dofetilide (P = 0.69). Similarly, no significant correlation was found between baseline QT and baseline APD measurements (P = 0.93). These results facilitate discussion into factors obscuring correlation between hiPSC-CM studies and clinical studies. In addition, the study hinted at the possibility that immaturity and inherent variability of iPSC-CMs may dim patient-specific drug response prediction in the clinic. Hence, to know the real effects of disopyramide in SQTS1-patients, clinical studies are still necessary in spite of the results in SQTS1-hiPSC-CMs.</p><p class="mb15">Other studies showed that disopyramide at 10 &#xb5;M caused EAD-like events and at 100 &#xb5;M caused ectopic beats (<a href="#B5">Bot et al., 2018</a>)&#xa0;and possess a high TdP (Torsade de pointes) risk (<a href="#B4">Blinova et al., 2018</a>). These studies suggest that when disopyramide, as many other antiarrhythmic drugs, is applied to patients, not only the antiarrhythmic but also the proarrhythmic effect should be considered.</p><p class="mb0">In summary, in SQTS1-hiPSC-CMs, the ionic mechanisms of disopyramide behind APD-prolonging and antiarrhythmic effects were investigated. The results demonstrated that the APD-prolonging and antiarrhythmic effects of disopyramide in SQTS1-hiPSC-CMs with N588K-HERG channels resulted from enhancing I<sub>Ca-L</sub>, I<sub>NCX</sub>, late I<sub>Na</sub>, and reducing I<sub>SK</sub> besides Na channel blocking.</p><h3>Study Limitations</h3><p class="mb15">Due to the difficulty to find SQTS1 patients from different families with the same mutation in HERG channels, we recruited only one SQTS1 patient for this study. Differences among individuals cannot be ruled out. However, the studies using cells from a single patient with a specific gene mutation may be also relevant, at least for precision medicine.</p><p class="mb15">The immaturity is another limitation of hiPSC-CMs to be considered. Without studies in mature human cardiomyocytes, the possibility that disopyramide displays effects in native cardiomyocytes of SQTS-patients different from that of the SQTS1-hiPSC-CMs cannot be excluded.</p><p class="mb0">Given the difference between hiPSC-CMs and adult human cardiomyocytes as well as the limitation of study in cells from only one patient, the clinical efficacy of disopyramide still needs to be examined in SQTS1-patients.</p><a id="h6" name="h6"></a><h2>Data Availability Statement</h2><p class="mb0">The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p><a id="h7" name="h7"></a><h2>Ethics Statement</h2><p class="mb0">The studies involving human participants were reviewed and approved by Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg (Stated in the manuscript). The patients/participants provided their written informed consent to participate in this study.</p><a id="h8" name="h8"></a><h2>Author Contributions</h2><p class="mb0">HL, QX, XL, RZ, and SL performed experiments and analyzed data. IE-B, LC, MB, XZ, and IA designed the study and wrote the paper. All authors contributed to the article and approved the submitted version.</p><a id="h9" name="h9"></a><h2>Funding</h2><p class="mb0">This study was supported by the German Center for Cardiovascular Research (DZHK) (81Z0500204) and National Natural Science Foundation of China (No. 31300947).</p><a id="h10" name="h10"></a><h2>Conflict of Interest</h2><p class="mb15">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><a id="h11" name="h11"></a><h2>Acknowledgments</h2><p class="mb0">We gratefully thank C. Liebetrau for excellent technical assistance. We thank the Chinese Scholarship Council (CSC) for the financial support for XL. Excellent technical support by the Stem Cell Unit, G&#xf6;ttingen is acknowledged.</p><a id="h12" name="h12"></a><h2>Supplementary Material</h2><p class="mb15">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fphar.2020.554422/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2020.554422/full#supplementary-material</a></p><a id="h13" name="h13"></a><h2>References</h2><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B1" id="B1"></a> Abriel, H., Rougier, J. S. (2013). beta-blockers in congenital short-QT syndrome as ion channel blockers. <i>J. Cardiovasc. Electrophysiol.</i> 24, 1172&#x2013;1174. doi: 10.1111/jce.12204</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23890274/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/jce.12204" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Abriel&amp;author=J.%20S.+Rougier&amp;publication_year=2013&amp;title=beta-blockers%20in%20congenital%20short-QT%20syndrome%20as%20ion%20channel%20blockers&amp;journal=J.+Cardiovasc.+Electrophysiol.&amp;volume=24&amp;pages=1172" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B2" id="B2"></a> Arechiga, I. A., Barrio-Echavarria, G. F., Rodriguez-Menchaca, A. A., Moreno-Galindo, E. G., Decher, N., Tristani-Firouzi, M., et al. (2008). Kv1.5 open channel block by the antiarrhythmic drug disopyramide: molecular determinants of block. <i>J. Pharmacol. Sci.</i> 108, 49&#x2013;55. doi: 10.1254/jphs.08084FP</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18818480/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1254/jphs.08084FP" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I.%20A.+Arechiga&amp;author=G.%20F.+Barrio-Echavarria&amp;author=A.%20A.+Rodriguez-Menchaca&amp;author=E.%20G.+Moreno-Galindo&amp;author=N.+Decher&amp;author=M.+Tristani-Firouzi&amp;publication_year=2008&amp;title=Kv1.5%20open%20channel%20block%20by%20the%20antiarrhythmic%20drug%20disopyramide%3A%20molecular%20determinants%20of%20block&amp;journal=J.+Pharmacol.+Sci.&amp;volume=108&amp;pages=49" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B3" id="B3"></a> Bjerregaard, P. (2018). The diagnosis and management of short QT syndrome. <i>Heart Rhythm.</i> 15 (8), 1261&#x2013;1267. doi:&#xa0;10.1016/j.hrthm.2018.02.034</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29501667/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.hrthm.2018.02.034" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P.+Bjerregaard&amp;publication_year=2018&amp;title=The%20diagnosis%20and%20management%20of%20short%20QT%20syndrome&amp;journal=Heart+Rhythm.&amp;volume=15&amp;pages=1261" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B4" id="B4"></a> Blinova, K., Schocken, D., Patel, D., Daluwatte, C., Vicente, J., Wu, J. C., et al. (2019). Clinical trial in a dish: Personalized stem cell-derived cardiomyocyte assay compared with clinical trial results for two QT-prolonging drugs. <i>Clin Transl Sci.</i> 12 (6), 687&#x2013;697. doi: 10.1111/cts.12674</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31328865/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cts.12674" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K.+Blinova&amp;author=D.+Schocken&amp;author=D.+Patel&amp;author=C.+Daluwatte&amp;author=J.+Vicente&amp;author=J.%20C.+Wu&amp;publication_year=2019&amp;title=Clinical%20trial%20in%20a%20dish%3A%20Personalized%20stem%20cell-derived%20cardiomyocyte%20assay%20compared%20with%20clinical%20trial%20results%20for%20two%20QT-prolonging%20drugs&amp;journal=Clin+Transl+Sci.&amp;volume=12&amp;pages=687" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B5" id="B5"></a> Bot, C. T., Juhasz, K., Haeusermann, F., Polonchuk, L., Traebert, M., Stoelzle-Feix, S. (2018). Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes. <i>J. Pharmacol. Toxicol. Methods</i> 93, 46&#x2013;58. doi: 10.1016/j.vascn.2018.06.006</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29940218/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.vascn.2018.06.006" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C.%20T.+Bot&amp;author=K.+Juhasz&amp;author=F.+Haeusermann&amp;author=L.+Polonchuk&amp;author=M.+Traebert&amp;author=S.+Stoelzle-Feix&amp;publication_year=2018&amp;title=Cross%20-%20site%20comparison%20of%20excitation-contraction%20coupling%20using%20impedance%20and%20field%20potential%20recordings%20in%20hiPSC%20cardiomyocytes&amp;journal=J.+Pharmacol.+Toxicol.+Methods&amp;volume=93&amp;pages=46" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B6" id="B6"></a> Brugada, R., Hong, K., Dumaine, R., Cordeiro, J., Gaita, F., Borggrefe, M., et al. (2004). Sudden death associated with short-QT syndrome linked to mutations in HERG. <i>Circulation</i> 109, 30&#x2013;35. doi: 10.1161/01.CIR.0000109482.92774.3A</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/14676148/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/01.CIR.0000109482.92774.3A" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Brugada&amp;author=K.+Hong&amp;author=R.+Dumaine&amp;author=J.+Cordeiro&amp;author=F.+Gaita&amp;author=M.+Borggrefe&amp;publication_year=2004&amp;title=Sudden%20death%20associated%20with%20short-QT%20syndrome%20linked%20to%20mutations%20in%20HERG&amp;journal=Circulation&amp;volume=109&amp;pages=30" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B7" id="B7"></a> Campuzano, O., Sarquella-Brugada, G., Cesar, S., Arbelo, E., Brugada, J., Brugada, R. (2018). Recent Advances in Short QT Syndrome. <i>Front. Cardiovasc. Med.</i> 5, 149. doi: 10.3389/fcvm.2018.00149</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30420954/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fcvm.2018.00149" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=O.+Campuzano&amp;author=G.+Sarquella-Brugada&amp;author=S.+Cesar&amp;author=E.+Arbelo&amp;author=J.+Brugada&amp;author=R.+Brugada&amp;publication_year=2018&amp;title=Recent%20Advances%20in%20Short%20QT%20Syndrome&amp;journal=Front.+Cardiovasc.+Med.&amp;volume=5&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B8" id="B8"></a> Coraboeuf, E., Deroubaix, E., Escande, D., Coulombe, A. (1988). Comparative effects of three class I antiarrhythmic drugs on plateau and pacemaker currents of sheep cardiac Purkinje fibres. <i>Cardiovasc. Res.</i> 22, 375&#x2013;384. doi: 10.1093/cvr/22.6.375</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/2852055/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/cvr/22.6.375" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E.+Coraboeuf&amp;author=E.+Deroubaix&amp;author=D.+Escande&amp;author=A.+Coulombe&amp;publication_year=1988&amp;title=Comparative%20effects%20of%20three%20class%20I%20antiarrhythmic%20drugs%20on%20plateau%20and%20pacemaker%20currents%20of%20sheep%20cardiac%20Purkinje%20fibres&amp;journal=Cardiovasc.+Res.&amp;volume=22&amp;pages=375" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B9" id="B9"></a> de Lorenzi, F. G., Bridal, T. R., Spinelli, W. (1995). Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes. <i>J. Pharmacol. Exp. Ther.</i> 272, 714&#x2013;723.
</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/7853185/" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.%20G.+de%20Lorenzi&amp;author=T.%20R.+Bridal&amp;author=W.+Spinelli&amp;publication_year=1995&amp;title=Voltage-dependent%20inhibition%20of%20the%20ATP-sensitive%20K%2B%20current%20by%20the%20class%20Ia%20agent%20disopyramide%20in%20cat%20ventricular%20myocytes&amp;journal=J.+Pharmacol.+Exp.+Ther.&amp;volume=272&amp;pages=714" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B10" id="B10"></a> Dritsas, A., Sbarouni, E., Gilligan, D., Nihoyannopoulos, P., Oakley, C. M. (1992). QT-interval abnormalities in hypertrophic cardiomyopathy. <i>Clin. Cardiol.</i> 15, 739&#x2013;742. doi: 10.1002/clc.4960151010</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/1395184/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/clc.4960151010" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Dritsas&amp;author=E.+Sbarouni&amp;author=D.+Gilligan&amp;author=P.+Nihoyannopoulos&amp;author=C.%20M.+Oakley&amp;publication_year=1992&amp;title=QT-interval%20abnormalities%20in%20hypertrophic%20cardiomyopathy&amp;journal=Clin.+Cardiol.&amp;volume=15&amp;pages=739" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B11" id="B11"></a> El Harchi, A., Melgari, D., Zhang, Y. H., Zhang, H., Hancox, J. C. (2012a). Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K(+) channel. <i>PLoS One</i> 7, e52451. doi: 10.1371/journal.pone.0052451</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23300672/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0052451" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+El%20Harchi&amp;author=D.+Melgari&amp;author=Y.%20H.+Zhang&amp;author=H.+Zhang&amp;author=J.%20C.+Hancox&amp;publication_year=2012&amp;title=Action%20potential%20clamp%20and%20pharmacology%20of%20the%20variant%201%20Short%20QT%20Syndrome%20T618I%20hERG%20K%28%2B%29%20channel&amp;journal=PLoS+One&amp;volume=7&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B12" id="B12"></a> El Harchi, A., Zhang, Y. H., Hussein, L., Dempsey, C. E., Hancox, J. C. (2012b). Molecular determinants of hERG potassium channel inhibition by disopyramide. <i>J. Mol. Cell. Cardiol.</i> 52, 185&#x2013;195. doi: 10.1016/j.yjmcc.2011.09.021</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21989164/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.yjmcc.2011.09.021" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+El%20Harchi&amp;author=Y.%20H.+Zhang&amp;author=L.+Hussein&amp;author=C.%20E.+Dempsey&amp;author=J.%20C.+Hancox&amp;publication_year=2012&amp;title=Molecular%20determinants%20of%20hERG%20potassium%20channel%20inhibition%20by%20disopyramide&amp;journal=J.+Mol.+Cell.+Cardiol.&amp;volume=52&amp;pages=185" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B13" id="B13"></a> El-Battrawy, I., Lan, H., Cyganek, L., Zhao, Z., Li, X., Buljubasic, F., et al. (2018). Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>J. Am. Heart Assoc.</i> 7 (7), e007394. doi: 10.1161/JAHA.117.007394</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29574456/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/JAHA.117.007394" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I.+El-Battrawy&amp;author=H.+Lan&amp;author=L.+Cyganek&amp;author=Z.+Zhao&amp;author=X.+Li&amp;author=F.+Buljubasic&amp;publication_year=2018&amp;title=Modeling%20Short%20QT%20Syndrome%20Using%20Human-Induced%20Pluripotent%20Stem%20Cell-Derived%20Cardiomyocytes&amp;journal=J.+Am.+Heart+Assoc.&amp;volume=7&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B14" id="B14"></a> Gaita, F., Giustetto, C., Bianchi, F., Schimpf, R., Haissaguerre, M., Calo, L., et al. (2004). Short QT syndrome: pharmacological treatment. <i>J. Am. Coll. Cardiol.</i> 43, 1494&#x2013;1499. doi: 10.1016/j.jacc.2004.02.034</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15093889/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2004.02.034" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Gaita&amp;author=C.+Giustetto&amp;author=F.+Bianchi&amp;author=R.+Schimpf&amp;author=M.+Haissaguerre&amp;author=L.+Calo&amp;publication_year=2004&amp;title=Short%20QT%20syndrome%3A%20pharmacological%20treatment&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=43&amp;pages=1494" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B15" id="B15"></a> Giustetto, C., Di Monte, F., Wolpert, C., Borggrefe, M., Schimpf, R., Sbragia, P., et al. (2006). Short QT syndrome: clinical findings and diagnostic-therapeutic implications. <i>Eur. Heart J.</i> 27, 2440&#x2013;2447. doi: 10.1093/eurheartj/ehl185</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16926178/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehl185" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C.+Giustetto&amp;author=F.+Di%20Monte&amp;author=C.+Wolpert&amp;author=M.+Borggrefe&amp;author=R.+Schimpf&amp;author=P.+Sbragia&amp;publication_year=2006&amp;title=Short%20QT%20syndrome%3A%20clinical%20findings%20and%20diagnostic-therapeutic%20implications&amp;journal=Eur.+Heart+J.&amp;volume=27&amp;pages=2440" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B16" id="B16"></a> Giustetto, C., Schimpf, R., Mazzanti, A., Scrocco, C., Maury, P., Anttonen, O., et al. (2011). Long-term follow-up of patients with short QT syndrome. <i>J. Am. Coll. Cardiol.</i> 58, 587&#x2013;595. doi: 10.1016/j.jacc.2011.03.038</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21798421/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2011.03.038" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C.+Giustetto&amp;author=R.+Schimpf&amp;author=A.+Mazzanti&amp;author=C.+Scrocco&amp;author=P.+Maury&amp;author=O.+Anttonen&amp;publication_year=2011&amp;title=Long-term%20follow-up%20of%20patients%20with%20short%20QT%20syndrome&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=58&amp;pages=587" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B17" id="B17"></a> Gussak, I., Brugada, P., Brugada, J., Wright, R. S., Kopecky, S. L., Chaitman, B. R., et al. (2000). Idiopathic short QT interval: a new clinical syndrome? <i>Cardiology</i> 94, 99&#x2013;102. doi: 10.1159/000047299</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/11173780/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1159/000047299" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I.+Gussak&amp;author=P.+Brugada&amp;author=J.+Brugada&amp;author=R.%20S.+Wright&amp;author=S.%20L.+Kopecky&amp;author=B.%20R.+Chaitman&amp;publication_year=2000&amp;title=Idiopathic%20short%20QT%20interval%3A%20a%20new%20clinical%20syndrome&amp;journal=Cardiology&amp;volume=94&amp;pages=99" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B18" id="B18"></a> Horie, M., Hayashi, S., Yuzuki, Y., Sasayama, S. (1992). Comparative studies of ATP sensitive potassium channels in heart and pancreatic beta cells using Vaughan-Williams class Ia antiarrhythmics. <i>Cardiovasc. Res.</i> 26, 1087&#x2013;1094. doi: 10.1093/cvr/26.11.1087</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/1291086/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/cvr/26.11.1087" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Horie&amp;author=S.+Hayashi&amp;author=Y.+Yuzuki&amp;author=S.+Sasayama&amp;publication_year=1992&amp;title=Comparative%20studies%20of%20ATP%20sensitive%20potassium%20channels%20in%20heart%20and%20pancreatic%20beta%20cells%20using%20Vaughan-Williams%20class%20Ia%20antiarrhythmics&amp;journal=Cardiovasc.+Res.&amp;volume=26&amp;pages=1087" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B19" id="B19"></a> Johnson, J. N., Grifoni, C., Bos, J. M., Saber-Ayad, M., Ommen, S. R., Nistri, S., et al. (2011). Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. <i>Eur. Heart J.</i> 32, 1114&#x2013;1120. doi: 10.1093/eurheartj/ehr021</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21345853/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehr021" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J.%20N.+Johnson&amp;author=C.+Grifoni&amp;author=J.%20M.+Bos&amp;author=M.+Saber-Ayad&amp;author=S.%20R.+Ommen&amp;author=S.+Nistri&amp;publication_year=2011&amp;title=Prevalence%20and%20clinical%20correlates%20of%20QT%20prolongation%20in%20patients%20with%20hypertrophic%20cardiomyopathy&amp;journal=Eur.+Heart+J.&amp;volume=32&amp;pages=1114" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B20" id="B20"></a> Kotake, H., Hasegawa, J., Mashiba, H. (1988). Effect of class I antiarrhythmic agents on slow Ca2+ channels of myocardial cells. <i>Jpn Circ. J.</i> 52, 238&#x2013;242. doi: 10.1253/jcj.52.238</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/2453688/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1253/jcj.52.238" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Kotake&amp;author=J.+Hasegawa&amp;author=H.+Mashiba&amp;publication_year=1988&amp;title=Effect%20of%20class%20I%20antiarrhythmic%20agents%20on%20slow%20Ca2%2B%20channels%20of%20myocardial%20cells&amp;journal=Jpn+Circ.+J.&amp;volume=52&amp;pages=238" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B21" id="B21"></a> Koumi, S., Sato, R., Hisatome, I., Hayakawa, H., Okumura, H., Katori, R. (1992). Disopyramide block of cardiac sodium current after removal of the fast inactivation process in guinea pig ventricular myocytes. <i>J. Pharmacol. Exp. Ther.</i> 261, 1167&#x2013;1174.
</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/1318373/" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+Koumi&amp;author=R.+Sato&amp;author=I.+Hisatome&amp;author=H.+Hayakawa&amp;author=H.+Okumura&amp;author=R.+Katori&amp;publication_year=1992&amp;title=Disopyramide%20block%20of%20cardiac%20sodium%20current%20after%20removal%20of%20the%20fast%20inactivation%20process%20in%20guinea%20pig%20ventricular%20myocytes&amp;journal=J.+Pharmacol.+Exp.+Ther.&amp;volume=261&amp;pages=1167" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B22" id="B22"></a> Blinova, K., Schocken, D., Patel, D., Daluwatte, C., Vicente, J., Wu, J. C., et al. (2019). Clinical Trial in a Dish: Personalized Stem Cell&#x2013;DerivedCardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs. <i>Citation: Clin. Transl. Sci.</i> 12, 687&#x2013;697. doi: 10.1111/cts.12674</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1111/cts.12674" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K.+Blinova&amp;author=D.+Schocken&amp;author=D.+Patel&amp;author=C.+Daluwatte&amp;author=J.+Vicente&amp;author=J.%20C.+Wu&amp;publication_year=2019&amp;title=Clinical%20Trial%20in%20a%20Dish%3A%20Personalized%20Stem%20Cell%E2%80%93DerivedCardiomyocyte%20Assay%20Compared%20With%20Clinical%20Trial%20Results%20for%20Two%20QT-Prolonging%20Drugs&amp;journal=Citation:+Clin.+Transl.+Sci.&amp;volume=12&amp;pages=687" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B23" id="B23"></a> Mazzanti, A., Kanthan, A., Monteforte, N., Memmi, M., Bloise, R., Novelli, V., et al. (2014). Novel insight into the natural history of short QT syndrome. <i>J. Am. Coll. Cardiol.</i> 63, 1300&#x2013;1308. doi: 10.1016/j.jacc.2013.09.078</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24291113/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2013.09.078" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Mazzanti&amp;author=A.+Kanthan&amp;author=N.+Monteforte&amp;author=M.+Memmi&amp;author=R.+Bloise&amp;author=V.+Novelli&amp;publication_year=2014&amp;title=Novel%20insight%20into%20the%20natural%20history%20of%20short%20QT%20syndrome&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=63&amp;pages=1300" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B24" id="B24"></a> McPate, M. J., Duncan, R. S., Hancox, J. C., Witchel, H. J. (2008). Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. <i>Br. J. Pharmacol.</i> 155, 957&#x2013;966. doi: 10.1038/bjp.2008.325</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18724381/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/bjp.2008.325" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.%20J.+McPate&amp;author=R.%20S.+Duncan&amp;author=J.%20C.+Hancox&amp;author=H.%20J.+Witchel&amp;publication_year=2008&amp;title=Pharmacology%20of%20the%20short%20QT%20syndrome%20N588K-hERG%20K%2B%20channel%20mutation%3A%20differential%20impact%20on%20selected%20class%20I%20and%20class%20III%20antiarrhythmic%20drugs&amp;journal=Br.+J.+Pharmacol.&amp;volume=155&amp;pages=957" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B25" id="B25"></a> McPate, M. J., Duncan, R. S., Witchel, H. J., Hancox, J. C. (2006). Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. <i>J. Mol. Cell. Cardiol.</i> 41, 563&#x2013;566. doi: 10.1016/j.yjmcc.2006.05.021</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16842817/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.yjmcc.2006.05.021" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.%20J.+McPate&amp;author=R.%20S.+Duncan&amp;author=H.%20J.+Witchel&amp;author=J.%20C.+Hancox&amp;publication_year=2006&amp;title=Disopyramide%20is%20an%20effective%20inhibitor%20of%20mutant%20HERG%20K%2B%20channels%20involved%20in%20variant%201%20short%20QT%20syndrome&amp;journal=J.+Mol.+Cell.+Cardiol.&amp;volume=41&amp;pages=563" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B26" id="B26"></a> Mirro, M. J., Manalan, A. S., Bailey, J. C., Watanabe, A. M. (1980). Anticholinergic effects of disopyramide and quinidine on guinea pig myocardium. Mediation by direct muscarinic receptor blockade. <i>Circ. Res.</i> 47, 855&#x2013;865. doi: 10.1161/01.RES.47.6.855</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/7192183/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/01.RES.47.6.855" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.%20J.+Mirro&amp;author=A.%20S.+Manalan&amp;author=J.%20C.+Bailey&amp;author=A.%20M.+Watanabe&amp;publication_year=1980&amp;title=Anticholinergic%20effects%20of%20disopyramide%20and%20quinidine%20on%20guinea%20pig%20myocardium.%20Mediation%20by%20direct%20muscarinic%20receptor%20blockade&amp;journal=Circ.+Res.&amp;volume=47&amp;pages=855" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B27" id="B27"></a> Mizobuchi, M., Enjoji, Y., Yamamoto, R., Ono, T., Funatsu, A., Kambayashi, D., et al. (2008). Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties. <i>Pacing Clin. Electrophysiol. PACE</i> 31, 1229&#x2013;1232. doi: 10.1111/j.1540-8159.2008.01169.x</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1111/j.1540-8159.2008.01169.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Mizobuchi&amp;author=Y.+Enjoji&amp;author=R.+Yamamoto&amp;author=T.+Ono&amp;author=A.+Funatsu&amp;author=D.+Kambayashi&amp;publication_year=2008&amp;title=Nifekalant%20and%20disopyramide%20in%20a%20patient%20with%20short%20QT%20syndrome%3A%20evaluation%20of%20pharmacological%20effects%20and%20electrophysiological%20properties&amp;journal=Pacing+Clin.+Electrophysiol.+PACE&amp;volume=31&amp;pages=1229" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B28" id="B28"></a> Morady, F., Scheinman, M. M., Desai, J. (1982). Disopyramide. <i>Ann. Internal Med.</i> 96, 337&#x2013;343. doi: 10.7326/0003-4819-96-3-337</p><p class="ReferencesCopy2"><a href="https://doi.org/10.7326/0003-4819-96-3-337" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Morady&amp;author=M.%20M.+Scheinman&amp;author=J.+Desai&amp;publication_year=1982&amp;title=Disopyramide&amp;journal=Ann.+Internal+Med.&amp;volume=96&amp;pages=337" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B29" id="B29"></a> Schimpf, R., Veltmann, C., Giustetto, C., Gaita, F., Borggrefe, M., Wolpert, C. (2007). In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study. <i>J. Cardiovasc. Electrophysiol.</i> 18, 1157&#x2013;1160. doi: 10.1111/j.1540-8167.2007.00925.x</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/17711440/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/j.1540-8167.2007.00925.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Schimpf&amp;author=C.+Veltmann&amp;author=C.+Giustetto&amp;author=F.+Gaita&amp;author=M.+Borggrefe&amp;author=C.+Wolpert&amp;publication_year=2007&amp;title=In%20vivo%20effects%20of%20mutant%20HERG%20K%2B%20channel%20inhibition%20by%20disopyramide%20in%20patients%20with%20a%20short%20QT-1%20syndrome%3A%20a%20pilot%20study&amp;journal=J.+Cardiovasc.+Electrophysiol.&amp;volume=18&amp;pages=1157" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B30" id="B30"></a> Sherrid, M. V., Barac, I., McKenna, W. J., Elliott, P. M., Dickie, S., Chojnowska, L., et al. (2005). Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. <i>J. Am. Coll. Cardiol.</i> 45, 1251&#x2013;1258. doi: 10.1016/j.jacc.2005.01.012</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15837258/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2005.01.012" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.%20V.+Sherrid&amp;author=I.+Barac&amp;author=W.%20J.+McKenna&amp;author=P.%20M.+Elliott&amp;author=S.+Dickie&amp;author=L.+Chojnowska&amp;publication_year=2005&amp;title=Multicenter%20study%20of%20the%20efficacy%20and%20safety%20of%20disopyramide%20in%20obstructive%20hypertrophic%20cardiomyopathy&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=45&amp;pages=1251" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B31" id="B31"></a> Shinnawi, R., Shaheen, N., Huber, I., Shiti, A., Arbel, G., Gepstein, A., et al. (2019). Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets. <i>J. Am. Coll. Cardiol.</i> 73, 2310&#x2013;2324. doi: 10.1016/j.jacc.2019.02.055</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31072576/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2019.02.055" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Shinnawi&amp;author=N.+Shaheen&amp;author=I.+Huber&amp;author=A.+Shiti&amp;author=G.+Arbel&amp;author=A.+Gepstein&amp;publication_year=2019&amp;title=Modeling%20Reentry%20in%20the%20Short%20QT%20Syndrome%20With%20Human-Induced%20Pluripotent%20Stem%20Cell-Derived%20Cardiac%20Cell%20Sheets&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=73&amp;pages=2310" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B32" id="B32"></a> Skibsbye, L., Poulet, C., Diness, J. G., Bentzen, B. H., Yuan, L., Kappert, U., et al. (2014). Small-conductance calcium-activated potassium (SK) channels contribute to action potential repolarization in human atria. <i>Cardiovasc. Res.</i> 103, 156&#x2013;167. doi: 10.1093/cvr/cvu121</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24817686/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/cvr/cvu121" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L.+Skibsbye&amp;author=C.+Poulet&amp;author=J.%20G.+Diness&amp;author=B.%20H.+Bentzen&amp;author=L.+Yuan&amp;author=U.+Kappert&amp;publication_year=2014&amp;title=Small-conductance%20calcium-activated%20potassium%20%28SK%29%20channels%20contribute%20to%20action%20potential%20repolarization%20in%20human%20atria&amp;journal=Cardiovasc.+Res.&amp;volume=103&amp;pages=156" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B33" id="B33"></a> Sunami, A., Fan, Z., Nitta, J., Hiraoka, M. (1991). Two components of use-dependent block of Na+ current by disopyramide and lidocaine in guinea pig ventricular myocytes. <i>Circ. Res.</i> 68, 653&#x2013;661. doi: 10.1161/01.RES.68.3.653</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/1660356/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/01.RES.68.3.653" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Sunami&amp;author=Z.+Fan&amp;author=J.+Nitta&amp;author=M.+Hiraoka&amp;publication_year=1991&amp;title=Two%20components%20of%20use-dependent%20block%20of%20Na%2B%20current%20by%20disopyramide%20and%20lidocaine%20in%20guinea%20pig%20ventricular%20myocytes&amp;journal=Circ.+Res.&amp;volume=68&amp;pages=653" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B34" id="B34"></a> Teichman, S. (1985). The anticholinergic side effects of disopyramide and controlled-release disopyramide. <i>Angiology</i> 36, 767&#x2013;771. doi: 10.1177/000331978503601101</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/4061965/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1177/000331978503601101" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+Teichman&amp;publication_year=1985&amp;title=The%20anticholinergic%20side%20effects%20of%20disopyramide%20and%20controlled-release%20disopyramide&amp;journal=Angiology&amp;volume=36&amp;pages=767" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B35" id="B35"></a> Thorsen, K., Dam, V. S., Kjaer-Sorensen, K., Pedersen, L. N., Skeberdis, V. A., Jurevicius, J., et al. (2017). Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome. <i>Nat. Commun.</i> 8, 1696. doi: 10.1038/s41467-017-01630-0</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29167417/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41467-017-01630-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K.+Thorsen&amp;author=V.%20S.+Dam&amp;author=K.+Kjaer-Sorensen&amp;author=L.%20N.+Pedersen&amp;author=V.%20A.+Skeberdis&amp;author=J.+Jurevicius&amp;publication_year=2017&amp;title=Loss-of-activity-mutation%20in%20the%20cardiac%20chloride-bicarbonate%20exchanger%20AE3%20causes%20short%20QT%20syndrome&amp;journal=Nat.+Commun.&amp;volume=8&amp;pages=1696" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B36" id="B36"></a> Tiburcy, M., Hudson, J. E., Balfanz, P., Schlick, S., Meyer, T., Chang Liao, M. L., et al. (2017). Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. <i>Circulation</i> 135, 1832&#x2013;1847. doi: 10.1161/CIRCULATIONAHA.116.024145</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28167635/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCULATIONAHA.116.024145" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Tiburcy&amp;author=J.%20E.+Hudson&amp;author=P.+Balfanz&amp;author=S.+Schlick&amp;author=T.+Meyer&amp;author=M.%20L.+Chang%20Liao&amp;publication_year=2017&amp;title=Defined%20Engineered%20Human%20Myocardium%20With%20Advanced%20Maturation%20for%20Applications%20in%20Heart%20Failure%20Modeling%20and%20Repair&amp;journal=Circulation&amp;volume=135&amp;pages=1832" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B37" id="B37"></a> Verlinden, N. J., Coons, J. C. (2015). Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. <i>Pharmacotherapy</i> 35, 1164&#x2013;1172. doi: 10.1002/phar.1664</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26684556/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/phar.1664" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N.%20J.+Verlinden&amp;author=J.%20C.+Coons&amp;publication_year=2015&amp;title=Disopyramide%20for%20Hypertrophic%20Cardiomyopathy%3A%20A%20Pragmatic%20Reappraisal%20of%20an%20Old%20Drug&amp;journal=Pharmacotherapy&amp;volume=35&amp;pages=1164" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B38" id="B38"></a> Virag, L., Varro, A., Papp, J. G. (1998). Effect of disopyramide on potassium currents in rabbit ventricular myocytes. <i>Naunyn-Schmiedeberg&#x2019;s Arch. Pharmacol.</i> 357, 268&#x2013;275. doi: 10.1007/pl00005167</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1007/pl00005167" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L.+Virag&amp;author=A.+Varro&amp;author=J.%20G.+Papp&amp;publication_year=1998&amp;title=Effect%20of%20disopyramide%20on%20potassium%20currents%20in%20rabbit%20ventricular%20myocytes&amp;journal=Naunyn-Schmiedeberg&#x2019;s+Arch.+Pharmacol.&amp;volume=357&amp;pages=268" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B39" id="B39"></a> Wang, G. K., Russell, G., Wang, S. Y. (2013). Persistent human cardiac Na+ currents in stably transfected mammalian cells: Robust expression and distinct open-channel selectivity among Class 1 antiarrhythmics. <i>Channels (Austin)</i> 7, 263&#x2013;274. doi: 10.4161/chan.25056</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23695971/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4161/chan.25056" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G.%20K.+Wang&amp;author=G.+Russell&amp;author=S.%20Y.+Wang&amp;publication_year=2013&amp;title=Persistent%20human%20cardiac%20Na%2B%20currents%20in%20stably%20transfected%20mammalian%20cells%3A%20Robust%20expression%20and%20distinct%20open-channel%20selectivity%20among%20Class%201%20antiarrhythmics&amp;journal=Channels+(Austin)&amp;volume=7&amp;pages=263" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B40" id="B40"></a> Zhang, X. D., Timofeyev, V., Li, N., Myers, R. E., Zhang, D. M., Singapuri, A., et al. (2014). Critical roles of a small conductance Ca(2)(+)-activated K(+) channel (SK3) in the repolarization process of atrial myocytes. <i>Cardiovasc. Res.</i> 101, 317&#x2013;325. doi: 10.1093/cvr/cvt262</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24282291/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/cvr/cvt262" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X.%20D.+Zhang&amp;author=V.+Timofeyev&amp;author=N.+Li&amp;author=R.%20E.+Myers&amp;author=D.%20M.+Zhang&amp;author=A.+Singapuri&amp;publication_year=2014&amp;title=Critical%20roles%20of%20a%20small%20conductance%20Ca%282%29%28%2B%29-activated%20K%28%2B%29%20channel%20%28SK3%29%20in%20the%20repolarization%20process%20of%20atrial%20myocytes&amp;journal=Cardiovasc.+Res.&amp;volume=101&amp;pages=317" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em;"><p class="ReferencesCopy1"><a name="B41" id="B41"></a> Zunkler, B. J., Kuhne, S., Rustenbeck, I., Ott, T., Hildebrandt, A. G. (2000). Disopyramide block of K(ATP) channels is mediated by the pore-forming subunit. <i>Life Sci.</i> 66, PL 245&#x2013;PL 252. doi: 10.1016/s0024-3205(00)00486-0</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1016/s0024-3205(00)00486-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B.%20J.+Zunkler&amp;author=S.+Kuhne&amp;author=I.+Rustenbeck&amp;author=T.+Ott&amp;author=A.%20G.+Hildebrandt&amp;publication_year=2000&amp;title=Disopyramide%20block%20of%20K%28ATP%29%20channels%20is%20mediated%20by%20the%20pore-forming%20subunit&amp;journal=Life+Sci.&amp;volume=66&amp;pages=PL 245" target="_blank">Google Scholar</a></p></div></div><div class="thinLineM20"></div><div class="AbstractSummary"><p><span>Keywords:</span> short QT syndrome, arrhythmias, antiarrhythmic drugs, disopyramide, human-induced pluripotent stem cell-derived cardiomyocytes</p><p><span>Citation:</span> Lan H, Xu Q, El-Battrawy I, Zhong R, Li X, Lang S, Cyganek L, Borggrefe M, Zhou X and Akin I (2020) Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. <i>Front. Pharmacol.</i> 11:554422. doi: 10.3389/fphar.2020.554422</p><p id="timestamps"><span>Received:</span> 22 April 2020; <span>Accepted:</span> 16 September 2020;<br><span>Published:</span> 12 October 2020.</p><div><p>Edited by:</p><a href="https://loop.frontiersin.org/people/23236">Nicolau Beckmann</a>, Novartis Institutes for BioMedical Research, Switzerland</div><div><p>Reviewed by:</p><a href="https://loop.frontiersin.org/people/973222">Andrea Anampa-Guzm&#xe1;n</a>, National University of San Marcos, Peru<br><a href="https://loop.frontiersin.org/people/31911">RaffaEle Coppini</a>, University of Florence, Italy<br><a href="https://loop.frontiersin.org/people/465333">Ksenia Blinova</a>, United States Food and Drug Administration, United States</div><p><span>Copyright</span> &#xa9; 2020 Lan, Xu, El-Battrawy, Zhong, Li, Lang, Cyganek, Borggrefe, Zhou and Akin. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p><p><span>*Correspondence:</span> Xiaobo Zhou, <a id="encmail">WGlhb2JvLnpob3VAbWVkbWEudW5pLWhlaWRlbGJlcmcuZGU=</a></p><p><span><sup>&#x2020;</sup></span>These authors have contributed equally to this work</p><div class="clear"></div></div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fphar.2020.554422" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">3K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">1,2K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">12</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/554422#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fphar.2020.554422" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fphar.2020.554422" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/23236/overview" data-event="editorInfo-a-nicolauBeckmann" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">N</span><span class="notranslate">B</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Nicolau  Beckmann</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Novartis Institutes for BioMedical Research, Switzerland</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/31911/overview" data-event="editorInfo-a-raffaEleCoppini" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">R</span><span class="notranslate">C</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">RaffaEle  Coppini</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of Florence, Italy</div></div></a><a href="https://loop.frontiersin.org/people/465333/overview" data-event="editorInfo-a-kseniaBlinova" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">K</span><span class="notranslate">B</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Ksenia  Blinova</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">United States Food and Drug Administration, United States</div></div></a><a href="https://loop.frontiersin.org/people/973222/overview" data-event="editorInfo-a-andreaAnampaGuzmn" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">A</span><span class="notranslate">A</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Andrea  Anampa-Guzmn</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">National University of San Marcos, Peru</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"><li><a href="#h1">Abstract</a></li><li><a href="#h2">Introduction</a></li><li><a href="#h3">Methods</a></li><li><a href="#h4">Results</a></li><li><a href="#h5">Discussion</a></li><li><a href="#h6">Data Availability Statement</a></li><li><a href="#h7">Ethics Statement</a></li><li><a href="#h8">Author Contributions</a></li><li><a href="#h9">Funding</a></li><li><a href="#h10">Conflict of Interest</a></li><li><a href="#h11">Acknowledgments</a></li><li><a href="#h12">Supplementary Material</a></li><li><a href="#h13">References</a></li></ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fphar.2020.554422" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/pharmacology/articles/10.3389/fphar.2020.554422/full",["Reactive",16],{"main":17,"user":511,"article":512,"articleHub":844,"mainHeader":848},{"ibar":18,"footer":264,"newsletterComponent":-1,"snackbarItem":346,"toggleShowSnackbar":347,"contentfulJournal":348,"graphJournal":412,"settingsFeaturesSwitchers":416,"templateToggleBanner":417,"tenantConfig":476},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":195,"aboutJournal":196,"mainLinks":245,"journalLinks":252,"helpCenterLink":261},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=62&specialtyid=0&entitytype=2&entityid=176",{"id":115,"name":116,"slug":117,"sections":118},176,"Frontiers in Pharmacology","pharmacology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191],{"id":120,"name":121,"slug":122},182,"Cardiovascular and Smooth Muscle Pharmacology","cardiovascular-and-smooth-muscle-pharmacology",{"id":124,"name":125,"slug":126},199,"Drug Metabolism and Transport","drug-metabolism-and-transport",{"id":128,"name":129,"slug":130},202,"Drugs Outcomes Research and Policies","drugs-outcomes-research-and-policies",{"id":132,"name":133,"slug":134},184,"Ethnopharmacology","ethnopharmacology",{"id":136,"name":137,"slug":138},183,"Experimental Pharmacology and Drug Discovery","experimental-pharmacology-and-drug-discovery",{"id":140,"name":141,"slug":142},186,"Gastrointestinal and Hepatic Pharmacology","gastrointestinal-and-hepatic-pharmacology",{"id":144,"name":145,"slug":146},188,"Inflammation Pharmacology","inflammation-pharmacology",{"id":148,"name":149,"slug":150},178,"Integrative and Regenerative Pharmacology","integrative-and-regenerative-pharmacology",{"id":152,"name":153,"slug":154},26,"Neuropharmacology","neuropharmacology",{"id":156,"name":157,"slug":158},196,"Obstetric and Pediatric Pharmacology","obstetric-and-pediatric-pharmacology",{"id":160,"name":161,"slug":162},2186,"Pharmacoepidemiology","pharmacoepidemiology",{"id":164,"name":165,"slug":166},198,"Pharmacogenetics and Pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":168,"name":169,"slug":170},192,"Pharmacology of Anti-Cancer Drugs","pharmacology-of-anti-cancer-drugs",{"id":172,"name":173,"slug":174},2216,"Pharmacology of Infectious Diseases","pharmacology-of-infectious-diseases",{"id":176,"name":177,"slug":178},179,"Pharmacology of Ion Channels and Channelopathies","pharmacology-of-ion-channels-and-channelopathies",{"id":180,"name":181,"slug":182},195,"Predictive Toxicology","predictive-toxicology",{"id":184,"name":185,"slug":186},1357,"Renal Pharmacology","renal-pharmacology",{"id":188,"name":189,"slug":190},190,"Respiratory Pharmacology","respiratory-pharmacology",{"id":192,"name":193,"slug":194},1251,"Translational Pharmacology","translational-pharmacology","Sections",[197,221],{"title":198,"links":199},"Scope",[200,203,206,209,212,215,218],{"text":201,"url":202,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/pharmacology/about#about-editors",{"text":204,"url":205,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/pharmacology/about#about-scope",{"text":207,"url":208,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/pharmacology/about#about-facts",{"text":210,"url":211,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/pharmacology/about#about-submission",{"text":213,"url":214,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/pharmacology/about#about-open",{"text":216,"url":217,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/pharmacology/about#copyright-statement",{"text":219,"url":220,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/pharmacology/about#about-quality",{"title":222,"links":223},"For authors",[224,227,230,233,236,239,242],{"text":225,"url":226,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit",{"text":228,"url":229,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/pharmacology/for-authors/article-types",{"text":231,"url":232,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines",{"text":234,"url":235,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines",{"text":237,"url":238,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees",{"text":240,"url":241,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist",{"text":243,"url":244,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office",[246,249],{"text":247,"url":248,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":250,"url":251,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[253,256,258],{"text":254,"url":255,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":257,"target":27,"ariaLabel":28},"research-topics",{"text":259,"url":260,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":262,"url":263,"target":77,"ariaLabel":262},"Help center","https://helpcenter.frontiersin.org",{"blocks":265,"socialLinks":319,"copyright":343,"termsAndConditionsUrl":344,"privacyPolicyUrl":345},[266,280,290,304],{"title":267,"links":268},"Guidelines",[269,271,274,277,279],{"text":231,"url":270,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":272,"url":273,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":275,"url":276,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":234,"url":278,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":281,"links":282},"Explore",[283,284,287,289],{"text":254,"url":251,"target":27,"ariaLabel":28},{"text":285,"url":286,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":288,"url":248,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":291,"links":292},"Outreach",[293,296,299,303],{"text":294,"url":92,"target":77,"ariaLabel":295},"Frontiers Forum ","Frontiers Forum website",{"text":297,"url":298,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":300,"url":301,"target":77,"ariaLabel":302},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":305,"links":306},"Connect",[307,308,312,315,318],{"text":262,"url":263,"target":77,"ariaLabel":262},{"text":309,"url":310,"target":77,"ariaLabel":311},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":313,"url":111,"target":27,"ariaLabel":314},"Contact us ","Subscribe to newsletter",{"text":316,"url":317,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[320,328,333,338],{"link":321,"type":324,"color":325,"icon":326,"size":327,"hiddenText":13},{"text":322,"url":323,"target":77,"ariaLabel":322},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":329,"type":324,"color":325,"icon":332,"size":327,"hiddenText":13},{"text":330,"url":331,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":334,"type":324,"color":325,"icon":337,"size":327,"hiddenText":13},{"text":335,"url":336,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":339,"type":324,"color":325,"icon":342,"size":327,"hiddenText":13},{"text":340,"url":341,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":349,"identifier":115,"name":116,"slug":117,"banner":350,"description":405,"mission":406,"palette":407,"impactFactor":408,"citeScore":409,"citations":410,"showTagline":28,"twitter":411},"Journal",[351],{"id":352,"src":353,"name":354,"tags":355,"type":363,"width":364,"height":365,"idHash":366,"archive":367,"brandId":368,"limited":367,"fileSize":369,"isPublic":370,"original":371,"copyright":372,"extension":373,"thumbnails":375,"dateCreated":383,"description":384,"orientation":385,"userCreated":386,"watermarked":367,"dateModified":383,"datePublished":387,"ecsArchiveFiles":388,"propertyOptions":389,"property_Channel":394,"property_Sub-Type":396,"property_Asset_Type":398,"activeOriginalFocusPoint":400,"property_Office_Department":403},"754E12A9-443F-4EA8-AB01E0811E45131D","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/webimage-9D720582-24AD-4D2E-9205AB9D241919DA.jpg","FPHAR_Main Visual_Purple_Website",[356,357,358,359,360,361,362],"pain","medical","pharmaceutical","antibiotic","concept","capsule","treatment","image",5844,3896,"79b643019a2651e0",0,"22C10171-81B3-4DA6-99342F272A32E8BB",8675243,1,"https://brand.frontiersin.org/m/79b643019a2651e0/original/FPHAR_Main-Visual_Purple_Website.jpeg","Copyright (c) 2017 Marian Weyo/Shutterstock.  No use without permission.",[374],"jpeg",{"mini":376,"thul":377,"webimage":353,"Guidelines":378,"WebsiteJpg_XL":379,"WebsiteWebP_L":380,"WebsiteWebP_M":381,"WebsiteWebP_XL":382},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/mini-97EEF455-249B-43BD-9D8F02FEE86046D3.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/thul-B2DBD910-1DDF-4ED3-B1500DF973953144.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/Guidelines-FPHAR_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/WebsiteJpg_XL-FPHAR_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/WebsiteWebP_L-FPHAR_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/WebsiteWebP_M-FPHAR_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/WebsiteWebP_XL-FPHAR_Main Visual_Purple_Website.webp","2022-06-27T10:00:45Z","Pills Tablets Capsule or Medicament freely laid on glass background.","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[390,391,392,393],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[395],"frontiersin_org",[397],"Main_Visual",[399],"Photography",{"x":401,"y":402},2922,1948,[404],"Publishing","The world's most cited pharmacology and pharmacy journal, advancing global pharmacological discoveries to prevent and treat human disease.","\u003Cp>Frontiers in Pharmacology is an interdisciplinary journal that publishes research on the interactions between drugs and living beings to prevent and cure human disease.\u003C/p>\n\n\u003Cp>Led by Field Chief Editor Heike Wulff (University of California, Davis, US), Frontiers in Pharmacology explores basic and clinical pharmacology, medicinal chemistry, pharmacy, and toxicology to clarify the fundamental processes of disease treatment and drug effects. Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, the journal welcomes academic, industrial, and clinical work focused on pharmacology.\u003C/p>\n\n\u003Cp>Topics include, but are not limited to:\u003C/p>\n\u003Cul>\n  \u003Cli>cardiovascular and smooth muscle pharmacology\u003C/li>\n  \u003Cli>drug metabolism and transport\u003C/li>\n  \u003Cli>drugs outcomes research and policies\u003C/li>\n  \u003Cli>ELSI in science and genetics\u003C/li>\n  \u003Cli>ethnopharmacology\u003C/li>\n  \u003Cli>experimental pharmacology and drug discovery\u003C/li>\n  \u003Cli>gastrointestinal and hepatic pharmacology\u003C/li>\n  \u003Cli>inflammation pharmacology\u003C/li>\n  \u003Cli>integrative and regenerative pharmacology\u003C/li>\n  \u003Cli>neuropharmacology\u003C/li>\n  \u003Cli>obstetric and pediatric pharmacology\u003C/li>\n  \u003Cli>pharmacoepidemiology\u003C/li>\n  \u003Cli>pharmacogenetics and pharmacogenomics\u003C/li>\n  \u003Cli>pharmacology of anti-cancer drugs\u003C/li>\n  \u003Cli>pharmacology of infectious diseases\u003C/li>\n  \u003Cli>pharmacology of ion channels and channelopathies\u003C/li>\n  \u003Cli>predictive toxicology\u003C/li>\n  \u003Cli>renal pharmacology\u003C/li>\n  \u003Cli>respiratory pharmacology\u003C/li>\n  \u003Cli>translational pharmacology.\u003C/li>\n\u003C/ul>\n\n\u003Cp>All submissions to the journal involving natural products, including plant extracts or preparations, must adhere to \u003Ci>'The Four Pillars of Ethnopharmacology'\u003C/i> to be considered for peer review, regardless of the specialty section, as a baseline standard for sample characterization. These are a set of mandatory guidelines designed to maintain the scientific, cultural, and ethical integrity of the Journal, and describe what the leading journals in the field consider as the basic aspects of good research (full ConPhyMP statement available \u003Ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.953205/full\" target=\"_blank\">here\u003C/a>, ConPhyMP statement overview \u003Ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1338710/full\" target=\"_blank\">here\u003C/a>, and GA-tool \u003Ca href=\"https://ga-online.org/best-practice/\" target=\"_blank\">here\u003C/a>). Please refer to the \u003Ca href=\"https://assets.ctfassets.net/41vi7p4898pd/63DCrRxGncG4B1stfaYeh8/1b87b9a742b0610ace5b19fd11f62359/Four_pillars_ethnopharmacology_2025.pdf\" target=\"_blank\">FULL VERSION\u003C/a> of these guidelines before submitting a manuscript to the journal.\u003C/p> \n\u003Cp>To be considered for publication in Frontiers in Pharmacology, studies incorporating complementary or alternative medicine must be based on a set of data linked to local or traditional uses that can be evaluated pharmacologically. A clear and plausible set of pharmacological data must be generated in these studies. Similarly, the journal endorses protocols including a minimum of 2 cell-lines in vitro as an evidential basis to demonstrate proposed anti-cancer effects in all relevant studies submitted to all specialty sections in the journal.\u003C/p>\n\u003Cp>Isolated data mining studies using disproportionality analyses of databases containing spontaneously reported adverse events, frequently lead to misinterpretation due to various reporting biases, lack of structured control, and insufficient demographic details. Presenting such analyses in isolation typically does not yield clinically actionable safety findings without the broader context of a comprehensive signal evaluation. To ensure rigor and relevance, all submissions to the journal must be complemented by a proper systematic review and/or thorough analyses of reported cases, and adhere to the READUS-PV guidelines (\u003Ca href=\"https://www.equator-network.org/reporting-guidelines/the-reporting-of-a-disproportionality-analysis-for-drug-safety-signal-detection-using-individual-case-safety-reports-in-pharmacovigilance-readus-pv-development-and-statement/\" target=\"_blank\">The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance\u003C/a>). Authors are expected to ensure compliance with the corresponding \u003Ca href=\"https://readus-statement.org/wp-content/uploads/2024/03/readus-checklist.pdf\" target=\"_blank\">checklist\u003C/a> before proceeding with submission to the journal. Full publication of the READUS-PV guidelines is available \u003Ca href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11116242/pdf/40264_2024_Article_1421.pdf\" target=\"_blank\">here\u003C/a>.\u003C/p>\n\n\u003Cp>Frontiers journals require that manuscripts primarily comprising computational studies of public data, such as NHANES or Mendelian Randomization studies, must include appropriate validation. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information. Manuscripts not adhering to these standards will not be considered.\u003Cp>\n\n\u003Cp>Further unique criteria for the conception and review of submissions may apply, where appropriate, for individual specialty sections.\u003C/p>\n\n\u003Cp>The journal welcomes submissions that support and advance the \u003Ca href=\"https://www.globalgoals.org/goals/\" target=\"_blank\">UN Sustainable Development Goals\u003C/a> (SDGs), notably the \u003Ca href=\"https://www.globalgoals.org/goals/3-good-health-and-well-being/\" target=\"_blank\">SDG 3: Good Health and Well-being\u003C/a>.\u003C/p>\n\n\u003Cp>Manuscripts that focus solely on clinical trials, patient management, or conventional therapies without a focus on pharmacological research are not suitable for publication in this journal. Additionally, studies that are purely statistical or predictive in nature, without providing novel insights into pharmacological mechanisms or drug development, are not within the scope of this journal.\u003C/p>\n\n\u003Cp>Frontiers in Pharmacology is committed to advancing developments in the field of pharmacological discoveries by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>\n\n\u003Cb>\u003Cp>Ethics Information\u003C/p>\u003C/b>\n\u003Cp>Research involving human subjects should comply with the ethical guidelines outlined in the \u003Ca href= https://www.wma.net/policies-post/wma-declaration-of-helsinki/ target=_blank>World Medical Associations Declaration of Helsinki\u003C/a>.\u003C/p>\n\u003Cp>Similarly, authors are required to specify the institutional and national standards adhered to for the care and use of laboratory animals. Transparent and accurate reporting of animal studies is required, with references to guidelines such as \u003Ca href=\"https://arriveguidelines.org/arrive-guidelines\" target=\"_blank\">ARRIVE\u003C/a> and \u003Ca href=\"https://nc3rs.org.uk/sites/default/files/2022-01/The%20IMPROVE%20Guidelines%20%28poster%29.pdf\" target=\"_blank\"> IMPROVE\u003C/a>.\u003C/p>\n\u003Cp>Extended information on research ethics can be found under the Frontiers Policies and Publication Ethics page.\u003C/p>","purple","5.6","6.3","531663","@FrontPharmacol",{"id":115,"name":116,"slug":117,"abbreviation":413,"isOnline":13,"isOpenForSubmissions":13,"citeScore":414,"impactFactor":415},"fphar",8.9,4.8,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":347},{"isPublic":13,"allowCompanyUsers":347,"whiteListEmails":418,"enableAllJournals":13,"whiteListJournals":440},[419,420,421,422,423,424,425,426,427,424,428,429,430,431,432,433,434,435,436,437,438,439],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[441,442,443,444,445,446,370,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,115,469,470,471,472,473,474,475],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,1440,403,1239,755,2136,609,1534,{"spaceId":370,"name":370,"availableJournalPages":477,"announcement":481},[255,260,257,478,479,480],"volumes","about","community-reviewers",{"__typename":482,"sys":483,"preHeader":42,"title":485,"description":486,"image":487,"link":509},"Announcement",{"id":484},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[488],{"archive":367,"brandId":368,"copyright":28,"dateCreated":489,"dateModified":490,"datePublished":491,"description":28,"extension":492,"fileSize":494,"height":495,"id":496,"isPublic":367,"limited":367,"name":497,"orientation":385,"original":28,"thumbnails":498,"type":363,"watermarked":367,"width":505,"videoPreviewURLs":506,"tags":507,"textMetaproperties":508,"src":499},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[493],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":499,"thul":500,"mini":501,"WebsiteWebP_L":502,"WebsiteWebP_M":503,"Guidelines":504},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":510,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":513,"isPreviewPage":347,"hasSupplementalData":347,"showCrossmarkWidget":13,"articleTemplate":694,"currentArticlePageMetaInfo":695,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":514,"doi":515,"title":516,"acceptanceDate":517,"receptionDate":518,"publicationDate":519,"lastModifiedDate":520,"isPublished":13,"abstract":521,"researchTopic":28,"articleType":522,"stage":525,"keywords":527,"authors":533,"editors":613,"reviewers":623,"journal":651,"section":658,"impactMetrics":660,"volume":664,"articleVolume":665,"relatedArticles":666,"isPublishedV2":347,"contents":667,"files":670},554422,"10.3389/fphar.2020.554422","Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1",["Date","2020-09-16T17:28:04.000Z"],["Date","2020-04-22T02:04:17.000Z"],["Date","2020-10-12T00:00:00.000Z"],["Date","2025-11-26T07:10:00.615Z"],"Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patients with SQTS type 1(SQTS1). The aim of this study was to investigate the mechanisms of disopyramide underlying its antiarrhythmic effects in SQTS1 with the N588K mutation in HERG channel. \nHuman-induced pluripotent stem cellderived cardiomyocytes (hiPSC-CMs) from a patient with SQTS1 and a healthy donor, patch clamp and calcium imaging measurements were employed to assess the drug effects. \nDisopyramide prolonged the action potential duration (APD) in hiPSC-CMs from a SQTS1-patient (SQTS1-hiPSC-CMs).  In spontaneously beating SQTS1-hiPSC-CMs challenged by carbachol plus epinephrine, disopyramide reduced the arrhythmic events. Disopyramide enhanced the inward L-type calcium channel current (ICa-L), the late sodium channel current (late INa) and the Na/Ca exchanger current (INCX), but it reduced the outward small-conductance calcium-activated potassium channel current (ISK), leading to APD-prolongation. Disopyramide displayed no effects on the rapidly and slowly activating delayed rectifier and ATP-sensitive potassium channel currents. In hiPSC-CMs from the healthy donor, disopyramide reduced peak INa, ICa-L, IKr and ISK but enhanced late INa and INCX.\nThe results demonstrated that disopyramide may be effective for preventing tachyarrhythmias in SQTS1-patients carrying the N588K mutation in HERG channel by APD-prolongation via enhancing ICa-L, late INa, INCX and reducing ISK.",{"id":523,"name":524},24,"Original Research",{"id":526,"name":19},18,[528,529,530,531,532],"short QT syndrome","arryhthmias","antiarryhthmic drugs","Disopyramide","Human-induced pluripotent stem cell-derived cardiomyocytes",[534,543,553,562,568,574,581,591,598,608],{"id":535,"firstName":536,"middleName":19,"lastName":537,"givenNames":538,"isCorresponding":347,"isProfilePublic":13,"userId":535,"email":-1,"affiliations":539},957655,"Huan","Lan","Huan ",[540],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},"Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University","China",{"id":367,"firstName":544,"middleName":19,"lastName":545,"givenNames":546,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":547},"Qiang","Xu","Qiang ",[548,551],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},"First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg","Germany",{"organizationName":552,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},"Department of Histology and Embryology, Southwest Medical University",{"id":554,"firstName":555,"middleName":19,"lastName":556,"givenNames":557,"isCorresponding":347,"isProfilePublic":13,"userId":554,"email":-1,"affiliations":558},368363,"Ibrahim","El-Battrawy","Ibrahim ",[559,560],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":561,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},"DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg-Mannheim",{"id":367,"firstName":563,"middleName":19,"lastName":564,"givenNames":565,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":566},"Rujia","Zhong","Rujia ",[567],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"id":367,"firstName":569,"middleName":19,"lastName":570,"givenNames":571,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":572},"Xin","Li","Xin ",[573],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"id":367,"firstName":575,"middleName":19,"lastName":576,"givenNames":577,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":578},"Siegfried","Lang","Siegfried ",[579,580],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":561,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"id":582,"firstName":583,"middleName":19,"lastName":584,"givenNames":585,"isCorresponding":347,"isProfilePublic":13,"userId":582,"email":-1,"affiliations":586},822000,"Lukas","Cyganek","Lukas ",[587,589],{"organizationName":588,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},"DZHK (German Center for Cardiovascular Research), Partner Site Gttingen",{"organizationName":590,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},"Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center Gttingen",{"id":367,"firstName":592,"middleName":19,"lastName":593,"givenNames":594,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":595},"Martin","Borggrefe","Martin ",[596,597],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":561,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"id":599,"firstName":600,"middleName":19,"lastName":601,"givenNames":602,"isCorresponding":13,"isProfilePublic":13,"userId":599,"email":603,"affiliations":604},815918,"Xiaobo","Zhou","Xiaobo ","Xiaobo.zhou@medma.uni-heidelberg.de",[605,606,607],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":561,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"id":367,"firstName":555,"middleName":19,"lastName":609,"givenNames":557,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":610},"Akin",[611,612],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":561,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},[614],{"id":615,"firstName":616,"middleName":19,"lastName":617,"givenNames":618,"isCorresponding":347,"isProfilePublic":13,"userId":615,"email":-1,"affiliations":619},23236,"Nicolau","Beckmann","Nicolau ",[620],{"organizationName":621,"countryName":622,"cityName":19,"stateName":19,"zipCode":19},"Novartis Institutes for BioMedical Research","Switzerland",[624,633,642],{"id":625,"firstName":626,"middleName":19,"lastName":627,"givenNames":628,"isCorresponding":347,"isProfilePublic":13,"userId":625,"email":-1,"affiliations":629},31911,"RaffaEle","Coppini","RaffaEle ",[630],{"organizationName":631,"countryName":632,"cityName":19,"stateName":19,"zipCode":19},"University of Florence","Italy",{"id":634,"firstName":635,"middleName":19,"lastName":636,"givenNames":637,"isCorresponding":347,"isProfilePublic":13,"userId":634,"email":-1,"affiliations":638},465333,"Ksenia","Blinova","Ksenia ",[639],{"organizationName":640,"countryName":641,"cityName":19,"stateName":19,"zipCode":19},"United States Food and Drug Administration","United States",{"id":643,"firstName":644,"middleName":19,"lastName":645,"givenNames":646,"isCorresponding":347,"isProfilePublic":13,"userId":643,"email":-1,"affiliations":647},973222,"Andrea","Anampa-Guzmn","Andrea ",[648],{"organizationName":649,"countryName":650,"cityName":19,"stateName":19,"zipCode":19},"National University of San Marcos","Peru",{"id":115,"slug":117,"name":116,"shortName":652,"electronicISSN":653,"field":654,"specialtyId":28,"journalSectionPaths":656},"Front. Pharmacol.","1663-9812",{"id":655,"domainId":370},62,[657],{"section":658},{"id":120,"name":121,"slug":122,"specialtyId":659},135,{"views":661,"downloads":662,"citations":663},3032,1174,12,11,"Volume 11 - 2020",[],{"titleHtml":516,"fullTextHtml":668,"menuHtml":669},"\u003Cdiv class=\"JournalAbstract\">\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/957655\" class=\"user-id-957655\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/957655/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Huan Lan&#x;\">Huan Lan\u003C/a>\u003Csup>1&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Qiang Xu,&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Qiang Xu\u003Csup>2,3&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/368363\" class=\"user-id-368363\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/368363/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Ibrahim El-Battrawy,\">Ibrahim El-Battrawy\u003C/a>\u003Csup>2,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Rujia Zhong\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Rujia Zhong\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Xin Li\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Xin Li\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Siegfried Lang,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Siegfried Lang\u003Csup>2,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/822000\" class=\"user-id-822000\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/822000/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Lukas Cyganek,\">Lukas Cyganek\u003C/a>\u003Csup>5,6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Martin Borggrefe,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Martin Borggrefe\u003Csup>2,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/815918\" class=\"user-id-815918\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/815918/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Xiaobo Zhou,,*\">Xiaobo Zhou\u003C/a>\u003Csup>1,2,4*\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Ibrahim Akin,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Ibrahim Akin\u003Csup>2,4\u003C/sup>\u003C/span>\u003C/div>\u003Cul class=\"notes\">\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China\u003C/li>\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany\u003C/li>\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Department of Histology and Embryology, Southwest Medical University, Luzhou, China\u003C/li>\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Mannheim, Germany\u003C/li>\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>DZHK (German Center for Cardiovascular Research), Partner Site G&#xf6;ttingen, G&#xf6;ttingen, Germany\u003C/li>\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany\u003C/li>\u003C/ul>\u003Cp>Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patients with SQTS type 1(SQTS1). The aim of this study was to investigate the mechanisms of disopyramide underlying its antiarrhythmic effects in SQTS1 with the N588K mutation in HERG channel. Human-induced pluripotent stem cell&#x2013;derived cardiomyocytes (hiPSC-CMs) from a patient with SQTS1 and a healthy donor, patch clamp, and calcium imaging measurements were employed to assess the drug effects. Disopyramide prolonged the action potential duration (APD) in hiPSC-CMs from a SQTS1-patient (SQTS1-hiPSC-CMs). In spontaneously beating SQTS1-hiPSC-CMs challenged by carbachol plus epinephrine, disopyramide reduced the arrhythmic events. Disopyramide enhanced the inward L-type calcium channel current (I\u003Csub>Ca-L\u003C/sub>), the late sodium channel current (late I\u003Csub>Na\u003C/sub>) and the Na/Ca exchanger current (I\u003Csub>NCX\u003C/sub>), but it reduced the outward small-conductance calcium-activated potassium channel current (I\u003Csub>SK\u003C/sub>), leading to APD-prolongation. Disopyramide displayed no effects on the rapidly and slowly activating delayed rectifier and ATP-sensitive potassium channel currents. In hiPSC-CMs from the healthy donor, disopyramide reduced peak I\u003Csub>Na\u003C/sub>, I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>Kr\u003C/sub>, and I\u003Csub>SK\u003C/sub> but enhanced late I\u003Csub>Na\u003C/sub> and I\u003Csub>NCX\u003C/sub>. The results demonstrated that disopyramide may be effective for preventing tachyarrhythmias in SQTS1-patients carrying the N588K mutation in HERG channel by APD-prolongation \u003Ci>via\u003C/i> enhancing I\u003Csub>Ca-L\u003C/sub>, late I\u003Csub>Na\u003C/sub>, I\u003Csub>NCX\u003C/sub>, and reducing I\u003Csub>SK\u003C/sub>.\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\u003Cdiv class=\"JournalFullText\">\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\u003Cp class=\"mb15\">Short QT syndrome (SQTS) is a rare, inheritable cardiac channelopathy associated with abbreviated corrected QT interval (QTc), tachyarrhythmias and sudden cardiac death (SCD) (\u003Ca href=\"#B17\">Gussak et al., 2000\u003C/a>; \u003Ca href=\"#B6\">Brugada et al., 2004\u003C/a>). So far, worldwide more than 200 SQTS-patients with different gene mutations have been reported and different types of SQTS have been described (\u003Ca href=\"#B3\">Bjerregaard, 2018\u003C/a>; \u003Ca href=\"#B7\">Campuzano et al., 2018\u003C/a>). SQTS types 1&#x2013;3 are linked to a gain of function of potassium channels led by mutations in the KCNH2 (SQTS1), KCNQ1 (SQTS2), and KCNJ2 (SQTS3) gene. SQTS types 4-6 are linked to a loss of function of calcium channels resulting from mutations in CACNA1C (SQTS4), CACNB2 (SQTS5), and CACNA2D1 (SQTS6) gene. Recently, a mutation in the cardiac Cl/HCO3 exchanger AE3 was detected in two SQTS-families (\u003Ca href=\"#B35\">Thorsen et al., 2017\u003C/a>; \u003Ca href=\"#B7\">Campuzano et al., 2018\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">The diagnostic and treatment approaches are still challenging because the prevalence of the disease is very low. Although implantable cardioverter defibrillator (ICD) can be useful for terminating arrhythmias in SQTS-patients, ICD cannot be used for every patient (\u003Ca href=\"#B15\">Giustetto et al., 2006\u003C/a>; \u003Ca href=\"#B23\">Mazzanti et al., 2014\u003C/a>). Therefore, pharmacotherapy is required at least for some SQTS-patients.\u003C/p>\u003Cp class=\"mb15\">To date, only a limited number of drugs have been examined in a small number of patients with SQTS1 (\u003Ca href=\"#B1\">Abriel and Rougier, 2013\u003C/a>), among which only one drug quinidine has been shown to be effective in the treatment (\u003Ca href=\"#B27\">Mizobuchi et al., 2008\u003C/a>; \u003Ca href=\"#B16\">Giustetto et al., 2011\u003C/a>). Quinidine cannot be used in some patients due to its severe side effects. Hence, searching for further drugs is urgently required. SQTS1 is caused by a gain-of-function of the KCNH2 channel. KCNH2 channel blockers should prolong QT interval and hence suppress arrhythmias in SQTS1patients. Surprisingly, clinical data demonstrated that some KCNH2 channel blockers including sotalol and ibutilide failed to prolong QT-interval in SQTS1-patients with KCNH2 mutations (\u003Ca href=\"#B14\">Gaita et al., 2004\u003C/a>). The reason for ineffectiveness of drugs is that the mutation (N588K) in the KCNH2 channel impairs inactivation of the channel and renders the channel resistant to blockers, which have the highest affinity to the inactivated state of KCNH2 channels. Quinidine has high affinity to both the open and inactivated states of KCNH2 channels. Therefore, its affinity is only partially reduced and it is effective in treating SQTS1. Given that a mutation in KCNH2 (or other channels) may change the sensitivity of channels to drugs (\u003Ca href=\"#B24\">McPate et al., 2008\u003C/a>), other factors like epigenetic and environmental factors may also influence drug effects. In different types of cells or in the same type of cells under different states, a drug may show different effects. It will be important to test drug effects in &#x201c;diseased&#x201d; cells if we want to know the efficacy of a drug for treating the disease.\u003C/p>\u003Cp class=\"mb15\">Disopyramide is a multiple channel blocker, mainly a sodium channel blocker (\u003Ca href=\"#B28\">Morady et al., 1982\u003C/a>; \u003Ca href=\"#B33\">Sunami et al., 1991\u003C/a>; \u003Ca href=\"#B21\">Koumi et al., 1992\u003C/a>). It has been used for atrial and ventricular arrhythmias (\u003Ca href=\"#B28\">Morady et al., 1982\u003C/a>; \u003Ca href=\"#B37\">Verlinden and Coons, 2015\u003C/a>). It was also tested in a SQTS-patient with unknown genotype (\u003Ca href=\"#B27\">Mizobuchi et al., 2008\u003C/a>). Although it normalized QT interval in that patient, its efficacy for treating SQTS is unclear because only one patient was recruited for the study. Disopyramide effects on HERG (also called I\u003Csub>Kr\u003C/sub> or KCNH2) channels, either the wild type or mutated, were investigated in different types of cells (\u003Ca href=\"#B38\">Virag et al., 1998\u003C/a>; \u003Ca href=\"#B25\">McPate et al., 2006\u003C/a>; \u003Ca href=\"#B11\">El Harchi et al., 2012a\u003C/a>; \u003Ca href=\"#B12\">El Harchi et al., 2012b\u003C/a>), but not in SQTS-cardiomyocytes. Recently, disopyramide was tested in hiPSC-CMs from a patient with SQTS1 and beneficial effects (APD-prolonging and antiarrhythmic effects) were detected (\u003Ca href=\"#B31\">Shinnawi et al., 2019\u003C/a>). However, in that study, the mechanisms of disopyramide underlying the APD-prolonging and antiarrhythmic effects were not investigated.\u003C/p>\u003Cp class=\"mb0\">This study was designed to investigate the ionic mechanisms for the APD-prolonging and antiarrhythmic effects of disopyramide using the cellular model of SQTS1-hiPSC-CMs established recently by our group.\u003C/p>\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Methods\u003C/h2>\u003Ch3>Ethics Statement\u003C/h3>\u003Cp class=\"mb0\">A skin biopsy from a SQTS1 patient was obtained with written informed consent. The study was approved by the Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg (approval numbers: 2018-565N-MA), the Ethics Committee of University Medical Center G&#xf6;ttingen (approval number: 10/9/15), and the Ethics Committee of Southwest Medical University (approval number:KY2013019). The study was carried out in accordance with the approved guidelines and conducted in accordance with the Helsinki Declaration of 1975 (\u003Ca href=\"https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/\">https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/\u003C/a>), revised in 2013.\u003C/p>\u003Ch3>Clinical Data\u003C/h3>\u003Cp class=\"mb0\">The fibroblasts for iPS cell generation were from a 29-year-old male patient with familial SQTS1 carrying a missense mutation (C to G substitution at nucleotide 1764). This mutation results in substitution of an amino acid at the position of 588 from asparagine to lysine (N588K) in the KCNH2 (also called HERG or \u003Ci>I\u003Csub>Kr\u003C/sub>\u003C/i>) channel. The clinical data of the patient has been provided in our recent publication (\u003Ca href=\"#B13\">El-Battrawy et al., 2018\u003C/a>).\u003C/p>\u003Ch3>Generation of Human iPS Cells\u003C/h3>\u003Cp class=\"mb0\">The methods for the generation of iPS cells from the patient and a healthy donor have been described in our previous study (\u003Ca href=\"#B13\">El-Battrawy et al., 2018\u003C/a>). Briefly, human iPS cells (hiPSCs) were generated from primary human fibroblasts derived from a skin biopsy. The hiPSC line was generated under feeder free culture conditions using the integration-free CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, #A16517). The Kit contains the reprogramming factors OCT4, KLF4, SOX2, c-MYC and was used according to manufacturer&#x2019;s instructions with modifications. The generated hiPSCs were characterized for their pluripotency and their \u003Ci>in vitro\u003C/i> differentiation potential (\u003Ca href=\"#B13\">El-Battrawy et al., 2018\u003C/a>).\u003C/p>\u003Ch3>Generation of hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">The hiPSCs were cultured without feeder cells and differentiated into hiPSC-CMs as described with some modifications (\u003Ca href=\"#B36\">Tiburcy et al., 2017\u003C/a>). In our lab the differentiation of hiPS cells into cardiomyocytes (hiPSC-CMs) is regularly performed every 2 to 3 weeks. The hiPSC-CMs from different differentiations were used for studies and the data were combined. Three clones of the hiPSCs were alternately used for the differentiation. At 40 to 60 days of culture with basic culture medium, cardiomyocytes were dissociated from 24 well plates and plated on Matrigel-coated 3.5&#xa0;cm petri dishes for patch-clamp and calcium transient measurements.\u003C/p>\u003Ch3>Patch-Clamp\u003C/h3>\u003Cp class=\"mb15\">Standard patch-clamp recording techniques were used to measure the action potential (AP) and channel currents in the whole-cell configuration at room temperature. Patch electrodes were pulled from borosilicate glass capillaries (MTW 150F; world Precision Instruments, Inc., Sarasota, FL) using a DMZ-Universal Puller (Zeitz-Instrumente Vertriebs GmbH, Martinsried, Germany) and filled with pre-filtered pipette solution (see below). Pipette resistance ranged from 1&#x2013;2 M&#x3a9; and 4&#x2013;5 M&#x3a9; for current and AP measurements, respectively. Electrode offset potentials were zero-adjusted before a Giga-seal was formed. After a Giga-seal was obtained, fast capacitance was first compensated and then the membrane under the pipette tip was disrupted by negative pressure to establish the whole-cell configuration. Signals were acquired at 10 kHz and filtered at 2 kHz with the Axon 200B amplifier and Digidata 1440A digitizer hardware as well as pClamp10.2 software (Molecular Devices, Sunnyvale, CA). APs were recorded in current clamp mode. For recording APs, brief current pulses (2 ms, 1 nA) were applied with different frequencies to trigger APs.\u003C/p>\u003Cp class=\"mb15\">The bath solution (PSS) for AP measurements contained (mmol/l): 130 NaCl, 5.9 KCl, 2.4 CaCl\u003Csub>2\u003C/sub>, 1.2 MgCl\u003Csub>2\u003C/sub>, 11 glucose, 10 HEPES, pH 7.4 (NaOH). The pipette solution contained (mmol/l): 10 HEPES, 126 KCl, 6 NaCl, 1.2 MgCl\u003Csub>2\u003C/sub>, 5 EGTA, 11 glucose and 1 MgATP, pH 7.2 (KOH).\u003C/p>\u003Cp class=\"mb15\">The bath solution for L-type (I\u003Csub>Ca-L\u003C/sub>) calcium channel current recordings contained (mmol/l): 140 TEA-Cl, 5 CaCl\u003Csub>2\u003C/sub>, 1 MgCl\u003Csub>2\u003C/sub>, 0.01 E-4031, 10 HEPES, 0.02 TTX, 3 4-AP, pH 7.4 (CsOH). Microelectrodes were filled with (mmol/l): 6 NaCl, 135 CsCl, 2 CaCl\u003Csub>2\u003C/sub>, 3 MgATP, 2 TEA-Cl, 5 EGTA, 10 HEPES, pH7.2 (CsOH).\u003C/p>\u003Cp class=\"mb15\">The bath solution for Na\u003Csup>+\u003C/sup>-Ca\u003Csup>2+\u003C/sup> exchanger current (I\u003Csub>NCX\u003C/sub>) measurements contained (mmol/l): 135 NaCl, 10 CsCl, 2 CaCl\u003Csub>2\u003C/sub>, 1 MgCl\u003Csub>2\u003C/sub>, 10 Hepes, 10 glucose, 0.01 nifedipine, 0.1 niflumic acid, 0.05 lidocaine, 0.02 dihydroouabain, pH 7.4 (CsOH). Microelectrodes were filled with (mmol/l): 10 NaOH, 150 CsOH, 2 CaCl\u003Csub>2\u003C/sub>, 1 MgCl\u003Csub>2\u003C/sub>, 75 aspartic acid, 5 EGTA, pH7.2 (CsOH). NiCl\u003Csub>2\u003C/sub> (5mM) was used to separate I\u003Csub>NCX\u003C/sub> from other currents. I\u003Csub>NCX\u003C/sub> was defined as NiCl\u003Csub>2\u003C/sub>-sensitive current.\u003C/p>\u003Cp class=\"mb15\">The bath solution for Na+ current measurements contained (mmol/l): 135 NaCl, 20 CsCl, 1.8 CaCl\u003Csub>2\u003C/sub>, 1 MgCl\u003Csub>2\u003C/sub>, 10 Hepes, 10 glucose, 0.001 nifedipine, pH 7.4 (CsOH). Microelectrodes were filled with (mmol/l): 10 NaCl, 135 CsCl, 2 CaCl\u003Csub>2\u003C/sub>, 3 MgATP, 2 TEA-Cl, 5 EGTA, and 10 HEPES (pH7.2 CsOH).\u003C/p>\u003Cp class=\"mb15\">The bath solution for K\u003Csup>+\u003C/sup> channel current measurements contained (mmol/l): 130 NaCl, 5.9 KCl, 2.4 CaCl\u003Csub>2\u003C/sub>, 1.2 MgCl\u003Csub>2\u003C/sub>, 11 glucose, 10 HEPES, pH 7.4 (NaOH). For slowly delayed rectifier (I\u003Csub>Ks\u003C/sub>) measurements, 10 &#xb5;M nifedipine, 3 mM 4-AP and 10 &#xb5;M TTX were added. The pipette solution contains 10 mM HEPES, 126 mM KCl, 6 mM NaCl, 1.2 mM MgCl\u003Csub>2\u003C/sub>, 5 mM EGTA, 11 mM glucose, and 1 mM MgATP, pH 7.4 (KOH). For measuring small conductance calcium-activated potassium channel currents (I\u003Csub>SK\u003C/sub>), appropriate CaCl\u003Csub>2\u003C/sub> was added to get the free-Ca\u003Csup>2+\u003C/sup> concentration of 0.5 &#xb5;M according to the calculation by the software MAXCHELATOR (\u003Ca href=\"http://web.stanford.edu/~cpatton/downloads.htm\">http://web.stanford.edu/~cpatton/downloads.htm\u003C/a>). For measuring ATP-sensitive K\u003Csup>+\u003C/sup> channel currents (I\u003Csub>KATP\u003C/sub>), the ATP-free pipette solution was used. I\u003Csub>Ks\u003C/sub> was defined as 3R4S-chromanol 293B-sensitive, I\u003Csub>KATP\u003C/sub> as nicorandil-sensitive and I\u003Csub>SK\u003C/sub> as apamin-sensitive currents.\u003C/p>\u003Cp class=\"mb0\">To separate I\u003Csub>Kr\u003C/sub> from other K\u003Csup>+\u003C/sup> channel currents, the Cs\u003Csup>+\u003C/sup> currents conducted by KCNH2 (\u003Ci>I\u003Csub>Kr\u003C/sub>\u003C/i>) channels were measured. External solution for Cs\u003Csup>+\u003C/sup> currents (mmol/L): 140 CsCl, 2 MgCl\u003Csub>2\u003C/sub>, 10 HEPES, 10 Glucose, pH=7.4 (CsOH). Pipette solution: 140 CsCl, 2 MgCl\u003Csub>2\u003C/sub>, 10 HEPES, 10 EGTA, pH=7.2 (CsOH).\u003C/p>\u003Ch3>Measurement of Intracellular Calcium Transients\u003C/h3>\u003Cp class=\"mb0\">To measure the intracellular Ca\u003Csup>2+\u003C/sup> transients, cells were loaded with the fluorescent Ca\u003Csup>2+\u003C/sup>-indicator Fluo-3 AM. First, 1.5&#xa0;ml PSS (see above) was added into a petri dish with hiPSC-CMs cultured for 2 to 4 days. Then, 50 &#xb5;g of the membrane permeable acetoxymethyl ester derivative of Fluo-3 was dissolved in 44&#xa0;&#xb5;l of the Pluronic F-127 stock solution (20% w/v in DMSO) to get a 1 mM Fluo-3 AM stock solution, which can be stored at -20&#xb0;C for a maximum of 1 week. Next, 15 &#xb5;l of the Fluo-3 AM stock solution were added into 1.5&#xa0;ml PSS resulting in a final concentration of 10 &#xb5;M Fluo-3 and the dish was agitated carefully. The cells were incubated at room temperature for 10&#xa0;min in an optically opaque box to protect from light. Thereafter, the PSS was carefully sucked out and discarded. The cells were washed with PSS for 4&#x2013;5 times. Finally, the cells in PSS were kept at room temperature for about 30&#xa0;min for de-esterification before measurements. After de-esterification, the fluorescence of the cells was measured by using Cairn Optoscan calcium imaging system (Cairn Research, UK). Fluorescence is excited by 488&#xa0;nm and emitted at 520&#xa0;nm. The calcium transients were recorded at room temperature.\u003C/p>\u003Ch3>Drugs\u003C/h3>\u003Cp class=\"mb0\">Disopyramide is from SigmaAldrich. The drug was applied to a cell sequentially from low to high concentrations by a perfusion pipette. The tested concentrations were selected according to previous or our preliminary studies in hiPSC-CMs. E-4031, chromanol 293B, nifedipine, NiCl\u003Csub>2\u003C/sub>, niflunic acid, lidocaine, and dihydroouabain are from Sigma Aldrich, 4-AP from RBI, apamin from Alomone Labs, TTX from Carl Roth. E-4031, NiCl\u003Csub>2\u003C/sub>, TTX, 4-AP, apamin, niflumic acid, and dihydrooubain were dissolved in H\u003Csub>2\u003C/sub>O. Nifedipine, and chromanol 293B were dissolved in DMSO, lidocaine in ethanol. Stock solutions were kept at -20 &#xb0;C.\u003C/p>\u003Ch3>Statistical Analysis\u003C/h3>\u003Cp class=\"mb0\">Data are shown as mean &#xb1; SEM and were analyzed using InStat\u003Csup>&#xa9;\u003C/sup> (GraphPad, San Diego, USA) and SigmaPlot 11.0 (Systat GmbH, Germany). By analyzing the data with the Kolmogorov Smirnov test, it was decided whether parametric or non-parametric tests were used for analysis. For parametric data of more than two groups, multiple comparisons with one-way ANOVA and Holm-Sidak post-test were performed. For repeated measurements, the method of one-way repeated measures ANOVA with Holm-Sidak post-test was applied. The I-V curve data were analyzed with mixed model analysis using repeated values for the same cells measured as control and treatment at different voltages. Paired t-test was used for comparisons of data before and after application of a drug. p&lt;0.05 (two-tailed) was considered significant.\u003C/p>\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\u003Ch3>Disopyramide Prolonged the Action Potential Duration in SQTS1-hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">Although disopyramide has been shown to prolong action potential duration and suppress arrhythmias in SQTS cells, we checked both effects in our SQTS1-hiPSC-CMs before investigating its ionic mechanisms. The AP parameters including action potential amplitude (APA), the maximal upstroke velocity (Vmax) and action potential durations at 50% and 90% repolarization (APD50 and APD90) were analyzed in the presence of disopyramide. Indeed, disopyramide at the concentration of 10 and 30 &#xb5;M prolonged APD90, while at 10 &#xb5;M significantly prolonged APD50 (\u003Ca href=\"#f1\">Figures 1A&#x2013;C\u003C/a>). At all the tested concentrations, disopyramide did not significantly affect RP, APA (\u003Ca href=\"#f1\">Figures 1D, E\u003C/a>), but reduced Vmax in a concentration-dependent manner (\u003Ca href=\"#f1\">Figure 1F\u003C/a>), consistent with its Na channel-blocking effect. In hiPSC-CMs from the healthy donor, disopyramide showed similar effects on AP parameters (\u003Ca href=\"#h12\">Figure S1\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 1\u003C/strong> Effects of disopyramide on action potentials in SQTS1-hiPSC-CMs. Action potentials were recorded at 1&#xa0;Hz. Disopyramide was applied to cells sequentially from low to high concentration (3 &#xb5;M, 10 &#xb5;M and 30 &#xb5;M). \u003Cstrong>(A)\u003C/strong> Representative action potential traces in absence (Ctr) and presence of 3 &#xb5;M, 10 &#xb5;M, and 30 &#xb5;M disopyramide. \u003Cstrong>(B)\u003C/strong> Averaged values of action potential duration at 50% repolarization (APD50). \u003Cstrong>(C)\u003C/strong> Averaged values of action potential duration at 90% repolarization (APD90). \u003Cstrong>(D)\u003C/strong> Averaged values of resting potential (RP). \u003Cstrong>(E)\u003C/strong> Averaged values of action potential amplitude (APA). \u003Cstrong>(F)\u003C/strong> Averaged values of maximal depolarization velocity (Vmax). Shown are mean &#xb1; SEM, n represents number of cells. The statistical significance was examined by One Way Repeated Measures ANOVA followed by Holm-Sidak method. ns, not significant.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">To check the effects of disopyramide at different beating frequencies, the same measurements were repeated in cells paced by stimulations at 0.5&#xa0;Hz, 1&#xa0;Hz, and 3&#xa0;Hz. As expected, disopyramide prolonged APDs at all the three frequencies without clear frequency-dependence (\u003Ca href=\"#f2\">Figure 2\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 2\u003C/strong> Effects of disopyramide on action potential duration (APD) at different frequencies in SQTS1-hiPSC-CMs. \u003Cstrong>(A, B)\u003C/strong> Averaged values of APD50 and APD90 at 0.5&#xa0;Hz, 1&#xa0;Hz, and 3&#xa0;Hz in absence (Ctr) and presence of 3 &#xb5;M, 10 &#xb5;M and 30 &#xb5;M disopyramide. \u003Cstrong>(C, D)\u003C/strong> Percent prolongation of APD50 and APD90 by disopyramide at 0.5&#xa0;Hz, 1&#xa0;Hz, and 3&#xa0;Hz. The values were calculated from the data in \u003Cstrong>(A, B)\u003C/strong>. Shown are mean &#xb1; SEM. The statistical significance was examined by One Way Repeated Measures ANOVA followed by Holm-Sidak method. *p&lt;0.05, **p&lt;0.01.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Disopyramide Reduced Arrhythmic Events in SQTS1-hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">Due to the APD-prolonging effect of disopyramide, its antiarrhythmic effects were further examined in SQTS1-hiPSC-CMs. In spontaneously beating cells challenged by carbachol (CCh, 10 &#xb5;M) plus epinephrine (Epi, 10 &#xb5;M), spontaneous calcium transients were measured to monitor arrhythmic events. CCh+Epi reduced the beating frequency but increased the episodes of arrhythmic events such as &#x201c;immature&#x201d; or irregularly triggered beats. Disopyramide reduced arrhythmic events induced by CCh+Epi (\u003Ca href=\"#f3\">Figures 3A&#x2013;D\u003C/a>). Of note, the duration of calcium transients was prolonged but the amplitude and basal line of calcium transients were not changed (\u003Ca href=\"#f3\">Figures 3E&#x2013;G\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 3\u003C/strong> Disopyramide reduced arrhythmic events in SQTS1-hiPSC-CMs. Calcium transients were measured in spontaneously beating cells. Then carbachol (10 &#xb5;M) plus epinephrine (10 &#xb5;M) was applied to cells to trigger arrhythmic events. In cells showing arrhythmias, disopyramide (10 &#xb5;M) was applied to the cell in presence of carbachol and epinephrine. \u003Cstrong>(A)\u003C/strong> Representative traces of calcium transients in a cell before challenging (Ctr). \u003Cstrong>(B)\u003C/strong> Representative traces of calcium transients in the cell challenged by carbachol plus epinephrine (CCh+Epi). \u003Cstrong>(C)\u003C/strong> Representative traces of calcium transients in the cell in the presence of carbachol plus epinephrine and disopyramide (CCh+Epi+Dis). \u003Cstrong>(D)\u003C/strong> Averaged values of arrhythmic events per minute. CCh+Epi slowed the beating but led to small and irregularly triggered beating. The arrhythmic events were defined as transients that are larger than 10% but smaller than 80% of the normal regular transients. The arrows indicate arrhythmic events. \u003Cstrong>(E)\u003C/strong> Mean values of the amplitude of calcium transients in absence (Ctr) and presence of disopyramide (10 &#xb5;M). \u003Cstrong>(F)\u003C/strong> Mean values of the duration of calcium transients. \u003Cstrong>(G)\u003C/strong> Mean values of the diastolic baseline of calcium transient. Shown are mean &#xb1; SEM, n represents number of cells. p values were determined by One Way ANOVA followed by Holm-Sidak method \u003Cstrong>(D)\u003C/strong> or paired t-test \u003Cstrong>(E&#x2013;G)\u003C/strong>. ns, not significant.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Disopyramide Failed to Suppress the HERG Channel Current in SQTS1-hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">The prolongation of action potential duration (APD) in SQTS1-hiPSC-CMs observed in this and previous study (\u003Ca href=\"#B31\">Shinnawi et al., 2019\u003C/a>) and the weak influence of the pathogenic mutation N588K in HERG channels on the channel-blocking by disopyramide (\u003Ca href=\"#B25\">McPate et al., 2006\u003C/a>)&#xa0;suggest that disopyramide should inhibit the HERG channel currents (I\u003Csub>Kr\u003C/sub>). Surprisingly, disopyramide up to 30 &#xb5;M failed to suppress I\u003Csub>Kr\u003C/sub> in SQT1-hiPSC-CMs under our conditions (\u003Ca href=\"#f4\">Figures 4A, B\u003C/a>). Likewise, disopyramide displayed no effects on the slowly activating delayed rectifier potassium channel current (\u003Ci>I\u003Csub>Ks\u003C/sub>\u003C/i>) (\u003Ca href=\"#f4\">Figures 4C, D\u003C/a>). In hiPSC-CMs from the healthy donor, disopyramide inhibited significantly I\u003Csub>Kr\u003C/sub> (\u003Ca href=\"#h12\">Figure S2\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 4\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g004.jpg\" alt=\"www.frontiersin.org\" id=\"f4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 4\u003C/strong> Effects of disopyramide on I\u003Csub>Kr\u003C/sub> and I\u003Csub>Ks\u003C/sub> in SQTS1-hiPSC-CMs. The currents (I\u003Csub>Kr\u003C/sub> and I\u003Csub>Ks\u003C/sub>) were evoked by the protocol indicated in \u003Cstrong>(A, C)\u003C/strong>. I\u003Csub>Kr\u003C/sub> was measured as Cs\u003Csup>+\u003C/sup> currents. I\u003Csub>Ks\u003C/sub> was analyzed as Chromalol-293B (10 &#xb5;M) sensitive currents. \u003Cstrong>(A)\u003C/strong> Representative traces of I\u003Csub>Kr\u003C/sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). \u003Cstrong>(B)\u003C/strong> I-V curves of I\u003Csub>Kr\u003C/sub> in absence (Ctr) and presence of disopyramide. \u003Cstrong>(C)\u003C/strong> Representative traces of I\u003Csub>Ks\u003C/sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). \u003Cstrong>(D)\u003C/strong> I-V curves of I\u003Csub>Ks\u003C/sub> in absence (Ctr) and presence of disopyramide. n, number of cells.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Disopyramide Reduced Small Ca\u003Csup>2+\u003C/sup>-Activated K\u003Csup>+\u003C/sup> Currents in SQTS1-hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">Then, we assessed other outward currents including the ATP-sensitive K channel current (I\u003Csub>KATP\u003C/sub>) and the small conductance Ca\u003Csup>2+\u003C/sup>-activated K\u003Csup>+\u003C/sup> channel current (I\u003Csub>SK\u003C/sub>). Disopyramide at the highest concentration (30 &#xb5;M) used in this study showed no significant effects on I\u003Csub>KATP\u003C/sub> but it reduced I\u003Csub>SK\u003C/sub> already at 10 &#xb5;M (\u003Ca href=\"#f5\">Figure 5\u003C/a>). In hiPSC-CMs from the healthy donor, disopyramide inhibited also I\u003Csub>SK\u003C/sub> (\u003Ca href=\"#h12\">Figure S3\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 5\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g005.jpg\" alt=\"www.frontiersin.org\" id=\"f5\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 5\u003C/strong> Effects of disopyramide on I\u003Csub>KATP\u003C/sub> and I\u003Csub>SK\u003C/sub> in SQTS1-hiPSC-CMs. The currents (I\u003Csub>KATP\u003C/sub> and I\u003Csub>SK\u003C/sub>) were evoked by the protocol indicated in \u003Cstrong>(A, D)\u003C/strong>. I\u003Csub>KATP\u003C/sub> was measured as nicorandil (10 &#xb5;M) sensitive currents. I\u003Csub>SK\u003C/sub> was analyzed as apamin (100 nM) sensitive currents. \u003Cstrong>(A)\u003C/strong> Representative traces of I\u003Csub>KATP\u003C/sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M) at -120 mV. \u003Cstrong>(B)\u003C/strong> I-V curves of I\u003Csub>KATP\u003C/sub> in absence (Ctr) and presence of disopyramide. \u003Cstrong>(C)\u003C/strong> Mean values of I\u003Csub>KATP\u003C/sub> at -120 mV in absence (Ctr) and presence of disopyramide (10 &#xb5;M). \u003Cstrong>(D)\u003C/strong> Representative traces of I\u003Csub>SK\u003C/sub> at +40 mV in absence (Ctr) and presence of disopyramide (10 &#xb5;M). \u003Cstrong>(E)\u003C/strong> I-V curves of I\u003Csub>SK\u003C/sub> in absence (Ctr) and presence of disopyramide. \u003Cstrong>(F)\u003C/strong> Mean values of I\u003Csub>SK\u003C/sub> at +40 mV in absence (Ctr) and presence of disopyramide (10 &#xb5;M). n, number of cells. *p&lt;0.05.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Disopyramide Enhanced L-Type Calcium Channel Currents in SQTS1-hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">Disopyramide (10 &#xb5;M) was applied to SQTS1-hiPSC-CMs through an extracellular perfusion-system to check the drug effects on L-type calcium channel currents (I\u003Csub>Ca-L\u003C/sub>) evoked by stimulations at a fixed frequency (1&#xa0;Hz). The I\u003Csub>Ca-L\u003C/sub> was significantly enhanced by 10 &#xb5;M disopyramide (\u003Ca href=\"#f6\">Figures 6A, B\u003C/a>). The activation curve of I\u003Csub>Ca-L\u003C/sub> was largely shifted to more negative potentials and the inactivation curve was only slightly shifted to more positive potentials, whereas the recovery from inactivation was decelerated (\u003Ca href=\"#f6\">Figures 6C&#x2013;H\u003C/a>). In hiPSC-CMs from the healthy donor, disopyramide inhibited significantly I\u003Csub>Ca-L\u003C/sub> (\u003Ca href=\"#h12\">Figure S4\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 6\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g006.jpg\" alt=\"www.frontiersin.org\" id=\"f6\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 6\u003C/strong> Effects of disopyramide on L-type calcium channel currents in SQTS1-hiPSC-CMs. The L-type Ca channel currents (I\u003Csub>Ca-L\u003C/sub>) were evoked by the protocol indicated in \u003Cstrong>(A)\u003C/strong>. \u003Cstrong>(A)\u003C/strong> Current-voltage relationship (I-V) curves of I\u003Csub>Ca-L\u003C/sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). \u003Cstrong>(B)\u003C/strong> The representative traces of I\u003Csub>Ca-L\u003C/sub> (upper panel) and current density (bottom panel) at 0 mV in absence (Ctr) and presence of disopyramide. \u003Cstrong>(C)\u003C/strong> The activation curves of I\u003Csub>Ca-L\u003C/sub>. \u003Cstrong>(D)\u003C/strong> Mean values of the potential at 50% activation (V0.5). \u003Cstrong>(E)\u003C/strong> The inactivation curves of I\u003Csub>Ca-L\u003C/sub>. \u003Cstrong>(F)\u003C/strong> Mean values of the potential at 50% inactivation (V0.5). \u003Cstrong>(G)\u003C/strong> The curves of recovery of I\u003Csub>Ca-L\u003C/sub> from inactivation. \u003Cstrong>(H)\u003C/strong> Mean values of the time constants (tau) of the recovery curves. Shown are mean &#xb1; SEM, n represents number of cells. \u003Csup>#\u003C/sup>p&lt;0.05.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Disopyramide Enhanced the Na/Ca Exchanger Currents in SQTS1-hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">To separate the Na/Ca exchanger current (I\u003Csub>NCX\u003C/sub>) from other currents, NiCl\u003Csub>2\u003C/sub> (5mM) was applied to cells and the NiCl\u003Csub>2\u003C/sub>-sensitive currents were defined as I\u003Csub>NCX\u003C/sub>. Disopyramide (10 &#xb5;M) increased I\u003Csub>NCX\u003C/sub>, especially the inward current at negative potentials (\u003Ca href=\"#f7\">Figures 7A&#x2013;C\u003C/a>). In hiPSC-CMs from the healthy donor, disopyramide enhanced also I\u003Csub>NCX\u003C/sub> (\u003Ca href=\"#h12\">Figure S5\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 7\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g007.jpg\" alt=\"www.frontiersin.org\" id=\"f7\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 7\u003C/strong> Effects disopyramide on late Na channel and Na/Ca exchanger currents in SQTS1-hiPSC-CMs. Late Na channel currents (late I\u003Csub>Na\u003C/sub>) were evoked by the protocol indicated in \u003Cstrong>(D)\u003C/strong> and measured at 300 ms after initiation of the depolarization pulse. TTX (30&#xb5;M) sensitive currents were analyzed as late I\u003Csub>Na\u003C/sub>. The Na/Ca exchanger currents (I\u003Csub>NCX\u003C/sub>) were evoked by the protocol indicated in \u003Cstrong>(A)\u003C/strong>. I\u003Csub>NCX\u003C/sub> was analyzed as NiCL2 (5mM) sensitive currents. \u003Cstrong>(A)\u003C/strong> Representative traces of I\u003Csub>NCX\u003C/sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). \u003Cstrong>(B)\u003C/strong> Mean values of I\u003Csub>NXC\u003C/sub> at +60 mV in absence (Ctr) and presence of disopyramide. \u003Cstrong>(C)\u003C/strong> Mean values of I\u003Csub>NXC\u003C/sub> at -100 mV in absence (Ctr) and presence of disopyramide. \u003Cstrong>(D)\u003C/strong> Representative traces of peak and late I\u003Csub>Na\u003C/sub> in absence (Ctr) and presence of disopyramide (10 &#xb5;M). \u003Cstrong>(E)\u003C/strong> Mean values of late I\u003Csub>Na\u003C/sub> at -40 mV in absence (Ctr) and presence of disopyramide. n, number of cells.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Disopyramide Enhanced the Late Na Channel Currents in SQTS1-hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">Measuring late Na channel current is challenging due to its small amplitude. To improve the measurements and reduced the influence of other currents, high concentration of extracellular Na concentration (140 mM) was used to increase the driving force and TTX (30&#xb5;M)-sensitive currents (late I\u003Csub>Na\u003C/sub>) were analyzed at 300 ms after initiation of depolarizing pulse. Under this condition 10 &#xb5;M disopyramide enhanced significantly the late I\u003Csub>Na\u003C/sub>, although it suppressed the peak I\u003Csub>Na\u003C/sub> (\u003Ca href=\"#f7\">Figures 7D, E\u003C/a>). In hiPSC-CMs from the healthy donor, disopyramide exerted similar effects (\u003Ca href=\"#h12\">Figure S6\u003C/a>).\u003C/p>\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\u003Cp class=\"mb15\">In the current study, for the first time, we investigated the ionic mechanism underlying the APD-prolonging and antiarrhythmic effects of disopyramide in hiPSC-CMs from a patient with SQTS type 1. The new findings in this study are: (1) Disopyramide enhanced I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>NCX\u003C/sub> and late I\u003Csub>Na\u003C/sub> in SQTS1-hiPSC-CMs; (2) Disopyramide reduced I\u003Csub>SK\u003C/sub> in SQTS1-hiPSC-CMs. These effects may underlie the APD-prolonging and antiarrhythmic effect of disopyramide.\u003C/p>\u003Cp class=\"mb15\">Disopyramide is a class Ia antiarrhythmic drug used in the therapy of atrial and ventricular arrhythmias. A major feature of class Ia antiarrhythmic drugs is a use-dependent block of the cardiac fast sodium current, which underlies the suppression of excitability and conduction speed (\u003Ca href=\"#B33\">Sunami et al., 1991\u003C/a>; \u003Ca href=\"#B41\">Zunkler et al., 2000\u003C/a>). The sodium channel blocking is an important effect of class I antiarrhythmic drugs including disopyramide for terminating tachyarrhythmias.\u003C/p>\u003Cp class=\"mb15\">Disopyramide has been reported to prolong the QTc interval and is considered to be a promising agent for normalizing the QTc by blocking potassium channels (\u003Ca href=\"#B10\">Dritsas et al., 1992\u003C/a>; \u003Ca href=\"#B30\">Sherrid et al., 2005\u003C/a>; \u003Ca href=\"#B29\">Schimpf et al., 2007\u003C/a>; \u003Ca href=\"#B19\">Johnson et al., 2011\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Disopyramide has also anticholinergic effect that may contribute to QT prolongation (\u003Ca href=\"#B26\">Mirro et al., 1980\u003C/a>; \u003Ca href=\"#B34\">Teichman, 1985\u003C/a>). At cellular level, disopyramide has been shown to prolong APD (\u003Ca href=\"#B31\">Shinnawi et al., 2019\u003C/a>), consistent with the QT-prolongation at organ level (\u003Ca href=\"#B27\">Mizobuchi et al., 2008\u003C/a>). The APD-and QT-prolongation could be another reason for disopyramide effect terminating arrhythmias.\u003C/p>\u003Cp class=\"mb15\">In the current study, we used hiPSC-CMs from a patient with SQTS1 to examine the APD-prolonging and antiarrhythmic effects of disopyramide, mainly the ionic mechanisms of the effects. In the SQTS1-hiPSC-CMs, disopyramide changed significantly APs, mainly the Vmax, APD50, and APD90 and reduced arrhythmic events induced by CCh+Epi. The reduction of Vmax is consistent with its Na channel blocking effect (suppressing peak I\u003Csub>Na\u003C/sub>). Both the reduction of Vmax and the APD-prolongation may contribute to the antiarrhythmic effect of disopyramide in SQTS1-hiPSC-CMs. However, how the APD was prolonged by disopyramide in SQTS1-hiPSC-CMs needs to be clarified.\u003C/p>\u003Cp class=\"mb15\">I\u003Csub>Kr\u003C/sub> is an important repolarizing current for determining APD and is the target of many drugs that influence APD. Although the effect of disopyramide on I\u003Csub>Kr\u003C/sub> has already been examined in different types of cells (\u003Ca href=\"#B38\">Virag et al., 1998\u003C/a>; \u003Ca href=\"#B12\">El Harchi et al., 2012b\u003C/a>), whether the APD-prolongation in SQTS1-hiPSC-CMs resulted from the suppression of I\u003Csub>Kr\u003C/sub> by disopyramide is still unknown. The effect of disopyramide on I\u003Csub>Kr\u003C/sub> has not been tested in SQTS1-hiPSC-CMs. In the current study, we examined the effects on I\u003Csub>Kr\u003C/sub> in our SQTS1-hiPSC-CMs carrying the HERG channel mutation N588K, which has been well investigated and confirmed as a pathogenic mutation for SQTS1 (\u003Ca href=\"#B13\">El-Battrawy et al., 2018\u003C/a>; \u003Ca href=\"#B31\">Shinnawi et al., 2019\u003C/a>). The result is surprising, showing that disopyramide did not significantly reduce I\u003Csub>Kr\u003C/sub> in our SQTS1-hiPSC-CMs, although it suppressed I\u003Csub>Kr\u003C/sub> in donor-hiPSC-CMs. The HERG channel mutation (N588K) in our cells could be a reason for the ineffectiveness of disopyramide because the mutation has been shown to render I\u003Csub>Kr\u003C/sub> resistant to other drugs (\u003Ca href=\"#B24\">McPate et al., 2008\u003C/a>; \u003Ca href=\"#B31\">Shinnawi et al., 2019\u003C/a>). Of note, in CHO cells expressing I\u003Csub>Kr\u003C/sub> channels carrying N588K, disopyramide inhibited I\u003Csub>Kr\u003C/sub> with an efficacy similar to that in cells expressing wild type I\u003Csub>Kr\u003C/sub> channels (\u003Ca href=\"#B25\">McPate et al., 2006\u003C/a>), indicating the mutation did not change the efficacy of disopyramide in CHO cells. Considering the difference between CHO cells and cardiomyocytes, we expect that some unknown factors in addition to the gene mutations can influence the drug effects. Why disopyramide did not inhibit I\u003Csub>Kr\u003C/sub> in SQTS1-hiPSC-CMs remains to be clarified.\u003C/p>\u003Cp class=\"mb15\">The failure of I\u003Csub>Kr\u003C/sub>-blocking suggests extra ionic mechanisms for the APD-prolongation by disopyramide in SQTS1-hiPSC-CMs. Therefore, other ion channel currents that may influence APD were investigated.\u003C/p>\u003Cp class=\"mb15\">Disopyramide was shown to block I\u003Csub>Kur\u003C/sub> (\u003Ca href=\"#B2\">Arechiga et al., 2008\u003C/a>), I\u003Csub>KAch\u003C/sub>, and I\u003Csub>to\u003C/sub> (\u003Ca href=\"#B38\">Virag et al., 1998\u003C/a>), but those currents were found specifically or predominantly in atrial myocytes. It is unlikely that those three currents contribute to the APD-prolongation by disopyramide in ventricular-like hiPSC-CMs measured in this study. I\u003Csub>Ks\u003C/sub> and I\u003Csub>KATP\u003C/sub> can also influence APD in cardiomyocytes. Disopyramide did not change both currents in our study, indicating that both currents are not involved in the APD-prolongation by disopyramide. The I\u003Csub>KATP\u003C/sub>, which is activated in ischemic/hypoxic conditions and leads to arrhythmogenic shortening of the APD, was reported to be suppressed by disopyramide (\u003Ca href=\"#B18\">Horie et al., 1992\u003C/a>; \u003Ca href=\"#B9\">de Lorenzi et al., 1995\u003C/a>). The disparity may result from differences of species or gene mutation related changes.\u003C/p>\u003Cp class=\"mb15\">I\u003Csub>SK\u003C/sub>, another outward K channel current, can also influence APD (\u003Ca href=\"#B32\">Skibsbye et al., 2014\u003C/a>; \u003Ca href=\"#B40\">Zhang et al., 2014\u003C/a>). We observed that disopyramide, indeed, reduced I\u003Csub>SK\u003C/sub> in our SQTS1- and donor-hiPSC-CMs, indicative of contribution of I\u003Csub>SK\u003C/sub> to the APD-prolongation in the presence of disopyramide.\u003C/p>\u003Cp class=\"mb15\">Disopyramide was shown to inhibit I\u003Csub>Ca-L\u003C/sub> in rabbit sinus node cells and sheep Purkinje fibers (\u003Ca href=\"#B8\">Coraboeuf et al., 1988\u003C/a>; \u003Ca href=\"#B20\">Kotake et al., 1988\u003C/a>). The second surprising finding in this study is the enhancement of I\u003Csub>Ca-L\u003C/sub> by disopyramide in SQTS1-hiPSC-CMs. Since disopyramide inhibited I\u003Csub>Ca-L\u003C/sub> in donor-hiPSC-CMs, the reason for the disparity is probably the mutation or disease related alteration. To date, the effect of disopyramide on I\u003Csub>Ca-L\u003C/sub> has been not tested in cardiomyocytes from SQTS-patients. The enhancement of I\u003Csub>Ca-L\u003C/sub> in SQTS1-hiPSC-CMs by disopyramide, which may contribute to APD-prolongation, suggests that the mutation in KCNH2 may cause changes in channels in addition to the HERG channel.\u003C/p>\u003Cp class=\"mb15\">The inward currents I\u003Csub>NCX\u003C/sub> and late I\u003Csub>Na\u003C/sub> may also influence APD. To our knowledge, disopyramide effect on I\u003Csub>NCX\u003C/sub> has not been reported. Inhibitory effect of disopyramide on late I\u003Csub>Na\u003C/sub> has been reported. A study showed that disopyramide inhibited persistent late human cardiac Na\u003Csup>+\u003C/sup> currents conducted by inactivation-deficient mutant Na\u003Csup>+\u003C/sup> channels (hNav1.5-CW mutant) expressed in HEK293 (\u003Ca href=\"#B39\">Wang et al., 2013\u003C/a>). Another study demonstrated that when the fast component of I\u003Csub>Na\u003C/sub> inactivation was removed by chloramine-T, I\u003Csub>Na\u003C/sub> amplitude was reduced by disopyramide (20 &#xb5;M) (\u003Ca href=\"#B21\">Koumi et al., 1992\u003C/a>). Those data indicate that disopyramide can reduced late I\u003Csub>Na\u003C/sub>. In current study, we observed that disopyramide enhanced I\u003Csub>NCX\u003C/sub> and late I\u003Csub>Na\u003C/sub> in both donor and SQTS1 hiPSC-CMs. How disopyramide enhanced both currents is not clear. Given that other types of sodium channels including SCN10A and SCN1B are also expressed in cardiomyocytes, it could be possible that disopyramide can activate SCN10A or other ion channels or proteins that can enhance late I\u003Csub>Na\u003C/sub>. Although exact mechanisms for the surprising findings in this study need to be clarified in future studies, these effects may help explain the APD-prolongation by disopyramide.\u003C/p>\u003Cp class=\"mb15\">Recently, a study (\u003Ca href=\"#B22\">Blinova et al., 2019\u003C/a>) examined effects of two drugs (dofetilide and moxifloxacin) on QT-intervals in subjects and action potential durations in hiPSC-CMs from the same subjects. The study showed no significant correlation between the subject-specific APD response slopes and clinical QT response slopes to either moxifloxacin (P = 0.75) or dofetilide (P = 0.69). Similarly, no significant correlation was found between baseline QT and baseline APD measurements (P = 0.93). These results facilitate discussion into factors obscuring correlation between hiPSC-CM studies and clinical studies. In addition, the study hinted at the possibility that immaturity and inherent variability of iPSC-CMs may dim patient-specific drug response prediction in the clinic. Hence, to know the real effects of disopyramide in SQTS1-patients, clinical studies are still necessary in spite of the results in SQTS1-hiPSC-CMs.\u003C/p>\u003Cp class=\"mb15\">Other studies showed that disopyramide at 10 &#xb5;M caused EAD-like events and at 100 &#xb5;M caused ectopic beats (\u003Ca href=\"#B5\">Bot et al., 2018\u003C/a>)&#xa0;and possess a high TdP (Torsade de pointes) risk (\u003Ca href=\"#B4\">Blinova et al., 2018\u003C/a>). These studies suggest that when disopyramide, as many other antiarrhythmic drugs, is applied to patients, not only the antiarrhythmic but also the proarrhythmic effect should be considered.\u003C/p>\u003Cp class=\"mb0\">In summary, in SQTS1-hiPSC-CMs, the ionic mechanisms of disopyramide behind APD-prolonging and antiarrhythmic effects were investigated. The results demonstrated that the APD-prolonging and antiarrhythmic effects of disopyramide in SQTS1-hiPSC-CMs with N588K-HERG channels resulted from enhancing I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>NCX\u003C/sub>, late I\u003Csub>Na\u003C/sub>, and reducing I\u003Csub>SK\u003C/sub> besides Na channel blocking.\u003C/p>\u003Ch3>Study Limitations\u003C/h3>\u003Cp class=\"mb15\">Due to the difficulty to find SQTS1 patients from different families with the same mutation in HERG channels, we recruited only one SQTS1 patient for this study. Differences among individuals cannot be ruled out. However, the studies using cells from a single patient with a specific gene mutation may be also relevant, at least for precision medicine.\u003C/p>\u003Cp class=\"mb15\">The immaturity is another limitation of hiPSC-CMs to be considered. Without studies in mature human cardiomyocytes, the possibility that disopyramide displays effects in native cardiomyocytes of SQTS-patients different from that of the SQTS1-hiPSC-CMs cannot be excluded.\u003C/p>\u003Cp class=\"mb0\">Given the difference between hiPSC-CMs and adult human cardiomyocytes as well as the limitation of study in cells from only one patient, the clinical efficacy of disopyramide still needs to be examined in SQTS1-patients.\u003C/p>\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Data Availability Statement\u003C/h2>\u003Cp class=\"mb0\">The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.\u003C/p>\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Ethics Statement\u003C/h2>\u003Cp class=\"mb0\">The studies involving human participants were reviewed and approved by Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg (Stated in the manuscript). The patients/participants provided their written informed consent to participate in this study.\u003C/p>\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\u003Cp class=\"mb0\">HL, QX, XL, RZ, and SL performed experiments and analyzed data. IE-B, LC, MB, XZ, and IA designed the study and wrote the paper. All authors contributed to the article and approved the submitted version.\u003C/p>\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Funding\u003C/h2>\u003Cp class=\"mb0\">This study was supported by the German Center for Cardiovascular Research (DZHK) (81Z0500204) and National Natural Science Foundation of China (No. 31300947).\u003C/p>\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Conflict of Interest\u003C/h2>\u003Cp class=\"mb15\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\u003Cp class=\"mb0\">We gratefully thank C. Liebetrau for excellent technical assistance. We thank the Chinese Scholarship Council (CSC) for the financial support for XL. Excellent technical support by the Stem Cell Unit, G&#xf6;ttingen is acknowledged.\u003C/p>\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\u003Cp class=\"mb15\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fphar.2020.554422/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fphar.2020.554422/full#supplementary-material\u003C/a>\u003C/p>\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>References\u003C/h2>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> Abriel, H., Rougier, J. S. (2013). beta-blockers in congenital short-QT syndrome as ion channel blockers. \u003Ci>J. Cardiovasc. Electrophysiol.\u003C/i> 24, 1172&#x2013;1174. doi: 10.1111/jce.12204\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23890274/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/jce.12204\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Abriel&amp;author=J.%20S.+Rougier&amp;publication_year=2013&amp;title=beta-blockers%20in%20congenital%20short-QT%20syndrome%20as%20ion%20channel%20blockers&amp;journal=J.+Cardiovasc.+Electrophysiol.&amp;volume=24&amp;pages=1172\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> Arechiga, I. A., Barrio-Echavarria, G. F., Rodriguez-Menchaca, A. A., Moreno-Galindo, E. G., Decher, N., Tristani-Firouzi, M., et al. (2008). Kv1.5 open channel block by the antiarrhythmic drug disopyramide: molecular determinants of block. \u003Ci>J. Pharmacol. Sci.\u003C/i> 108, 49&#x2013;55. doi: 10.1254/jphs.08084FP\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18818480/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1254/jphs.08084FP\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I.%20A.+Arechiga&amp;author=G.%20F.+Barrio-Echavarria&amp;author=A.%20A.+Rodriguez-Menchaca&amp;author=E.%20G.+Moreno-Galindo&amp;author=N.+Decher&amp;author=M.+Tristani-Firouzi&amp;publication_year=2008&amp;title=Kv1.5%20open%20channel%20block%20by%20the%20antiarrhythmic%20drug%20disopyramide%3A%20molecular%20determinants%20of%20block&amp;journal=J.+Pharmacol.+Sci.&amp;volume=108&amp;pages=49\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> Bjerregaard, P. (2018). The diagnosis and management of short QT syndrome. \u003Ci>Heart Rhythm.\u003C/i> 15 (8), 1261&#x2013;1267. doi:&#xa0;10.1016/j.hrthm.2018.02.034\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29501667/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.hrthm.2018.02.034\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P.+Bjerregaard&amp;publication_year=2018&amp;title=The%20diagnosis%20and%20management%20of%20short%20QT%20syndrome&amp;journal=Heart+Rhythm.&amp;volume=15&amp;pages=1261\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> Blinova, K., Schocken, D., Patel, D., Daluwatte, C., Vicente, J., Wu, J. C., et al. (2019). Clinical trial in a dish: Personalized stem cell-derived cardiomyocyte assay compared with clinical trial results for two QT-prolonging drugs. \u003Ci>Clin Transl Sci.\u003C/i> 12 (6), 687&#x2013;697. doi: 10.1111/cts.12674\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31328865/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cts.12674\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K.+Blinova&amp;author=D.+Schocken&amp;author=D.+Patel&amp;author=C.+Daluwatte&amp;author=J.+Vicente&amp;author=J.%20C.+Wu&amp;publication_year=2019&amp;title=Clinical%20trial%20in%20a%20dish%3A%20Personalized%20stem%20cell-derived%20cardiomyocyte%20assay%20compared%20with%20clinical%20trial%20results%20for%20two%20QT-prolonging%20drugs&amp;journal=Clin+Transl+Sci.&amp;volume=12&amp;pages=687\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> Bot, C. T., Juhasz, K., Haeusermann, F., Polonchuk, L., Traebert, M., Stoelzle-Feix, S. (2018). Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes. \u003Ci>J. Pharmacol. Toxicol. Methods\u003C/i> 93, 46&#x2013;58. doi: 10.1016/j.vascn.2018.06.006\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29940218/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.vascn.2018.06.006\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C.%20T.+Bot&amp;author=K.+Juhasz&amp;author=F.+Haeusermann&amp;author=L.+Polonchuk&amp;author=M.+Traebert&amp;author=S.+Stoelzle-Feix&amp;publication_year=2018&amp;title=Cross%20-%20site%20comparison%20of%20excitation-contraction%20coupling%20using%20impedance%20and%20field%20potential%20recordings%20in%20hiPSC%20cardiomyocytes&amp;journal=J.+Pharmacol.+Toxicol.+Methods&amp;volume=93&amp;pages=46\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> Brugada, R., Hong, K., Dumaine, R., Cordeiro, J., Gaita, F., Borggrefe, M., et al. (2004). Sudden death associated with short-QT syndrome linked to mutations in HERG. \u003Ci>Circulation\u003C/i> 109, 30&#x2013;35. doi: 10.1161/01.CIR.0000109482.92774.3A\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/14676148/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/01.CIR.0000109482.92774.3A\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Brugada&amp;author=K.+Hong&amp;author=R.+Dumaine&amp;author=J.+Cordeiro&amp;author=F.+Gaita&amp;author=M.+Borggrefe&amp;publication_year=2004&amp;title=Sudden%20death%20associated%20with%20short-QT%20syndrome%20linked%20to%20mutations%20in%20HERG&amp;journal=Circulation&amp;volume=109&amp;pages=30\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> Campuzano, O., Sarquella-Brugada, G., Cesar, S., Arbelo, E., Brugada, J., Brugada, R. (2018). Recent Advances in Short QT Syndrome. \u003Ci>Front. Cardiovasc. Med.\u003C/i> 5, 149. doi: 10.3389/fcvm.2018.00149\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30420954/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fcvm.2018.00149\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=O.+Campuzano&amp;author=G.+Sarquella-Brugada&amp;author=S.+Cesar&amp;author=E.+Arbelo&amp;author=J.+Brugada&amp;author=R.+Brugada&amp;publication_year=2018&amp;title=Recent%20Advances%20in%20Short%20QT%20Syndrome&amp;journal=Front.+Cardiovasc.+Med.&amp;volume=5&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> Coraboeuf, E., Deroubaix, E., Escande, D., Coulombe, A. (1988). Comparative effects of three class I antiarrhythmic drugs on plateau and pacemaker currents of sheep cardiac Purkinje fibres. \u003Ci>Cardiovasc. Res.\u003C/i> 22, 375&#x2013;384. doi: 10.1093/cvr/22.6.375\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/2852055/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/cvr/22.6.375\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E.+Coraboeuf&amp;author=E.+Deroubaix&amp;author=D.+Escande&amp;author=A.+Coulombe&amp;publication_year=1988&amp;title=Comparative%20effects%20of%20three%20class%20I%20antiarrhythmic%20drugs%20on%20plateau%20and%20pacemaker%20currents%20of%20sheep%20cardiac%20Purkinje%20fibres&amp;journal=Cardiovasc.+Res.&amp;volume=22&amp;pages=375\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> de Lorenzi, F. G., Bridal, T. R., Spinelli, W. (1995). Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes. \u003Ci>J. Pharmacol. Exp. Ther.\u003C/i> 272, 714&#x2013;723.\n\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7853185/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.%20G.+de%20Lorenzi&amp;author=T.%20R.+Bridal&amp;author=W.+Spinelli&amp;publication_year=1995&amp;title=Voltage-dependent%20inhibition%20of%20the%20ATP-sensitive%20K%2B%20current%20by%20the%20class%20Ia%20agent%20disopyramide%20in%20cat%20ventricular%20myocytes&amp;journal=J.+Pharmacol.+Exp.+Ther.&amp;volume=272&amp;pages=714\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> Dritsas, A., Sbarouni, E., Gilligan, D., Nihoyannopoulos, P., Oakley, C. M. (1992). QT-interval abnormalities in hypertrophic cardiomyopathy. \u003Ci>Clin. Cardiol.\u003C/i> 15, 739&#x2013;742. doi: 10.1002/clc.4960151010\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/1395184/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/clc.4960151010\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Dritsas&amp;author=E.+Sbarouni&amp;author=D.+Gilligan&amp;author=P.+Nihoyannopoulos&amp;author=C.%20M.+Oakley&amp;publication_year=1992&amp;title=QT-interval%20abnormalities%20in%20hypertrophic%20cardiomyopathy&amp;journal=Clin.+Cardiol.&amp;volume=15&amp;pages=739\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> El Harchi, A., Melgari, D., Zhang, Y. H., Zhang, H., Hancox, J. C. (2012a). Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K(+) channel. \u003Ci>PLoS One\u003C/i> 7, e52451. doi: 10.1371/journal.pone.0052451\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23300672/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pone.0052451\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+El%20Harchi&amp;author=D.+Melgari&amp;author=Y.%20H.+Zhang&amp;author=H.+Zhang&amp;author=J.%20C.+Hancox&amp;publication_year=2012&amp;title=Action%20potential%20clamp%20and%20pharmacology%20of%20the%20variant%201%20Short%20QT%20Syndrome%20T618I%20hERG%20K%28%2B%29%20channel&amp;journal=PLoS+One&amp;volume=7&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> El Harchi, A., Zhang, Y. H., Hussein, L., Dempsey, C. E., Hancox, J. C. (2012b). Molecular determinants of hERG potassium channel inhibition by disopyramide. \u003Ci>J. Mol. Cell. Cardiol.\u003C/i> 52, 185&#x2013;195. doi: 10.1016/j.yjmcc.2011.09.021\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21989164/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.yjmcc.2011.09.021\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+El%20Harchi&amp;author=Y.%20H.+Zhang&amp;author=L.+Hussein&amp;author=C.%20E.+Dempsey&amp;author=J.%20C.+Hancox&amp;publication_year=2012&amp;title=Molecular%20determinants%20of%20hERG%20potassium%20channel%20inhibition%20by%20disopyramide&amp;journal=J.+Mol.+Cell.+Cardiol.&amp;volume=52&amp;pages=185\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> El-Battrawy, I., Lan, H., Cyganek, L., Zhao, Z., Li, X., Buljubasic, F., et al. (2018). Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. \u003Ci>J. Am. Heart Assoc.\u003C/i> 7 (7), e007394. doi: 10.1161/JAHA.117.007394\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29574456/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/JAHA.117.007394\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I.+El-Battrawy&amp;author=H.+Lan&amp;author=L.+Cyganek&amp;author=Z.+Zhao&amp;author=X.+Li&amp;author=F.+Buljubasic&amp;publication_year=2018&amp;title=Modeling%20Short%20QT%20Syndrome%20Using%20Human-Induced%20Pluripotent%20Stem%20Cell-Derived%20Cardiomyocytes&amp;journal=J.+Am.+Heart+Assoc.&amp;volume=7&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> Gaita, F., Giustetto, C., Bianchi, F., Schimpf, R., Haissaguerre, M., Calo, L., et al. (2004). Short QT syndrome: pharmacological treatment. \u003Ci>J. Am. Coll. Cardiol.\u003C/i> 43, 1494&#x2013;1499. doi: 10.1016/j.jacc.2004.02.034\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15093889/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2004.02.034\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Gaita&amp;author=C.+Giustetto&amp;author=F.+Bianchi&amp;author=R.+Schimpf&amp;author=M.+Haissaguerre&amp;author=L.+Calo&amp;publication_year=2004&amp;title=Short%20QT%20syndrome%3A%20pharmacological%20treatment&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=43&amp;pages=1494\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> Giustetto, C., Di Monte, F., Wolpert, C., Borggrefe, M., Schimpf, R., Sbragia, P., et al. (2006). Short QT syndrome: clinical findings and diagnostic-therapeutic implications. \u003Ci>Eur. Heart J.\u003C/i> 27, 2440&#x2013;2447. doi: 10.1093/eurheartj/ehl185\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16926178/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehl185\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C.+Giustetto&amp;author=F.+Di%20Monte&amp;author=C.+Wolpert&amp;author=M.+Borggrefe&amp;author=R.+Schimpf&amp;author=P.+Sbragia&amp;publication_year=2006&amp;title=Short%20QT%20syndrome%3A%20clinical%20findings%20and%20diagnostic-therapeutic%20implications&amp;journal=Eur.+Heart+J.&amp;volume=27&amp;pages=2440\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> Giustetto, C., Schimpf, R., Mazzanti, A., Scrocco, C., Maury, P., Anttonen, O., et al. (2011). Long-term follow-up of patients with short QT syndrome. \u003Ci>J. Am. Coll. Cardiol.\u003C/i> 58, 587&#x2013;595. doi: 10.1016/j.jacc.2011.03.038\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21798421/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2011.03.038\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C.+Giustetto&amp;author=R.+Schimpf&amp;author=A.+Mazzanti&amp;author=C.+Scrocco&amp;author=P.+Maury&amp;author=O.+Anttonen&amp;publication_year=2011&amp;title=Long-term%20follow-up%20of%20patients%20with%20short%20QT%20syndrome&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=58&amp;pages=587\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> Gussak, I., Brugada, P., Brugada, J., Wright, R. S., Kopecky, S. L., Chaitman, B. R., et al. (2000). Idiopathic short QT interval: a new clinical syndrome? \u003Ci>Cardiology\u003C/i> 94, 99&#x2013;102. doi: 10.1159/000047299\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11173780/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1159/000047299\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I.+Gussak&amp;author=P.+Brugada&amp;author=J.+Brugada&amp;author=R.%20S.+Wright&amp;author=S.%20L.+Kopecky&amp;author=B.%20R.+Chaitman&amp;publication_year=2000&amp;title=Idiopathic%20short%20QT%20interval%3A%20a%20new%20clinical%20syndrome&amp;journal=Cardiology&amp;volume=94&amp;pages=99\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> Horie, M., Hayashi, S., Yuzuki, Y., Sasayama, S. (1992). Comparative studies of ATP sensitive potassium channels in heart and pancreatic beta cells using Vaughan-Williams class Ia antiarrhythmics. \u003Ci>Cardiovasc. Res.\u003C/i> 26, 1087&#x2013;1094. doi: 10.1093/cvr/26.11.1087\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/1291086/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/cvr/26.11.1087\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Horie&amp;author=S.+Hayashi&amp;author=Y.+Yuzuki&amp;author=S.+Sasayama&amp;publication_year=1992&amp;title=Comparative%20studies%20of%20ATP%20sensitive%20potassium%20channels%20in%20heart%20and%20pancreatic%20beta%20cells%20using%20Vaughan-Williams%20class%20Ia%20antiarrhythmics&amp;journal=Cardiovasc.+Res.&amp;volume=26&amp;pages=1087\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> Johnson, J. N., Grifoni, C., Bos, J. M., Saber-Ayad, M., Ommen, S. R., Nistri, S., et al. (2011). Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. \u003Ci>Eur. Heart J.\u003C/i> 32, 1114&#x2013;1120. doi: 10.1093/eurheartj/ehr021\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21345853/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehr021\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J.%20N.+Johnson&amp;author=C.+Grifoni&amp;author=J.%20M.+Bos&amp;author=M.+Saber-Ayad&amp;author=S.%20R.+Ommen&amp;author=S.+Nistri&amp;publication_year=2011&amp;title=Prevalence%20and%20clinical%20correlates%20of%20QT%20prolongation%20in%20patients%20with%20hypertrophic%20cardiomyopathy&amp;journal=Eur.+Heart+J.&amp;volume=32&amp;pages=1114\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> Kotake, H., Hasegawa, J., Mashiba, H. (1988). Effect of class I antiarrhythmic agents on slow Ca2+ channels of myocardial cells. \u003Ci>Jpn Circ. J.\u003C/i> 52, 238&#x2013;242. doi: 10.1253/jcj.52.238\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/2453688/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1253/jcj.52.238\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Kotake&amp;author=J.+Hasegawa&amp;author=H.+Mashiba&amp;publication_year=1988&amp;title=Effect%20of%20class%20I%20antiarrhythmic%20agents%20on%20slow%20Ca2%2B%20channels%20of%20myocardial%20cells&amp;journal=Jpn+Circ.+J.&amp;volume=52&amp;pages=238\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> Koumi, S., Sato, R., Hisatome, I., Hayakawa, H., Okumura, H., Katori, R. (1992). Disopyramide block of cardiac sodium current after removal of the fast inactivation process in guinea pig ventricular myocytes. \u003Ci>J. Pharmacol. Exp. Ther.\u003C/i> 261, 1167&#x2013;1174.\n\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/1318373/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+Koumi&amp;author=R.+Sato&amp;author=I.+Hisatome&amp;author=H.+Hayakawa&amp;author=H.+Okumura&amp;author=R.+Katori&amp;publication_year=1992&amp;title=Disopyramide%20block%20of%20cardiac%20sodium%20current%20after%20removal%20of%20the%20fast%20inactivation%20process%20in%20guinea%20pig%20ventricular%20myocytes&amp;journal=J.+Pharmacol.+Exp.+Ther.&amp;volume=261&amp;pages=1167\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> Blinova, K., Schocken, D., Patel, D., Daluwatte, C., Vicente, J., Wu, J. C., et al. (2019). Clinical Trial in a Dish: Personalized Stem Cell&#x2013;DerivedCardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs. \u003Ci>Citation: Clin. Transl. Sci.\u003C/i> 12, 687&#x2013;697. doi: 10.1111/cts.12674\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1111/cts.12674\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K.+Blinova&amp;author=D.+Schocken&amp;author=D.+Patel&amp;author=C.+Daluwatte&amp;author=J.+Vicente&amp;author=J.%20C.+Wu&amp;publication_year=2019&amp;title=Clinical%20Trial%20in%20a%20Dish%3A%20Personalized%20Stem%20Cell%E2%80%93DerivedCardiomyocyte%20Assay%20Compared%20With%20Clinical%20Trial%20Results%20for%20Two%20QT-Prolonging%20Drugs&amp;journal=Citation:+Clin.+Transl.+Sci.&amp;volume=12&amp;pages=687\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> Mazzanti, A., Kanthan, A., Monteforte, N., Memmi, M., Bloise, R., Novelli, V., et al. (2014). Novel insight into the natural history of short QT syndrome. \u003Ci>J. Am. Coll. Cardiol.\u003C/i> 63, 1300&#x2013;1308. doi: 10.1016/j.jacc.2013.09.078\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24291113/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2013.09.078\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Mazzanti&amp;author=A.+Kanthan&amp;author=N.+Monteforte&amp;author=M.+Memmi&amp;author=R.+Bloise&amp;author=V.+Novelli&amp;publication_year=2014&amp;title=Novel%20insight%20into%20the%20natural%20history%20of%20short%20QT%20syndrome&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=63&amp;pages=1300\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> McPate, M. J., Duncan, R. S., Hancox, J. C., Witchel, H. J. (2008). Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. \u003Ci>Br. J. Pharmacol.\u003C/i> 155, 957&#x2013;966. doi: 10.1038/bjp.2008.325\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18724381/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/bjp.2008.325\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.%20J.+McPate&amp;author=R.%20S.+Duncan&amp;author=J.%20C.+Hancox&amp;author=H.%20J.+Witchel&amp;publication_year=2008&amp;title=Pharmacology%20of%20the%20short%20QT%20syndrome%20N588K-hERG%20K%2B%20channel%20mutation%3A%20differential%20impact%20on%20selected%20class%20I%20and%20class%20III%20antiarrhythmic%20drugs&amp;journal=Br.+J.+Pharmacol.&amp;volume=155&amp;pages=957\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> McPate, M. J., Duncan, R. S., Witchel, H. J., Hancox, J. C. (2006). Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. \u003Ci>J. Mol. Cell. Cardiol.\u003C/i> 41, 563&#x2013;566. doi: 10.1016/j.yjmcc.2006.05.021\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16842817/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.yjmcc.2006.05.021\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.%20J.+McPate&amp;author=R.%20S.+Duncan&amp;author=H.%20J.+Witchel&amp;author=J.%20C.+Hancox&amp;publication_year=2006&amp;title=Disopyramide%20is%20an%20effective%20inhibitor%20of%20mutant%20HERG%20K%2B%20channels%20involved%20in%20variant%201%20short%20QT%20syndrome&amp;journal=J.+Mol.+Cell.+Cardiol.&amp;volume=41&amp;pages=563\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> Mirro, M. J., Manalan, A. S., Bailey, J. C., Watanabe, A. M. (1980). Anticholinergic effects of disopyramide and quinidine on guinea pig myocardium. Mediation by direct muscarinic receptor blockade. \u003Ci>Circ. Res.\u003C/i> 47, 855&#x2013;865. doi: 10.1161/01.RES.47.6.855\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7192183/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/01.RES.47.6.855\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.%20J.+Mirro&amp;author=A.%20S.+Manalan&amp;author=J.%20C.+Bailey&amp;author=A.%20M.+Watanabe&amp;publication_year=1980&amp;title=Anticholinergic%20effects%20of%20disopyramide%20and%20quinidine%20on%20guinea%20pig%20myocardium.%20Mediation%20by%20direct%20muscarinic%20receptor%20blockade&amp;journal=Circ.+Res.&amp;volume=47&amp;pages=855\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> Mizobuchi, M., Enjoji, Y., Yamamoto, R., Ono, T., Funatsu, A., Kambayashi, D., et al. (2008). Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties. \u003Ci>Pacing Clin. Electrophysiol. PACE\u003C/i> 31, 1229&#x2013;1232. doi: 10.1111/j.1540-8159.2008.01169.x\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1111/j.1540-8159.2008.01169.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Mizobuchi&amp;author=Y.+Enjoji&amp;author=R.+Yamamoto&amp;author=T.+Ono&amp;author=A.+Funatsu&amp;author=D.+Kambayashi&amp;publication_year=2008&amp;title=Nifekalant%20and%20disopyramide%20in%20a%20patient%20with%20short%20QT%20syndrome%3A%20evaluation%20of%20pharmacological%20effects%20and%20electrophysiological%20properties&amp;journal=Pacing+Clin.+Electrophysiol.+PACE&amp;volume=31&amp;pages=1229\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> Morady, F., Scheinman, M. M., Desai, J. (1982). Disopyramide. \u003Ci>Ann. Internal Med.\u003C/i> 96, 337&#x2013;343. doi: 10.7326/0003-4819-96-3-337\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.7326/0003-4819-96-3-337\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Morady&amp;author=M.%20M.+Scheinman&amp;author=J.+Desai&amp;publication_year=1982&amp;title=Disopyramide&amp;journal=Ann.+Internal+Med.&amp;volume=96&amp;pages=337\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a> Schimpf, R., Veltmann, C., Giustetto, C., Gaita, F., Borggrefe, M., Wolpert, C. (2007). In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study. \u003Ci>J. Cardiovasc. Electrophysiol.\u003C/i> 18, 1157&#x2013;1160. doi: 10.1111/j.1540-8167.2007.00925.x\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17711440/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/j.1540-8167.2007.00925.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Schimpf&amp;author=C.+Veltmann&amp;author=C.+Giustetto&amp;author=F.+Gaita&amp;author=M.+Borggrefe&amp;author=C.+Wolpert&amp;publication_year=2007&amp;title=In%20vivo%20effects%20of%20mutant%20HERG%20K%2B%20channel%20inhibition%20by%20disopyramide%20in%20patients%20with%20a%20short%20QT-1%20syndrome%3A%20a%20pilot%20study&amp;journal=J.+Cardiovasc.+Electrophysiol.&amp;volume=18&amp;pages=1157\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a> Sherrid, M. V., Barac, I., McKenna, W. J., Elliott, P. M., Dickie, S., Chojnowska, L., et al. (2005). Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. \u003Ci>J. Am. Coll. Cardiol.\u003C/i> 45, 1251&#x2013;1258. doi: 10.1016/j.jacc.2005.01.012\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15837258/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2005.01.012\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.%20V.+Sherrid&amp;author=I.+Barac&amp;author=W.%20J.+McKenna&amp;author=P.%20M.+Elliott&amp;author=S.+Dickie&amp;author=L.+Chojnowska&amp;publication_year=2005&amp;title=Multicenter%20study%20of%20the%20efficacy%20and%20safety%20of%20disopyramide%20in%20obstructive%20hypertrophic%20cardiomyopathy&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=45&amp;pages=1251\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a> Shinnawi, R., Shaheen, N., Huber, I., Shiti, A., Arbel, G., Gepstein, A., et al. (2019). Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets. \u003Ci>J. Am. Coll. Cardiol.\u003C/i> 73, 2310&#x2013;2324. doi: 10.1016/j.jacc.2019.02.055\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31072576/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2019.02.055\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Shinnawi&amp;author=N.+Shaheen&amp;author=I.+Huber&amp;author=A.+Shiti&amp;author=G.+Arbel&amp;author=A.+Gepstein&amp;publication_year=2019&amp;title=Modeling%20Reentry%20in%20the%20Short%20QT%20Syndrome%20With%20Human-Induced%20Pluripotent%20Stem%20Cell-Derived%20Cardiac%20Cell%20Sheets&amp;journal=J.+Am.+Coll.+Cardiol.&amp;volume=73&amp;pages=2310\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a> Skibsbye, L., Poulet, C., Diness, J. G., Bentzen, B. H., Yuan, L., Kappert, U., et al. (2014). Small-conductance calcium-activated potassium (SK) channels contribute to action potential repolarization in human atria. \u003Ci>Cardiovasc. Res.\u003C/i> 103, 156&#x2013;167. doi: 10.1093/cvr/cvu121\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24817686/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/cvr/cvu121\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L.+Skibsbye&amp;author=C.+Poulet&amp;author=J.%20G.+Diness&amp;author=B.%20H.+Bentzen&amp;author=L.+Yuan&amp;author=U.+Kappert&amp;publication_year=2014&amp;title=Small-conductance%20calcium-activated%20potassium%20%28SK%29%20channels%20contribute%20to%20action%20potential%20repolarization%20in%20human%20atria&amp;journal=Cardiovasc.+Res.&amp;volume=103&amp;pages=156\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a> Sunami, A., Fan, Z., Nitta, J., Hiraoka, M. (1991). Two components of use-dependent block of Na+ current by disopyramide and lidocaine in guinea pig ventricular myocytes. \u003Ci>Circ. Res.\u003C/i> 68, 653&#x2013;661. doi: 10.1161/01.RES.68.3.653\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/1660356/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/01.RES.68.3.653\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Sunami&amp;author=Z.+Fan&amp;author=J.+Nitta&amp;author=M.+Hiraoka&amp;publication_year=1991&amp;title=Two%20components%20of%20use-dependent%20block%20of%20Na%2B%20current%20by%20disopyramide%20and%20lidocaine%20in%20guinea%20pig%20ventricular%20myocytes&amp;journal=Circ.+Res.&amp;volume=68&amp;pages=653\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a> Teichman, S. (1985). The anticholinergic side effects of disopyramide and controlled-release disopyramide. \u003Ci>Angiology\u003C/i> 36, 767&#x2013;771. doi: 10.1177/000331978503601101\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/4061965/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1177/000331978503601101\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+Teichman&amp;publication_year=1985&amp;title=The%20anticholinergic%20side%20effects%20of%20disopyramide%20and%20controlled-release%20disopyramide&amp;journal=Angiology&amp;volume=36&amp;pages=767\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a> Thorsen, K., Dam, V. S., Kjaer-Sorensen, K., Pedersen, L. N., Skeberdis, V. A., Jurevicius, J., et al. (2017). Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome. \u003Ci>Nat. Commun.\u003C/i> 8, 1696. doi: 10.1038/s41467-017-01630-0\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29167417/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41467-017-01630-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K.+Thorsen&amp;author=V.%20S.+Dam&amp;author=K.+Kjaer-Sorensen&amp;author=L.%20N.+Pedersen&amp;author=V.%20A.+Skeberdis&amp;author=J.+Jurevicius&amp;publication_year=2017&amp;title=Loss-of-activity-mutation%20in%20the%20cardiac%20chloride-bicarbonate%20exchanger%20AE3%20causes%20short%20QT%20syndrome&amp;journal=Nat.+Commun.&amp;volume=8&amp;pages=1696\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a> Tiburcy, M., Hudson, J. E., Balfanz, P., Schlick, S., Meyer, T., Chang Liao, M. L., et al. (2017). Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. \u003Ci>Circulation\u003C/i> 135, 1832&#x2013;1847. doi: 10.1161/CIRCULATIONAHA.116.024145\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28167635/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCULATIONAHA.116.024145\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Tiburcy&amp;author=J.%20E.+Hudson&amp;author=P.+Balfanz&amp;author=S.+Schlick&amp;author=T.+Meyer&amp;author=M.%20L.+Chang%20Liao&amp;publication_year=2017&amp;title=Defined%20Engineered%20Human%20Myocardium%20With%20Advanced%20Maturation%20for%20Applications%20in%20Heart%20Failure%20Modeling%20and%20Repair&amp;journal=Circulation&amp;volume=135&amp;pages=1832\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a> Verlinden, N. J., Coons, J. C. (2015). Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. \u003Ci>Pharmacotherapy\u003C/i> 35, 1164&#x2013;1172. doi: 10.1002/phar.1664\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26684556/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/phar.1664\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N.%20J.+Verlinden&amp;author=J.%20C.+Coons&amp;publication_year=2015&amp;title=Disopyramide%20for%20Hypertrophic%20Cardiomyopathy%3A%20A%20Pragmatic%20Reappraisal%20of%20an%20Old%20Drug&amp;journal=Pharmacotherapy&amp;volume=35&amp;pages=1164\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a> Virag, L., Varro, A., Papp, J. G. (1998). Effect of disopyramide on potassium currents in rabbit ventricular myocytes. \u003Ci>Naunyn-Schmiedeberg&#x2019;s Arch. Pharmacol.\u003C/i> 357, 268&#x2013;275. doi: 10.1007/pl00005167\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1007/pl00005167\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L.+Virag&amp;author=A.+Varro&amp;author=J.%20G.+Papp&amp;publication_year=1998&amp;title=Effect%20of%20disopyramide%20on%20potassium%20currents%20in%20rabbit%20ventricular%20myocytes&amp;journal=Naunyn-Schmiedeberg&#x2019;s+Arch.+Pharmacol.&amp;volume=357&amp;pages=268\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a> Wang, G. K., Russell, G., Wang, S. Y. (2013). Persistent human cardiac Na+ currents in stably transfected mammalian cells: Robust expression and distinct open-channel selectivity among Class 1 antiarrhythmics. \u003Ci>Channels (Austin)\u003C/i> 7, 263&#x2013;274. doi: 10.4161/chan.25056\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23695971/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4161/chan.25056\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G.%20K.+Wang&amp;author=G.+Russell&amp;author=S.%20Y.+Wang&amp;publication_year=2013&amp;title=Persistent%20human%20cardiac%20Na%2B%20currents%20in%20stably%20transfected%20mammalian%20cells%3A%20Robust%20expression%20and%20distinct%20open-channel%20selectivity%20among%20Class%201%20antiarrhythmics&amp;journal=Channels+(Austin)&amp;volume=7&amp;pages=263\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a> Zhang, X. D., Timofeyev, V., Li, N., Myers, R. E., Zhang, D. M., Singapuri, A., et al. (2014). Critical roles of a small conductance Ca(2)(+)-activated K(+) channel (SK3) in the repolarization process of atrial myocytes. \u003Ci>Cardiovasc. Res.\u003C/i> 101, 317&#x2013;325. doi: 10.1093/cvr/cvt262\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24282291/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/cvr/cvt262\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=X.%20D.+Zhang&amp;author=V.+Timofeyev&amp;author=N.+Li&amp;author=R.%20E.+Myers&amp;author=D.%20M.+Zhang&amp;author=A.+Singapuri&amp;publication_year=2014&amp;title=Critical%20roles%20of%20a%20small%20conductance%20Ca%282%29%28%2B%29-activated%20K%28%2B%29%20channel%20%28SK3%29%20in%20the%20repolarization%20process%20of%20atrial%20myocytes&amp;journal=Cardiovasc.+Res.&amp;volume=101&amp;pages=317\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a> Zunkler, B. J., Kuhne, S., Rustenbeck, I., Ott, T., Hildebrandt, A. G. (2000). Disopyramide block of K(ATP) channels is mediated by the pore-forming subunit. \u003Ci>Life Sci.\u003C/i> 66, PL 245&#x2013;PL 252. doi: 10.1016/s0024-3205(00)00486-0\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1016/s0024-3205(00)00486-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B.%20J.+Zunkler&amp;author=S.+Kuhne&amp;author=I.+Rustenbeck&amp;author=T.+Ott&amp;author=A.%20G.+Hildebrandt&amp;publication_year=2000&amp;title=Disopyramide%20block%20of%20K%28ATP%29%20channels%20is%20mediated%20by%20the%20pore-forming%20subunit&amp;journal=Life+Sci.&amp;volume=66&amp;pages=PL 245\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003C/div>\u003Cdiv class=\"thinLineM20\">\u003C/div>\u003Cdiv class=\"AbstractSummary\">\u003Cp>\u003Cspan>Keywords:\u003C/span> short QT syndrome, arrhythmias, antiarrhythmic drugs, disopyramide, human-induced pluripotent stem cell-derived cardiomyocytes\u003C/p>\u003Cp>\u003Cspan>Citation:\u003C/span> Lan H, Xu Q, El-Battrawy I, Zhong R, Li X, Lang S, Cyganek L, Borggrefe M, Zhou X and Akin I (2020) Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. \u003Ci>Front. Pharmacol.\u003C/i> 11:554422. doi: 10.3389/fphar.2020.554422\u003C/p>\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 22 April 2020; \u003Cspan>Accepted:\u003C/span> 16 September 2020;\u003Cbr>\u003Cspan>Published:\u003C/span> 12 October 2020.\u003C/p>\u003Cdiv>\u003Cp>Edited by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/23236\">Nicolau Beckmann\u003C/a>, Novartis Institutes for BioMedical Research, Switzerland\u003C/div>\u003Cdiv>\u003Cp>Reviewed by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/973222\">Andrea Anampa-Guzm&#xe1;n\u003C/a>, National University of San Marcos, Peru\u003Cbr>\u003Ca href=\"https://loop.frontiersin.org/people/31911\">RaffaEle Coppini\u003C/a>, University of Florence, Italy\u003Cbr>\u003Ca href=\"https://loop.frontiersin.org/people/465333\">Ksenia Blinova\u003C/a>, United States Food and Drug Administration, United States\u003C/div>\u003Cp>\u003Cspan>Copyright\u003C/span> &#xa9; 2020 Lan, Xu, El-Battrawy, Zhong, Li, Lang, Cyganek, Borggrefe, Zhou and Akin. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Xiaobo Zhou, \u003Ca id=\"encmail\">WGlhb2JvLnpob3VAbWVkbWEudW5pLWhlaWRlbGJlcmcuZGU=\u003C/a>\u003C/p>\u003Cp>\u003Cspan>\u003Csup>&#x2020;\u003C/sup>\u003C/span>These authors have contributed equally to this work\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>","\u003Cul class=\"flyoutJournal\">\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h3\">Methods\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h6\">Data Availability Statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h7\">Ethics Statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h8\">Author Contributions\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h9\">Funding\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h10\">Conflict of Interest\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h11\">Acknowledgments\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h12\">Supplementary Material\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h13\">References\u003C/a>\u003C/li>\u003C/ul>",[671,677,682,685,690],{"name":672,"fileServerPackageEntryId":19,"fileServerId":673,"fileServerVersionNumber":674,"type":675},"EPUB.epub","554422/epub",2,{"code":676,"name":676},"EPUB",{"name":678,"fileServerPackageEntryId":678,"fileServerId":679,"fileServerVersionNumber":674,"type":680},"fphar-11-554422.pdf","554422/pubmed-zip",{"code":681,"name":681},"PDF",{"name":678,"fileServerPackageEntryId":19,"fileServerId":683,"fileServerVersionNumber":674,"type":684},"554422/publishers-proof/pdf",{"code":681,"name":681},{"name":686,"fileServerPackageEntryId":686,"fileServerId":679,"fileServerVersionNumber":674,"type":687},"fphar-11-554422.xml",{"code":688,"name":689},"NLM_XML","XML",{"name":691,"fileServerPackageEntryId":19,"fileServerId":692,"fileServerVersionNumber":370,"type":693},"Provisional PDF.pdf","554422/provisional-pdf",{"code":681,"name":681},"v3",{"title":696,"link":697,"meta":701,"script":832},"Frontiers | Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1",[698],{"rel":699,"href":700},"canonical","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/full",[702,705,708,710,713,717,720,724,727,730,733,735,737,739,741,743,746,749,751,754,757,759,762,765,768,771,774,778,782,785,788,791,793,796,798,801,803,806,808,811,814,817,819,822,824,827,829],{"hid":703,"property":703,"name":703,"content":704},"description","Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patien...",{"hid":706,"property":706,"name":707,"content":696},"og:title","title",{"hid":709,"property":709,"name":703,"content":704},"og:description",{"hid":711,"name":711,"content":712},"keywords","short QT syndrome,arryhthmias,antiarryhthmic drugs,Disopyramide,Human-induced pluripotent stem cell-derived cardiomyocytes",{"hid":714,"property":714,"name":715,"content":716},"og:site_name","site_name","Frontiers",{"hid":718,"property":718,"name":363,"content":719},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/554422/fphar-11-554422-HTML-r1/image_m/fphar-11-554422-g001.jpg",{"hid":721,"property":721,"name":722,"content":723},"og:type","type","article",{"hid":725,"property":725,"name":726,"content":700},"og:url","url",{"hid":728,"name":728,"content":729},"twitter:card","summary_large_image",{"hid":731,"name":731,"content":732},"citation_volume","11",{"hid":734,"name":734,"content":116},"citation_journal_title",{"hid":736,"name":736,"content":716},"citation_publisher",{"hid":738,"name":738,"content":652},"citation_journal_abbrev",{"hid":740,"name":740,"content":653},"citation_issn",{"hid":742,"name":742,"content":515},"citation_doi",{"hid":744,"name":744,"content":745},"citation_firstpage","554422",{"hid":747,"name":747,"content":748},"citation_language","English",{"hid":750,"name":750,"content":516},"citation_title",{"hid":752,"name":752,"content":753},"citation_keywords","short QT syndrome; arryhthmias; antiarryhthmic drugs; Disopyramide; Human-induced pluripotent stem cell-derived cardiomyocytes",{"hid":755,"name":755,"content":756},"citation_abstract","Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patients with SQTS type 1(SQTS1). The aim of this study was to investigate the mechanisms of disopyramide underlying its antiarrhythmic effects in SQTS1 with the N588K mutation in HERG channel. Human-induced pluripotent stem cellderived cardiomyocytes (hiPSC-CMs) from a patient with SQTS1 and a healthy donor, patch clamp and calcium imaging measurements were employed to assess the drug effects. Disopyramide prolonged the action potential duration (APD) in hiPSC-CMs from a SQTS1-patient (SQTS1-hiPSC-CMs).  In spontaneously beating SQTS1-hiPSC-CMs challenged by carbachol plus epinephrine, disopyramide reduced the arrhythmic events. Disopyramide enhanced the inward L-type calcium channel current (ICa-L), the late sodium channel current (late INa) and the Na/Ca exchanger current (INCX), but it reduced the outward small-conductance calcium-activated potassium channel current (ISK), leading to APD-prolongation. Disopyramide displayed no effects on the rapidly and slowly activating delayed rectifier and ATP-sensitive potassium channel currents. In hiPSC-CMs from the healthy donor, disopyramide reduced peak INa, ICa-L, IKr and ISK but enhanced late INa and INCX.The results demonstrated that disopyramide may be effective for preventing tachyarrhythmias in SQTS1-patients carrying the N588K mutation in HERG channel by APD-prolongation via enhancing ICa-L, late INa, INCX and reducing ISK.",{"hid":758,"name":758,"content":524},"citation_article_type",{"hid":760,"name":760,"content":761},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/pdf",{"hid":763,"name":763,"content":764},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554422/xml",{"hid":766,"name":766,"content":767},"citation_fulltext_world_readable","yes",{"hid":769,"name":769,"content":770},"citation_online_date","2020/09/16",{"hid":772,"name":772,"content":773},"citation_publication_date","2020/10/12",{"hid":775,"name":776,"content":777},"citation_author_0","citation_author","Lan, Huan ",{"hid":779,"name":780,"content":781},"citation_author_institution_0","citation_author_institution","Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, China",{"hid":783,"name":776,"content":784},"citation_author_1","Xu, Qiang ",{"hid":786,"name":780,"content":787},"citation_author_institution_1","First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany",{"hid":789,"name":776,"content":790},"citation_author_2","El-Battrawy, Ibrahim ",{"hid":792,"name":780,"content":787},"citation_author_institution_2",{"hid":794,"name":776,"content":795},"citation_author_3","Zhong, Rujia ",{"hid":797,"name":780,"content":787},"citation_author_institution_3",{"hid":799,"name":776,"content":800},"citation_author_4","Li, Xin ",{"hid":802,"name":780,"content":787},"citation_author_institution_4",{"hid":804,"name":776,"content":805},"citation_author_5","Lang, Siegfried ",{"hid":807,"name":780,"content":787},"citation_author_institution_5",{"hid":809,"name":776,"content":810},"citation_author_6","Cyganek, Lukas ",{"hid":812,"name":780,"content":813},"citation_author_institution_6","DZHK (German Center for Cardiovascular Research), Partner Site Gttingen, Germany",{"hid":815,"name":776,"content":816},"citation_author_7","Borggrefe, Martin ",{"hid":818,"name":780,"content":787},"citation_author_institution_7",{"hid":820,"name":776,"content":821},"citation_author_8","Zhou, Xiaobo ",{"hid":823,"name":780,"content":781},"citation_author_institution_8",{"hid":825,"name":776,"content":826},"citation_author_9","Akin, Ibrahim ",{"hid":828,"name":780,"content":787},"citation_author_institution_9",{"hid":830,"name":830,"content":831},"dc.identifier","doi:10.3389/fphar.2020.554422",[833,836,838,840,842],{"src":834,"body":13,"type":835,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":837,"body":13,"type":835,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":839,"body":13,"type":835,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":841,"body":13,"type":835,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fphar.2020.554422?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":843,"body":13,"type":835,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":845,"articleHubArticlesList":846,"canJournalHasArticleHub":347,"articleDoiList":847},{},[],[],{"title":19,"image":-1,"breadcrumbs":849,"linksCollection":850,"metricsCollection":852},[],{"total":367,"items":851},[],{"total":367,"items":853},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fphar.2020.554422?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>